

CHEST[®] Physician

THE NEWSPAPER OF THE AMERICAN COLLEGE OF CHEST PHYSICIANS



XIXINXING/THINKSTOCK

Sepsis, septic shock redefined by critical care groups

‘Severe sepsis’ term is eliminated.

BY KARI OAKES
Frontline Medical News

ORLANDO – New consensus definitions for sepsis and septic shock focus on host dysregulation in the face of infection, propose a three-item quick-scoring option for bedside assessment, and introduce serum lactate as an important marker of cellular metabolic stress in identifying septic shock.

Sepsis is now defined as “life-threatening organ dysfunction caused by a dysregulated host response to infection,” according to a 19-member task force convened jointly by the U.S. Society for Critical

Care Medicine (SCCM) and the European Society of Intensive Care Medicine (ESICM) (JAMA. 2016;315[8]:801-10. doi: 10.1001/jama.2016.0287).

Since sepsis itself is inherently a life-threatening diagnosis, the term “severe sepsis” is redundant and should be eliminated, according to Dr. Mervyn Singer and his fellow task force members and coauthors. Together with his coauthors, Dr. Singer, professor of intensive care medicine at University College London, also recommended moving away from an “excessive focus on inflammation” and “the

See **Sepsis** • page 6

Chronic cough guidelines issued

BY SHARON WORCESTER
Frontline Medical News

FROM CHEST

Neuromodulatory therapies and speech pathology-based cough suppression are suggested treatment options for unexplained chronic cough in new guidelines from the CHEST Expert Cough Panel.

The panel noted, however, that evidence supporting the diagnosis and management of unexplained chronic cough is limited. As part of the guideline development, they considered approaches for improving related research.

“Persistent cough of unexplained origin is a significant health issue that

occurs in up to 5% to 10% of patients seeking medical assistance for a chronic cough and from 0% to 46% of patients referred to specialty cough clinics. Patients with unexplained chronic cough experience significant impairments in quality of life ... there is a need to identify effective treatment

See **Cough** • page 4

LUNG SAFE: ARDS goes unrecognized

BY KARI OAKES
Frontline Medical News

ORLANDO – Many patients meeting the criteria for acute respiratory distress syndrome (ARDS) went unrecognized in a global sample of ICU patients, and those ARDS patients did not receive adjusted ventilator management or positioning and pharmacologic adjunctive treatments, based on the results of the LUNG SAFE study.

Enrolling nearly 30,000 patients in 50 countries on five continents, the LUNG SAFE study (Large Observational Study to Understand the Global Impact of Severe Acute Respiratory Failure)

looked for real-world answers to whether and how patients with ARDS are treated. The LUNG SAFE results were published concurrently with the presentation of results in a late-breaking session at the Critical Care Congress, sponsored by the Society of Critical Care Medicine (JAMA. 2016;315[8]:759-61). The first author is Dr. Giacomo Bellani, professor of medicine at the University of Milan-Bicocca, Monza, Italy, and Dr. John Laffey, professor of anesthesia, critical care, and physiology at the University of Toronto, presented the results at the meeting.

About 10% of the enrolled

See **ARDS** • page 7

INSIDE

Pulmonary Medicine Aspergillosis

Pulmonary aspergillosis guidelines issued. • 10

Cardiology Game changers

HF care and ivadradine, sacubitril/valsartan. • 15

Sleep Medicine Sleep Strategies

A new paradigm for sleep apnea care delivery. • 20

Critical Care Medicine Alcohol withdrawal

Deciding on intubation. • 28

Cardiothoracic Surgery Risk calculator

NSQIP measure falls short for stage I NSCLC. • 34

Practice Economics Medicare

CMS clarifies how to report overpayments. • 58



CHEST[®]
Annual Meeting
2016

Call for Abstracts and Case Reports

chest2016.abstractcentral.com

Submission deadline: April 1

Recommended by the
ATS/ERS/JRS/ALAT Clinical Practice
Guideline for the treatment of IPF.
Conditional recommendation, moderate
confidence in estimates of effect.^{1*}



FOCUSING ON THE LUNG FUNCTION YOU CAN HELP PRESERVE

REDUCE LUNG FUNCTION DECLINE WITH ESBRIET²⁻⁵

Indication

Esbriet® (pirfenidone) is indicated for the treatment of idiopathic pulmonary fibrosis (IPF).

Select Important Safety Information

Elevated liver enzymes: Increases in ALT and AST $>3\times$ ULN have been reported in patients treated with Esbriet. Rarely these have been associated with concomitant elevations in bilirubin. Patients treated with Esbriet had a higher incidence of elevations in ALT or AST than placebo patients (3.7% vs 0.8%, respectively). No cases of liver transplant or death due to liver failure that were related to Esbriet have been reported. However, the combination of transaminase elevations and elevated bilirubin without evidence of obstruction is generally recognized as an important predictor of severe liver injury that could lead to death or the need for liver transplants in some patients. Conduct liver function tests (ALT, AST, and bilirubin) prior to initiating Esbriet, then monthly for the first 6 months and every 3 months thereafter. Dosage modifications or interruption may be necessary.

Photosensitivity reaction or rash: Patients treated with Esbriet had a higher incidence of photosensitivity reactions (9%) compared with patients treated with placebo (1%). Patients should avoid or minimize exposure to sunlight (including sunlamps), use a sunblock (SPF 50 or higher), and wear clothing that protects against sun exposure. Patients should avoid concomitant medications that cause photosensitivity. Dosage reduction or discontinuation may be necessary.

Gastrointestinal disorders: Gastrointestinal events of nausea, diarrhea, dyspepsia, vomiting, gastroesophageal reflux disease, and abdominal pain were more frequently reported in patients treated with Esbriet. Dosage reduction or interruption for gastrointestinal events was required in 18.5% of patients in the Esbriet 2403 mg/day group, as compared to 5.8% of patients in the placebo group; 2.2% of patients in the Esbriet 2403 mg/day group discontinued treatment due to a gastrointestinal event, as compared to 1.0% in the placebo group. The most common ($>2\%$) gastrointestinal events that led to dosage reduction or interruption were nausea, diarrhea, vomiting, and dyspepsia. Dosage modifications may be necessary in some cases.

Adverse reactions: The most common adverse reactions ($\geq 10\%$) were nausea, rash, abdominal pain, upper respiratory tract infection, diarrhea, fatigue, headache, dyspepsia, dizziness, vomiting, anorexia, gastroesophageal reflux disease, sinusitis, insomnia, weight decreased, and arthralgia.

Drug interactions: Concomitant administration with strong inhibitors of CYP1A2 (eg, fluvoxamine) significantly increases systemic exposure of Esbriet and is not recommended. Discontinue prior to administration of Esbriet. If strong CYP1A2 inhibitors cannot be avoided, dosage reductions of Esbriet are recommended. Monitor for adverse reactions and consider discontinuation of Esbriet as needed.

Start preserving more lung function for patients with IPF⁴

- ▶ Esbriet had a significant impact on lung function vs placebo in ASCEND^{3,4†}
 - 48% relative reduction in risk of a meaningful decline in lung function at 52 weeks for patients on Esbriet vs placebo** (17% vs 32%; 15% absolute difference; $P<0.001$)
 - 2.3× as many patients on Esbriet maintained their baseline function at 52 weeks vs placebo** (23% vs 10% of patients; 13% absolute difference; $P<0.001$)
- ▶ Esbriet delayed progression of IPF vs placebo through a sustained impact on lung function decline in ASCEND^{3,4†}
 - Patients on Esbriet maintained an average of 193 mL more lung function at 52 weeks vs placebo** (-235 mL vs -428 mL; $P<0.001$)
- ▶ **No statistically significant difference vs placebo in change in %FVC or decline in FVC volume from baseline to 72 weeks was observed in CAPACITY 006^{3,5}**
- ▶ Esbriet has been approved outside the US since 2011, with approximately 15,000 patients treated with pirfenidone worldwide²

Learn more about Esbriet and how to access medication at EsbrietHCP.com.

ATS=American Thoracic Society; ERS=European Respiratory Society; JRS=Japanese Respiratory Society; ALAT=Latin American Thoracic Association; %FVC=percent predicted forced vital capacity.

*Recognize that different choices will be appropriate for individual patients and that you must help each patient arrive at a management decision consistent with his or her values and preferences.

†The efficacy of Esbriet was evaluated in three phase 3, randomized, double-blind, placebo-controlled trials. In ASCEND, 555 patients with IPF were randomized to receive Esbriet 2403 mg/day or placebo for 52 weeks. Eligible patients had %FVC between 50%-90% and %DL_{CO} between 30%-90%. The primary endpoint was change in %FVC from baseline to week 52.

Concomitant administration of Esbriet and ciprofloxacin (a moderate inhibitor of CYP1A2) moderately increases exposure to Esbriet. If ciprofloxacin at the dosage of 750 mg twice daily cannot be avoided, dosage reductions are recommended. Monitor patients closely when ciprofloxacin is used.

Agents that are moderate or strong inhibitors of both CYP1A2 and CYP isoenzymes involved in the metabolism of Esbriet should be avoided during treatment.

The concomitant use of a CYP1A2 inducer may decrease the exposure of Esbriet, and may lead to loss of efficacy. Concomitant use of strong CYP1A2 inducers should be avoided.

Specific populations: Esbriet should be used with caution in patients with mild to moderate (Child-Pugh Class A and B) hepatic impairment. Monitor for adverse reactions and consider dosage modification or discontinuation of Esbriet as needed. The safety, efficacy, and pharmacokinetics of Esbriet have not been studied in patients with severe hepatic impairment. Esbriet is not recommended for use in patients with severe (Child-Pugh Class C) hepatic impairment.

Esbriet should be used with caution in patients with mild (CL_{cr} 50-80 mL/min), moderate (CL_{cr} 30-50 mL/min), or severe (CL_{cr} less than 30 mL/min) renal impairment. Monitor for adverse reactions and consider dosage modification or discontinuation of Esbriet as needed. The safety, efficacy, and pharmacokinetics of Esbriet have not been studied in patients with end-stage renal disease requiring dialysis. Use of Esbriet in patients with end-stage renal disease requiring dialysis is not recommended.

Smoking causes decreased exposure to Esbriet, which may alter the efficacy profile of Esbriet. Instruct patients to stop smoking prior to treatment with Esbriet and to avoid smoking when using Esbriet.

You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.

Please see Brief Summary of Prescribing Information on adjacent pages for additional Important Safety Information.

References: **1.** Raghu G, Rochwerg B, Zhang Y, et al; ATS, ERS, JRS, and ALAT. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. *Am J Respir Crit Care Med.* 2015;192(2):e3-e19. **2.** Data on file. Genentech, Inc. **3.** Esbriet Prescribing Information. InterMune, Inc. October 2014. **4.** King TE Jr, Bradford WZ, Castro-Bernardini S, et al; for the ASCEND Study Group. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis [published correction appears in *N Engl J Med.* 2014;371(12):1172]. *N Engl J Med.* 2014;370(22):2083-2092. **5.** Noble PW, Albera C, Bradford WZ, et al; for the CAPACITY Study Group. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. *Lancet.* 2011;377(9779):1760-1769.

Genentech

A Member of the Roche Group

© 2015 Genentech USA, Inc. All rights reserved. ESB/021215/0039(1)a 12/15

Esbriet
(pirfenidone) capsules 267mg



Speech therapy, steroids advised

Cough from page 1

approaches,” Dr. Peter Gibson of Hunter Medical Research Institute, New South Wales, Australia, and his colleagues reported on behalf of the panel (Chest. 2016;149[1]:27-44).

The panel defined unexplained chronic cough as a cough that persists longer than 8 weeks, and that remains unexplained after evaluations and supervised therapeutic

trials are conducted according to guidelines.

The panel also suggested the following therapeutic approaches:

- That adult patients have objective testing for bronchial hyperresponsiveness and eosinophilic bronchitis, or be offered a trial of corticosteroid therapy.

- That adult patients have a trial of multi-modality speech pathology therapy.
- That inhaled corticosteroids not be prescribed in adult patients who test negative for bronchial hyperresponsiveness and eosinophilia.
- That a therapeutic trial of gabapentin be offered as long as the

Esbriet
(pirfenidone) capsules 267mg

Rx only

BRIEF SUMMARY

The following is a brief summary of the full Prescribing Information for ESBRIET® (pirfenidone). Please review the full Prescribing Information prior to prescribing ESBRIET.

1 INDICATIONS AND USAGE

ESBRIET is indicated for the treatment of idiopathic pulmonary fibrosis (IPF).

4 CONTRAINDICATIONS

None.

5 WARNINGS AND PRECAUTIONS

5.1 Elevated Liver Enzymes

Increases in ALT and AST $>3 \times$ ULN have been reported in patients treated with ESBRIET. Rarely these have been associated with concomitant elevations in bilirubin. Patients treated with ESBRIET 2403 mg/day in the three Phase 3 trials had a higher incidence of elevations in ALT or AST $\geq 3 \times$ ULN than placebo patients (3.7% vs. 0.8%, respectively). Elevations $\geq 10 \times$ ULN in ALT or AST occurred in 0.3% of patients in the ESBRIET 2403 mg/day group and in 0.2% of patients in the placebo group. Increases in ALT and AST $\geq 3 \times$ ULN were reversible with dose modification or treatment discontinuation. No cases of liver transplant or death due to liver failure that were related to ESBRIET have been reported. However, the combination of transaminase elevations and elevated bilirubin without evidence of obstruction is generally recognized as an important predictor of severe liver injury, that could lead to death or the need for liver transplants in some patients. Conduct liver function tests (ALT, AST, and bilirubin) prior to the initiation of therapy with ESBRIET in all patients, then monthly for the first 6 months and every 3 months thereafter. Dosage modifications or interruption may be necessary for liver enzyme elevations [see *Dosage and Administration sections 2.1 and 2.3 in full Prescribing Information*].

5.2 Photosensitivity Reaction or Rash

Patients treated with ESBRIET 2403 mg/day in the three Phase 3 studies had a higher incidence of photosensitivity reactions (9%) compared with patients treated with placebo (1%). The majority of the photosensitivity reactions occurred during the initial 6 months. Instruct patients to avoid or minimize exposure to sunlight (including sunlamps), to use a sunblock (SPF 50 or higher), and to wear clothing that protects against sun exposure. Additionally, instruct patients to avoid concomitant medications known to cause photosensitivity. Dosage reduction or discontinuation may be necessary in some cases of photosensitivity reaction or rash [see *Dosage and Administration section 2.3 in full Prescribing Information*].

5.3 Gastrointestinal Disorders

In the clinical studies, gastrointestinal events of nausea, diarrhea, dyspepsia, vomiting, gastro-esophageal reflux disease, and abdominal pain were more frequently reported by patients in the ESBRIET treatment groups than in those taking placebo. Dosage reduction or interruption for gastrointestinal events was required in 18.5% of patients in the 2403 mg/day group, as compared to 5.8% of patients in the placebo group; 2.2% of patients in the ESBRIET 2403 mg/day group discontinued treatment due to a gastrointestinal event, as compared to 1.0% in the placebo group. The most common ($>2\%$) gastrointestinal events that led to dosage reduction or interruption were nausea, diarrhea, vomiting, and dyspepsia. The incidence of gastrointestinal events was highest early in the course of treatment (with highest incidence occurring during the initial 3 months) and decreased over time. Dosage modifications may be necessary in some cases of gastrointestinal adverse reactions [see *Dosage and Administration section 2.3 in full Prescribing Information*].

6 ADVERSE REACTIONS

The following adverse reactions are discussed in greater detail in other sections of the labeling:

- Liver Enzyme Elevations [see *Warnings and Precautions (5.1)*]
- Photosensitivity Reaction or Rash [see *Warnings and Precautions (5.2)*]
- Gastrointestinal Disorders [see *Warnings and Precautions (5.3)*]

ESBRIET® (pirfenidone)

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety of pirfenidone has been evaluated in more than 1400 subjects with over 170 subjects exposed to pirfenidone for more than 5 years in clinical trials.

ESBRIET was studied in 3 randomized, double-blind, placebo-controlled trials (Studies 1, 2, and 3) in which a total of 623 patients received 2403 mg/day of ESBRIET and 624 patients received placebo. Subjects ages ranged from 40 to 80 years (mean age of 67 years). Most patients were male (74%) and Caucasian (95%). The mean duration of exposure to ESBRIET was 62 weeks (range: 2 to 118 weeks) in these 3 trials.

At the recommended dosage of 2403 mg/day, 14.6% of patients on ESBRIET compared to 9.6% on placebo permanently discontinued treatment because of an adverse event. The most common ($>1\%$) adverse reactions leading to discontinuation were rash and nausea. The most common ($>3\%$) adverse reactions leading to dosage reduction or interruption were rash, nausea, diarrhea, and photosensitivity reaction.

The most common adverse reactions with an incidence of $\geq 10\%$ and more frequent in the ESBRIET than placebo treatment group are listed in Table 1.

Table 1. Adverse Reactions Occurring in $\geq 10\%$ of ESBRIET-Treated Patients and More Commonly Than Placebo in Studies 1, 2, and 3

Adverse Reaction	% of Patients (0 to 118 Weeks)	
	ESBRIET 2403 mg/day (N = 623)	Placebo (N = 624)
Nausea	36%	16%
Rash	30%	10%
Abdominal Pain ¹	24%	15%
Upper Respiratory Tract Infection	27%	25%
Diarrhea	26%	20%
Fatigue	26%	19%
Headache	22%	19%
Dyspepsia	19%	7%
Dizziness	18%	11%
Vomiting	13%	6%
Anorexia	13%	5%
Gastro-esophageal Reflux Disease	11%	7%
Sinusitis	11%	10%
Insomnia	10%	7%
Weight Decreased	10%	5%
Arthralgia	10%	7%

¹ Includes abdominal pain, upper abdominal pain, abdominal distension, and stomach discomfort.

Adverse reactions occurring in ≥ 5 to $<10\%$ of ESBRIET-treated patients and more commonly than placebo are photosensitivity reaction (9% vs. 1%), decreased appetite (8% vs. 3%), pruritus (8% vs. 5%), asthenia (6% vs. 4%), dysgeusia (6% vs. 2%), and non-cardiac chest pain (5% vs. 4%).

6.2 Postmarketing Experience

In addition to adverse reactions identified from clinical trials, the following adverse reactions have been identified during postapproval use of pirfenidone. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency.

Blood and Lymphatic System Disorders
Agranulocytosis

Immune System Disorders
Angioedema

Hepatobiliary Disorders

Bilirubin increased in combination with increases of ALT and AST

risk-benefit profile is discussed with the patient, and as long as reassessment of the risk-benefit profile be conducted at 6 months – before continuing the drug. The recommended starting dose is 300 mg daily in those without contraindications, with dose escalation daily as tolerated up to a maximum

Persistent cough of unexplained origin is a significant health issue that occurs in up to 5% to 10% of patients seeking medical assistance for a chronic cough.

tolerable dose of 1,800 mg daily in two divided doses.
• That adult patients with a negative workup for acid gastroesophageal

reflux disease not be prescribed a proton pump inhibitor.
The panel's suggestions are the result of a systematic review of 11

randomized controlled trials and 5 systematic reviews to discern whether treatment is more efficacious than usual care with respect to cough severity, cough frequency, and cough-related quality of life.

Studies reviewed included data on 570 subjects over age 12 years with chronic cough who received a variety of interventions.

Positive effects on cough-related quality of life were noted for both gabapentin and morphine, but the panel determined that only gabapentin was supported as a treatment recommendation.

After controlling for intervention fidelity bias, inhaled corticosteroids were not found to be effective for unexplained chronic cough, and esomeprazole was not effective in patients without features of gastroesophageal acid reflux.

Most of the recommendations are based on consensus opinion and limited data.

As a result, the panel examined clinical trial design, chronic cough registries, and potential research questions in an effort to identify ways to improve research. Among other conclusions, the panel said future trials should include comparison groups as a significant placebo effect can occur in cough trials. Also, quality of life should be used as the primary study outcome.

“Registries for unexplained chronic cough could be used to document patient characteristics and outcomes, as well as clinical trials in progress. They could also serve as a source of research participants for trials and may allow for phenotyping according to age, sex, cough duration, cough severity, cough reflex sensitivity, and other biomarkers. Registries can be used for genetic studies in chronic cough.”

“Unexplained chronic cough requires further study to determine consistent terminology and the optimal methods of investigation using established criteria for intervention fidelity,” the panel concluded.

Dr. Gibson reported having no disclosures. One other author, Dr. Lorcan McGarvey, reported serving on advisory boards for Novartis and GlaxoSmithKline in relation to novel compounds with a potential role in treatment of cough, and serving as chairman for the Mortality Adjudication Committee for UPLIFT and TIOSPIR – two phase IV chronic obstructive pulmonary disease clinical trials for Boehringer Ingelheim.

ESBRIET® (pirfenidone)

7 DRUG INTERACTIONS

7.1 CYP1A2 Inhibitors

Pirfenidone is metabolized primarily (70 to 80%) via CYP1A2 with minor contributions from other CYP isoenzymes including CYP2C9, 2C19, 2D6 and 2E1.

Strong CYP1A2 Inhibitors

The concomitant administration of ESBRIET and fluvoxamine or other strong CYP1A2 inhibitors (e.g., enoxacin) is not recommended because it significantly increases exposure to ESBRIET [see *Clinical Pharmacology section 12.3 in full Prescribing Information*]. Use of fluvoxamine or other strong CYP1A2 inhibitors should be discontinued prior to administration of ESBRIET and avoided during ESBRIET treatment. In the event that fluvoxamine or other strong CYP1A2 inhibitors are the only drug of choice, dosage reductions are recommended. Monitor for adverse reactions and consider discontinuation of ESBRIET as needed [see *Dosage and Administration section 2.4 in full Prescribing Information*].

Moderate CYP1A2 Inhibitors

Concomitant administration of ESBRIET and ciprofloxacin (a moderate inhibitor of CYP1A2) moderately increases exposure to ESBRIET [see *Clinical Pharmacology section 12.3 in full Prescribing Information*]. If ciprofloxacin at the dosage of 750 mg twice daily cannot be avoided, dosage reductions are recommended [see *Dosage and Administration section 2.4 in full Prescribing Information*]. Monitor patients closely when ciprofloxacin is used at a dosage of 250 mg or 500 mg once daily.

Concomitant CYP1A2 and other CYP Inhibitors

Agents or combinations of agents that are moderate or strong inhibitors of both CYP1A2 and one or more other CYP isoenzymes involved in the metabolism of ESBRIET (i.e., CYP2C9, 2C19, 2D6, and 2E1) should be discontinued prior to and avoided during ESBRIET treatment.

7.2 CYP1A2 Inducers

The concomitant use of ESBRIET and a CYP1A2 inducer may decrease the exposure of ESBRIET and this may lead to loss of efficacy. Therefore, discontinue use of strong CYP1A2 inducers prior to ESBRIET treatment and avoid the concomitant use of ESBRIET and a strong CYP1A2 inducer [see *Clinical Pharmacology section 12.3 in full Prescribing Information*].

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Teratogenic Effects: **Pregnancy Category C.**

There are no adequate and well-controlled studies of ESBRIET in pregnant women. Pirfenidone was not teratogenic in rats and rabbits. Because animal reproduction studies are not always predictive of human response, ESBRIET should be used during pregnancy only if the benefit outweighs the risk to the patient.

A fertility and embryo-fetal development study with rats and an embryo-fetal development study with rabbits that received oral doses up to 3 and 2 times, respectively, the maximum recommended daily dose (MRDD) in adults (on mg/m² basis at maternal doses up to 1000 and 300 mg/kg/day, respectively) revealed no evidence of impaired fertility or harm to the fetus due to pirfenidone. In the presence of maternal toxicity, acyclic/irregular cycles (e.g., prolonged estrous cycle) were seen in rats at doses approximately equal to and higher than the MRDD in adults (on a mg/m² basis at maternal doses of 450 mg/kg/day and higher). In a pre- and post-natal development study, prolongation of the gestation period, decreased numbers of live newborn, and reduced pup viability and body weights were seen in rats at an oral dosage approximately 3 times the MRDD in adults (on a mg/m² basis at a maternal dose of 1000 mg/kg/day).

8.3 Nursing Mothers

A study with radio-labeled pirfenidone in rats has shown that pirfenidone or its metabolites are excreted in milk. It is not known whether ESBRIET is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue ESBRIET, taking into account the importance of the drug to the mother.

8.4 Pediatric Use

Safety and effectiveness of ESBRIET in pediatric patients have not been established.

8.5 Geriatric Use

Of the total number of subjects in the clinical studies receiving ESBRIET, 714 (67%) were 65 years old and over, while 231 (22%) were 75 years old and over. No overall differences in safety or effectiveness were observed between older and younger patients. No dosage adjustment is required based upon age.

ESBRIET® (pirfenidone)

8.6 Hepatic Impairment

ESBRIET should be used with caution in patients with mild (Child Pugh Class A) to moderate (Child Pugh Class B) hepatic impairment. Monitor for adverse reactions and consider dosage modification or discontinuation of ESBRIET as needed [see *Dosage and Administration section 2.2 in full Prescribing Information*].

The safety, efficacy, and pharmacokinetics of ESBRIET have not been studied in patients with severe hepatic impairment. ESBRIET is not recommended for use in patients with severe (Child Pugh Class C) hepatic impairment [see *Clinical Pharmacology section 12.3 in full Prescribing Information*].

8.7 Renal Impairment

ESBRIET should be used with caution in patients with mild (CL_{cr} 50–80 mL/min), moderate (CL_{cr} 30–50 mL/min), or severe (CL_{cr} less than 30 mL/min) renal impairment [see *Clinical Pharmacology section 12.3 in full Prescribing Information*]. Monitor for adverse reactions and consider dosage modification or discontinuation of ESBRIET as needed [see *Dosage and Administration section 2.3 in full Prescribing Information*]. The safety, efficacy, and pharmacokinetics of ESBRIET have not been studied in patients with end-stage renal disease requiring dialysis. Use of ESBRIET in patients with end-stage renal diseases requiring dialysis is not recommended.

8.8 Smokers

Smoking causes decreased exposure to ESBRIET [see *Clinical Pharmacology section 12.3 in full Prescribing Information*], which may alter the efficacy profile of ESBRIET. Instruct patients to stop smoking prior to treatment with ESBRIET and to avoid smoking when using ESBRIET.

10 OVERDOSAGE

There is limited clinical experience with overdosage. Multiple dosages of ESBRIET up to a maximum tolerated dose of 4005 mg per day were administered as five 267 mg capsules three times daily to healthy adult volunteers over a 12-day dose escalation.

In the event of a suspected overdosage, appropriate supportive medical care should be provided, including monitoring of vital signs and observation of the clinical status of the patient.

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Liver Enzyme Elevations

Advise patients that they may be required to undergo liver function testing periodically. Instruct patients to immediately report any symptoms of a liver problem (e.g., skin or the white of eyes turn yellow, urine turns dark or brown [tea colored], pain on the right side of stomach, bleed or bruise more easily than normal, lethargy) [see *Warnings and Precautions (5.1)*].

Photosensitivity Reaction or Rash

Advise patients to avoid or minimize exposure to sunlight (including sunlamps) during use of ESBRIET because of concern for photosensitivity reactions or rash. Instruct patients to use a sunblock and to wear clothing that protects against sun exposure. Instruct patients to report symptoms of photosensitivity reaction or rash to their physician. Temporary dosage reductions or discontinuations may be required [see *Warnings and Precautions (5.2)*].

Gastrointestinal Events

Instruct patients to report symptoms of persistent gastrointestinal effects including nausea, diarrhea, dyspepsia, vomiting, gastro-esophageal reflux disease, and abdominal pain. Temporary dosage reductions or discontinuations may be required [see *Warnings and Precautions (5.3)*].

Smokers

Encourage patients to stop smoking prior to treatment with ESBRIET and to avoid smoking when using ESBRIET [see *Clinical Pharmacology section 12.3 in full Prescribing Information*].

Take with Food

Instruct patients to take ESBRIET with food to help decrease nausea and dizziness.

Distributed by:
Genentech USA, Inc.
A Member of the Roche Group
1 DNA Way
South San Francisco, CA 94080-4990

Genentech

A Member of the Roche Group

All marks used herein are property of Genentech, Inc.
© 2015 Genentech, Inc. All rights reserved. ESB/100115/0470 10/15

SIRS differs from sepsis

Sepsis from page 1

misleading model that sepsis follows a continuum through severe sepsis to shock.”

Systemic inflammatory response syndrome (SIRS) is a serious manifestation of an appropriate host response to infection, rather than the dysregulated host response that characterizes sepsis. So although it's no longer included in sepsis criteria, “we are not discounting SIRS,” Dr. Singer said in a presentation at the Critical Care Congress, sponsored by the Society for Critical Care Medicine.


The consensus statement was released and the presentation was made simultaneously.

Organ dysfunction, for the purposes of the revised definition, is defined as a 2 or more point increase in the Sequential [Sepsis-related]

Organ Failure Assessment (SOFA) score. This increase is associated with a 10% or more rise in mortality while in hospital. Task force members, after review, recommended standardizing sepsis assessment with the SOFA score.

The criteria require an increase of 2 or more points on the SOFA score because many patients suspected of sepsis will have comorbidities that will “earn” them SOFA points at baseline, said Dr. Singer.

Operationalizing the sepsis definition through SOFA made sense, said Dr. Singer, because the set of five laboratory measures and one clinician-administered scale – the Glasgow Coma Scale (GCS) – are already likely to be part of daily assessments for a seriously ill hospitalized adult.



©INVISIONER/THINKSTOCK

Septic shock, as defined by the task force, is associated with in-hospital mortality of over 40%. Septic shock is now defined as “a subset of sepsis in which particularly profound circulatory, cellular, and metabolic abnormalities are associated with a greater risk of mortality than with sepsis alone.”

Clinically, patients have septic shock if they require a vasopressor to maintain a mean arterial pressure of 65 mm Hg or greater, and have a serum lactate level greater than 18 mg/dL (2 mmol/L) without hypovolemia.

The definitions introduce an abbreviated bedside sepsis identification tool termed quickSOFA (qSOFA). For adults suspected of infection, qSOFA requires two of the three clinical criteria of respiratory rate of

22 breaths/min or greater, altered mentation, or systolic blood pressure of 100 mm Hg or less.

“This model was robust to multiple sensitivity analyses,” wrote Dr. Singer and his coauthors, and worked well in out-of-hospital, emergency department, and ward settings within and outside of the United States.

“We are encouraging prospective validation in different health care settings,” for example, in resource-poor environments, said Dr. Singer.

The extensive review process included a large meta-analysis and systematic review of observational studies of adults with sepsis to evaluate diagnostic systems and criteria currently in use. The results of the review were used to inform the task force's Delphi study, which then led

Continued on following page

IN THIS ISSUE

News From CHEST • 40

A letter to the President

Ratification sought for Framework Convention on Tobacco Control. • 40

CHEST Physician Is Online

CHEST Physician is available on the Web at chestphysician.org



Dr. Vera A. De Palo, MBA, FCCP, is Medical Editor in Chief of CHEST Physician.

CHEST Physician

THE NEWSPAPER OF THE AMERICAN COLLEGE OF CHEST PHYSICIANS

AMERICAN COLLEGE OF CHEST PHYSICIANS (CHEST)

Editor in Chief Vera A. De Palo, M.D., MBA, FCCP
Deputy Editor in Chief David A. Schulman, M.D., FCCP
President Barbara Phillips, MD, MSPH, FCCP
Executive Vice President and CEO Paul A. Markowski, CAE
Senior VP/Publisher, Publications/Digital Content Stephen J. Welch
Manager, Editorial Resources Pamela L. Goorsky
Senior Publications Specialist Martha Zaborowski
Section Editors
 Nitin Puri, M.D., FCCP - **Pulmonary Perspectives**
 Lee E. Morrow, M.D., FCCP - **Critical Care Commentary**
 Jeremy A. Weingarten, M.D., FCCP - **Sleep Strategies**

EDITORIAL ADVISORY BOARD

G. Hossein Almassi, M.D., FCCP, Wisconsin
 Jennifer Cox, M.D., FCCP, Florida
 Jacques-Pierre Fontaine, M.D., FCCP, Florida
 Eric Gartman, M.D., FCCP, Rhode Island
 Octavian C. Ioachimescu, M.D., PhD, FCCP, Georgia
 Jason Lazar, M.D., FCCP, New York
 James A.L. Mathers Jr. M.D., FCCP, Virginia
 Susan Millard, M.D., FCCP, Michigan
 Michael E. Nelson, M.D., FCCP, Kansas
 Daniel Ouellette, M.D., FCCP, Michigan
 Frank Podbielski, M.D., FCCP, Massachusetts
 Eleanor Summerhill, M.D., FCCP, Rhode Island
 Krishna Sundar, M.D., FCCP, Utah

E-mail: chestphysiciannews@chestnet.org

CHEST PHYSICIAN, the newspaper of the American College of Chest Physicians, provides cutting-edge reports from clinical meetings, FDA coverage, clinical trial results, expert commentary, and reporting on the business and politics of chest medicine. Each issue also provides material exclusive to CHEST members. Content for CHEST PHYSICIAN is provided by Frontline Medical Communications Inc. Content for News From Chest is provided by the American College of Chest Physicians.

The statements and opinions expressed in CHEST PHYSICIAN do not necessarily reflect those of the American College of Chest Physicians, or of its officers, regents, members, and employees, or those of the Publisher. The American College of Chest Physicians, its officers, regents, members, and employees, and Frontline Medical Communications Inc. do not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in this publication, including any claims related to products, drugs, or services mentioned herein.

POSTMASTER: Send change of address (with old mailing label) to CHEST PHYSICIAN, Subscription Service, 151 Fairchild Ave., Suite 2, Plainview, NY 11803-1709.

CHEST PHYSICIAN (ISSN 1558-6200) is published monthly for the American College of Chest Physicians by Frontline Medical Communications Inc., 7 Century Drive, Suite 302, Parsippany, NJ 07054-4609. Subscription price is \$230.00 per year. Phone 973-206-3434, fax 973-206-9378.

EDITORIAL OFFICES 5635 Fishers Lane, Suite 6100, Rockville, MD 20852, 240-221-2400, fax 240-221-2548
ADVERTISING OFFICES 7 Century Drive, Suite 302, Parsippany, NJ 07054-4609 973-206-3434, fax 973-206-9378

©Copyright 2016, by the American College of Chest Physicians

FRONTLINE MEDICAL COMMUNICATIONS SOCIETY PARTNERS

VP/Group Publisher; Director, FMC Society Partners Mark Branca
Editor in Chief Mary Jo M. Dales
Executive Editors Denise Fulton, Kathy Scarbeck
Creative Director Louise A. Koenig
Director, Production/Manufacturing Rebecca Slobodnik
Senior Director of Classified Sales Tim LaPella, 484-921-5001, tlapella@frontlinemedcom.com
Display Advertising Managers Lauren Provenzano, 609-306-5776, lprovenzano@americanmedicalcomm.com, Michael O'Brien, 978-578-4514, mobrien@americanmedicalcomm.com
Classified Sales Representative Lauren Morgan 267-980-6087, lmorgan@americanmedicalcomm.com

FRONTLINE MEDICAL COMMUNICATIONS

FRONTLINE MEDICAL COMMUNICATIONS
Chairman Stephen Stoneburn
EVP Digital Business Development/CFO Douglas E. Grose
President/CEO Alan J. Imhoff
President, Custom Solutions JoAnn Wahl
Vice President, Finance Dennis Quirk
Vice President, Operations Jim Chicca
Vice President, Audience Development Donna Sickles
Vice President, Custom Programs Carol Nathan
Vice President, Custom Solutions Wendy Raupers
Vice President, eBusiness Development Lee Schweizer
Vice President, Human Resources & Facility Operations Carolyn Caccavelli
Vice President, Marketing & Customer Advocacy Jim McDonough
Vice President, Sales Phil Soufleris
Vice President, Society Partners Mark Branca
Corporate Director, Research & Communications Lori Raskin
 In affiliation with Global Academy for Medical Education, LLC
Vice President, Medical Education & Conferences Sylvia H. Reitman, MBA
Vice President, Events David J. Small, MBA



Scan this QR Code to visit chestnet.org/chestphysician

Few clinicians using higher PEEP levels

ARDS from page 1

patients met ARDS criteria; of those, less than two-thirds received ventilator tidal volumes of 8 mL/kg or less of predicted body weight. Fewer than 18% of patients received positive end-expiratory pressure (PEEP) of more than 12 cm H₂O, and clinicians used prone positioning for about 16% of patients with severe ARDS.

Clinicians recognized 60.2% of ARDS cases overall; recognition ranged from 51.3% of the cases of mild ARDS to 78.5% of the severe ARDS cases. For all patients, ARDS was associated with an in-hospital mortality rate of 40%. Nearly half of those with severe ARDS died, as did over a third of those with mild ARDS.

To this end, the LUNG SAFE investigators chose 4 consecutive weeks in the winter to enroll patients from a convenience sample of ICUs that they attempted to make broadly representative. They enrolled during February and March 2014 in the Northern hemisphere and July and August 2014 in the Southern hemisphere, and included all patients 16 years and older who were admitted to a participating ICU and received invasive or noninvasive ventilation.

Enrolled patients received daily evaluation for acute hypoxemic respiratory failure. Patients who met these criteria were then tracked with expanded data collection up to day 28 after respiratory failure was identified, or until ICU discharge or death. Overall, 3,022 patients met the Berlin Definition for ARDS.


All but 436 patients (85.4%) received invasive ventilation, and those who did not were excluded from most data analysis.

One unexpected finding, said Dr. Laffey in an interview, was how common ARDS was in this ICU population.

“Based on prior studies, we had anticipated find-

ing an incidence of ARDS of approximately half of what we actually found in the LUNG SAFE study. We think that the difference is explained by the fact that we did not rely on clinician recognition of ARDS, but rather collected data directly on each of the Berlin diagnostic criteria, enabling us to make the diagnosis directly.” One possibility is that choosing the winter months for data collection may have resulted in overrepresentation of ARDS.

But Dr. Laffey said that LUNG SAFE’s most surprising finding was the low percentage of clinicians using higher PEEP levels. “It appeared that clinicians used lower-than-expected levels of



PEEP, and that the use of PEEP didn’t increase in patients with the more severe forms of ARDS,” he said. “We think we need to increase our efforts to find more reliable ways to diagnose ARDS,” said Dr. Laffey. “While the reasons underlying clinician failure to recognize ARDS in critically ill patients are complex, the fact that there is no single test for diagnosing ARDS is a likely contributing factor.”

“This finding likely reflects the lack of a clear evidence base for the effectiveness of higher levels of PEEP in patients with ARDS” said Dr.

Laffey. “It emphasizes the need for additional research to answer this and other important questions relating to the optimal treatment of patients with ARDS.”

However, if physicians did recognize ARDS, then they were more likely to use higher PEEPs (mean 8.9 cm H₂O vs. 7.5 cm H₂O for nonrecognized ARDS; *P* less than .001), prone positioning, and neuromuscular blockade (43.9% adjunctive treatment vs. 21.7% adjunctive treatment for nonrecognized ARDS; *P* less than .001), though they didn’t adjust the breath size used in ventilation.

In multivariable analysis, factors that made it more likely that ARDS would be recognized were higher nurse-to-patient and physician-to-patient ratios, younger patient age, lower PaO₂/FiO₂ ratios, and a pneumonia or pancreatitis diagnosis. Patients



©ANDREI MALOV/THINKSTOCK

without an identified risk factor, and those with heart failure, were less likely to be diagnosed with ARDS.

The study was supported by the European Society of Intensive Care Medicine, by St. Michael’s Hospital, Toronto, and by the University of Milan-Bicocca, Monza, Italy. The authors reported no conflicts of interest.

koakes@frontlinemedcom.com

On Twitter @karioakes

Continued from previous page

to cohort studies to test the proposed variables, through the Surviving Sepsis Campaign.

A comprehensive description of the work of the task force was published concurrently with the new sepsis and septic shock definitions (JAMA. 2016;315[8]:775-87. doi: 10.1001/jama.2016.0289).

“We had what I call a soft launch” of the new definitions, said Dr. Singer. The definitions and criteria have been available for review and discussion for about a year, and discussions in the public forum are already shaping thoughts about the way forward. “We expect lots and lots of discussion,” said Dr. Singer.

Limitations of the new definitions were enumerated by Dr. Singer and his coauthors, and also brought forward in an accompanying editorial by Dr. Edward Abraham, dean of the Wake Forest School of Medicine, Winston-Salem, N.C.

These include that sepsis is not defined for children, that the reliance on serum lactate levels may not be feasible in resource-poor environments, and that there are limitations to the datasets used to generate the new guidelines.

The guidelines also offer suggested International Classification of Diseases-9 (ICD-9) and ICD-10 codes for sepsis and septic shock, in the hope that “greater clarity and consistency will also facilitate research and more accurate coding,” wrote Dr. Singer and his coauthors.

Multiple task force members reported relationships with pharmaceutical companies.

The work of the task force was supported in part by grants from SCCM and ESICM.

The guidelines and accompanying information are available at www.sccm.org/sepsisredefined.

koakes@frontlinemedcom.com

On Twitter @karioakes

Enhance your reading experience.



FREE APP DOWNLOAD

Optimized for mobile and tablets

chestphysician.org

iOS, Android and Amazon Kindle

CHEST[®] Physician

THE NEWSPAPER OF THE AMERICAN COLLEGE OF CHEST PHYSICIANS

Pulmonary vascular distensibility loss precedes PH

BY MARY ANN MOON
Frontline Medical News

FROM CHEST

Loss of distensibility in the pulmonary vasculature may be a marker that allows earlier detection of impending pulmonary hypertension, based on hemodynamic data from the medical records of 90 patients across the spectrum of pulmonary vascular disease.

Normal pulmonary circulation allows distension and recruitment of the pulmonary vasculature during exertion that in turn reduces pulmonary vascular resistance. Loss of this distensibility increases resistance and thus pulmonary arterial pressure, and is a characteristic of mild pulmonary vascular disease. Such disease is a precursor of full-blown pulmonary hypertension (PH), which “is a relatively late hemodynamic event in the evolution of pulmonary vascular disease,” wrote Dr. Edmund M. T. Lau of Université Paris-Sud, and his associates.

The percentage change in vascular diameter per mm Hg increase in distending pressure has been proposed for estimating the distensibility of resistive pulmonary vessels. This “distensibility value” has been assessed in animal studies and in healthy human subjects, but has not yet been assessed as a possible marker of mild pulmonary vascular disease or PH.

The researchers assessed this distensibility value in 31 patients with PH, 33 with mild pulmonary vascular disease but no PH as yet, and 26 control subjects with no pulmonary

vascular disease. The data were obtained from the medical records of these patients, who had undergone right-sided heart catheterization, both at rest and during exercise, over a 6-year period.

The percentage change in vascular diameter per mm Hg increase in distending pressure was “strikingly reduced” (0.45%/mm Hg) in the mild pulmonary vascular disease group compared with the control group (1.4%/mm Hg). As expected, the group with PH had the lowest distensibility value, at 0.25%/mm Hg.

Using a cutoff value of 0.76%/mm Hg allowed the researchers to distinguish control subjects from patients with mild disease with a sensitivity of 88% and a specificity of 100%.

“To our knowledge, this is the first study to validate the fit of [this] model in subjects with pulmonary vascular disease and to demonstrate that [percentage change in vascular diameter per mm Hg increase in distending pressure] is dramatically reduced in patients who have mild pulmonary vascular disease without manifest PH.

“Taken together, our findings suggest that vascular distensibility is markedly attenuated prior to the development of PH and that [this value] may serve as a useful vascular index in the setting of early disease detection,” Dr. Lau and his associates wrote (CHEST 2016;149:353-61).

The distensibility value calculated (1.4%/mm Hg) for this study’s control group was slightly lower than that reported in the literature for normal, healthy subjects and in vitro animal vessels (2%/mm Hg). That

VIEW ON THE NEWS

Findings may revamp screening process

These findings have the potential to completely revamp screening for pulmonary vascular disease, but first they must be validated in further research.

It will also be important to determine whether, as the authors suggest, a noninvasive method to determine vascular distensibility can be developed, perhaps using stress echocardiography or stress cardiac magnetic resonance testing. Only then can this measure – the percentage change in vascular diameter per mm Hg increase in distending pressure – translate from the realm of novel research into real-world clinical practice.

Dr. Richa Agarwal is in the department of medicine at Temple University, Philadelphia, and at the Cardiovascular Institute at Allegheny General Hospital, Pittsburgh. Dr. Mardi Gomberg-Maitland is in the department of medicine at the University of Chicago. Dr. Agarwal reported having no relevant financial disclosures; Dr. Gomberg-Maitland reported ties to Actelion, Bayer, Gen, Gilead, Medtronic, Novartis, Lung Biotechnology, Reata, Bellerophon, United Therapeutics, Medscape, and ABComm. Dr. Agarwal and Dr. Gomberg-Maitland made these remarks in an editorial accompanying Dr. Lau’s report (Chest 2016;149:295-7).

is likely because the control participants were older than the subjects in previous studies, and vascular distensibility is known to decrease with increasing age, the researchers said.

They added that it might be useful to calculate the distensibility value when patients suspected of having pulmonary vascular disease undergo invasive pulmonary hemodynamic evaluations. “It would be of particular interest to assess [it] in populations at a high risk of developing PH, such as carriers of the BMPR2 mutation and patients with systemic sclerosis.”

Obviously, estimating the distensibility value using noninvasive evaluation would be preferable,

the researchers noted. Preliminary studies of healthy control subjects and carriers of the BMPR2 mutation undergoing stress ECG testing have shown that calculating the distensibility value is feasible using Doppler echocardiography data, the researchers added.

This study was supported by Fonds de Dotation Recherche en Santé Respiratoire, Fondation du Souffle, and the INSERM–University of Sydney Exchange Grant. Dr. Lau reported having no relevant financial disclosures; his associates reported ties to Actelion, Aires, Bayer, Bristol-Myers Squibb, GlaxoSmithKline, Novartis, Pfizer, and United Therapeutics Corporation.

Late risks of breast cancer RT are higher for smokers

BY SUSAN LONDON
Frontline Medical News

SAN ANTONIO – The late side effects of modern radiation therapy for breast cancer depend in part on a woman’s smoking status, based on the results of a meta-analysis of data from more than 40,000 women presented at the San Antonio Breast Cancer Symposium.

For nonsmokers, radiation therapy had little impact on the absolute risks of lung cancer or cardiac death, the main risks identified, which in combination totaled less than 1%, Dr. Carolyn Taylor reported on behalf of the Early Breast Cancer Trialists’ Collaborative Group. But for women who had smoked throughout their adult life and continued to do so during and after treatment, it increased that absolute risk to roughly 2%.

“Smoking status can determine the net long-term effects of breast cancer radiotherapy on mortality. Stopping smoking at the time of radiotherapy may avoid much of the risk, and that’s because most of the risk of lung cancer starts more than 10 years after radiotherapy,” said Dr. Taylor, a radiation oncologist at the University of Oxford (England).

Radiation therapy remains an important tool in treating breast cancer, ultimately reducing the likelihood of death from the disease, she said.

“The absolute benefit in women treated according to current guidelines is a few percent. Let’s remember the magnitude of that benefit as we think about the risks of radiotherapy.”



Attendee Dr. Steven Vogl of Montefiore Medical Center, New York, asked whether information was available on the location of the lung cancers that occurred in the trials.

Stopping smoking at the time of radiotherapy may avoid much of the risk, as risk starts over 10 years after RT.

DR. GOODWIN

“In the last 4 years, we’ve had very good information that annual CT screening substantially and very quickly reduces the mortality from lung can-

“We didn’t have the location of the lung cancers. We didn’t even know if it was ipsilateral or contralateral to the previous breast cancer in this study,” Dr. Taylor replied. “But we’ve done other studies where we have known the location of the lung cancer, and there were similar findings in those studies.”

Continued on following page

Continued from previous page

cer,” Dr. Vogl added as a comment. “Any of us who care for patients who have been radiated where, really, any lung has been treated, who continue to smoke, should be screened – and screened and screened and screened again,” he remarked.

The researchers analyzed data from 40,781 women with breast cancer from 75 randomized trials conducted worldwide that compared outcomes with and without radiation therapy.

The median year of trial entry was 1983. On average, women in the trials received 10 Gy to both lungs combined and 6 Gy to the heart.

Comparing women who did and did not receive radiation therapy, the rate ratio for lung cancer was 2.1 at 10 or more years out, and the rate ratio for cardiac mortality was 1.3 overall.

Given the mean radiation doses in the trials, the excess risk translated to 12% per Gray for lung cancer and 4% per Gray for cardiac mortality. “These rate ratios are likely to apply today,” Dr. Taylor maintained.

However, she noted, contemporary breast cancer radiation therapy techniques are much better at sparing normal tissues.

To derive absolute risk estimates that are relevant today, she and her colleagues reviewed the literature for 2010-2015 and determined that women now receive an average of 5 Gy to both lungs combined and 4 Gy to the heart, with some centers achieving even lower values.

Among nonsmokers, the estimated cumulative 30-year risk of lung cancer was 0.5% for women who did not receive radiation therapy and 0.8% for those who received radiation therapy with a mean dose of 5 Gy to both lungs combined, Dr. Taylor reported. However, among long-term smokers, it was 9.4% without radiation and a substantially higher 13.8% with it.

Similarly, among nonsmokers, the estimated cumulative 30-year risk of ischemic heart disease death was 1.8% for women who did not receive radiation therapy and 2.0% for women who received radiation therapy with a mean dose of 2 Gy to the heart. Among long-term smokers, it was 8.0% without radiation and a slightly higher 8.6% with it.

Additional analyses looking at other late side effects showed no radiation therapy–related excess risk of sarcomas, according to Dr. Taylor. The risk of leukemia was increased with radiation, but actual

numbers of cases were very small, she cautioned.

Attendee Dr. Pamela Goodwin, University of Toronto, said, “I’m just wondering whether you considered if it was valid to assume that there was a linear relationship between radiation dose and the risk of lung cancer in the range of radiation dos-

es that you looked at, so, from the higher range in the earlier studies to the much lower dose now.”

Numbers of heart disease events were sufficient to establish a linear relationship, according to Dr. Taylor. Numbers of lung cancers were not, but case-control studies in the literature with adequate numbers have

identified a linear relationship there, too.

“We use what we can, and we have got now several hundred events, if you combine all of the literature together. And they do suggest the dose-response relationship is linear, but we can’t know that for certain,” she said.

SYMBICORT 160/4.5 for the maintenance treatment of COPD

REV THE FEV₁

SYMBICORT offers something extra—
sustained* control with better breathing
starting within 5 minutes each time¹⁻³

- SYMBICORT is **NOT** a rescue medication and does **NOT** replace fast-acting inhalers to treat acute symptoms
- Mean percent change from baseline in FEV₁ was measured at day of randomization, months 6 and 12³

FAST CONTROL
Majority of FEV₁ improvement at 5 minutes each time[†] in a subset of SUN Study patients taking SYMBICORT 160/4.5 (n=121)⁴

SUSTAINED EFFECT
Significant lung function improvement with continuous control, as demonstrated over 12 months in the SUN Study (n=494)^{1,4}

REASSURING SENSE OF CONTROL

- The most common adverse reactions ≥3% reported in COPD clinical trials included nasopharyngitis, oral candidiasis, bronchitis, sinusitis, and upper respiratory tract infection

*Sustained improvement in lung function was demonstrated in a 12-month efficacy and safety study.
†In a serial spirometry subset of patients taking SYMBICORT 160/4.5 (n=121) in the SUN Study, 67% of 1-hour postdose FEV₁ improvement occurred at 5 minutes on day of randomization, 83% at month 6, and 84% at end of treatment. See SUN Study design on next page.

IMPORTANT SAFETY INFORMATION, INCLUDING BOXED WARNING

- ▶ **WARNING:** Long-acting beta₂-adrenergic agonists (LABA), such as formoterol, one of the active ingredients in SYMBICORT, increase the risk of asthma-related death. A placebo-controlled study with another LABA (salmeterol) showed an increase in asthma-related deaths in patients receiving salmeterol. This finding with salmeterol is considered a class effect of LABA, including formoterol. Currently available data are inadequate to determine whether concurrent use of inhaled corticosteroids or other long-term asthma control drugs mitigates the increased risk of asthma-related death from LABA. Available data from controlled clinical trials suggest that LABA increase the risk of asthma-related hospitalization in pediatric and adolescent patients
- ▶ When treating patients with asthma, prescribe SYMBICORT only for patients not adequately controlled on a long-term asthma control medication, such as an inhaled corticosteroid or whose disease severity clearly warrants initiation of treatment with both an inhaled corticosteroid and LABA. Once asthma control is achieved and maintained, assess the patient at regular intervals and step down therapy (eg, discontinue SYMBICORT) if possible without loss of asthma control, and maintain the patient on a long-term asthma control medication, such as an inhaled corticosteroid. Do not use SYMBICORT for patients whose asthma is adequately controlled on low or medium dose inhaled corticosteroids
- ▶ SYMBICORT is **NOT** a rescue medication and does **NOT** replace fast-acting inhalers to treat acute symptoms
- ▶ SYMBICORT should not be initiated in patients during rapidly deteriorating episodes of asthma or COPD
- ▶ Patients who are receiving SYMBICORT should not use additional formoterol or other LABA for any reason
- ▶ Localized infections of the mouth and pharynx with *Candida albicans* has occurred in patients treated with SYMBICORT. Patients should rinse the mouth after inhalation of SYMBICORT
- ▶ Lower respiratory tract infections, including pneumonia, have been reported following the inhaled administration of corticosteroids

Please see additional Important Safety Information and Brief Summary of full Prescribing Information, including Boxed WARNING, on following pages.



Chronic pulmonary aspergillosis guidelines issued

BY NEIL OSTERWEIL
Frontline Medical News

European respiratory disease and infectious disease specialists have banded together to issue new clinical guidelines on the diagnosis and man-

agement of an uncommon but serious problem: chronic pulmonary aspergillosis (CPA).

Pulmonary infections with *Aspergillus* species can be a complicating factor in several lung diseases, especially tuberculosis, and aspergillosis is a serious, often fatal opportunistic infection in trans-

plant recipients who are on chronic immunosuppression or patients who are immunocompromised from disease or cytotoxic chemotherapy.


Approximately 240,000 people in Europe and 3 million people worldwide have chronic pulmonary aspergillosis (CPA). The Centers for Disease Con-

SYMBICORT 160/4.5 for the maintenance treatment of COPD

Fast control at 5 minutes each time^{1,4}

SYMBICORT IS ON
EXPRESS SCRIPTS[®]
NATIONAL PREFERRED
FORMULARY
INDICATED
FOR BOTH COPD AND ASTHMA.
FOR APPROPRIATE PATIENTS.

Percent of 1-hour improvement in FEV₁ occurring at 5 minutes over the 12-month study (serial spirometry subset)⁴



SUN: A 12-month efficacy and safety study. A 12-month, randomized, double-blind, double-dummy, placebo-controlled, parallel-group, multicenter study of 1964 patients with COPD compared SYMBICORT pMDI 160/4.5 mcg (n=494), SYMBICORT pMDI 80/4.5 mcg (n=494), formoterol 4.5 mcg (n=495), and placebo (n=481), each administered as 2 inhalations twice daily. Subjects were current or ex-smokers with a smoking history of ≥ 10 pack-years, aged ≥ 40 years with a clinical diagnosis of COPD and symptoms for >2 years. The study included a 2-week run-in period followed by a 12-month treatment period. This study was designed to assess change from baseline to the average over the randomized treatment period in predose FEV₁ and in 1-hour postdose FEV₁. The prespecified primary comparisons for predose FEV₁ were vs placebo and formoterol and the primary comparison for 1-hour postdose was vs placebo.

- SYMBICORT is NOT a rescue medication and does NOT replace fast-acting inhalers to treat acute symptoms

COMPARATOR ARMS: Mean improvement in 1-hour postdose FEV₁ (mL%) over 12 months (serial spirometry subset)
Day of randomization: SYMBICORT 160/4.5 mcg (240 mL/26%), formoterol 4.5 mcg (180 mL/20%), placebo (40 mL/5%).
6 months: SYMBICORT 160/4.5 mcg (270 mL/28%), formoterol 4.5 mcg (200 mL/23%), placebo (60 mL/7%).
End of month 12 (LOCF): SYMBICORT 160/4.5 mcg (240 mL/26%), formoterol 4.5 mcg (170 mL/19%), placebo (30 mL/5%).
SYMBICORT 160/4.5 mcg[†] (n=121), formoterol 4.5 mcg[†] (n=124), placebo[†] (n=125).

*Baseline is defined as the predose FEV₁ value on the day of randomization.

[†]Month 12, last observation carried forward (LOCF).

[‡]Administered as 2 inhalations twice daily.

IMPORTANT SAFETY INFORMATION, INCLUDING BOXED WARNING (cont'd)

- ▶ Due to possible immunosuppression, potential worsening of infections could occur. A more serious or even fatal course of chickenpox or measles can occur in susceptible patients
- ▶ It is possible that systemic corticosteroid effects such as hypercorticism and adrenal suppression may occur, particularly at higher doses. Particular care is needed for patients who are transferred from systemically active corticosteroids to inhaled corticosteroids. Deaths due to adrenal insufficiency have occurred in asthmatic patients during and after transfer from systemic corticosteroids to less systemically available inhaled corticosteroids
- ▶ Caution should be exercised when considering administration of SYMBICORT in patients on long-term ketoconazole and other known potent CYP3A4 inhibitors
- ▶ As with other inhaled medications, paradoxical bronchospasm may occur with SYMBICORT
- ▶ Immediate hypersensitivity reactions may occur as demonstrated by cases of urticaria, angioedema, rash, and bronchospasm
- ▶ Excessive beta-adrenergic stimulation has been associated with central nervous system and cardiovascular effects. SYMBICORT should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension
- ▶ Long-term use of orally inhaled corticosteroids may result in a decrease in bone mineral density (BMD). Since patients with COPD often have multiple risk factors for reduced BMD, assessment of BMD is recommended prior to initiating SYMBICORT and periodically thereafter
- ▶ Orally inhaled corticosteroids may result in a reduction in growth velocity when administered to pediatric patients
- ▶ Glaucoma, increased intraocular pressure, and cataracts have been reported following the inhaled administration of corticosteroids, including budesonide, a component of SYMBICORT. Close monitoring is warranted in patients with a change in vision or history of increased intraocular pressure, glaucoma, or cataracts
- ▶ In rare cases, patients on inhaled corticosteroids may present with systemic eosinophilic conditions
- ▶ SYMBICORT should be used with caution in patients with convulsive disorders, thyrotoxicosis, diabetes mellitus, ketoacidosis, and in patients who are unusually responsive to sympathomimetic amines
- ▶ Beta-adrenergic agonist medications may produce hypokalemia and hyperglycemia in some patients

trol and Prevention notes that because aspergillosis is not classified as a reportable disease, data on the actual incidence of infections in the United States are hard to come by.

"You don't see this every day, whether you're an infectious disease specialist or pulmonologist, so you really can't rely on your experience to guide you in managing these cases, which is why guidelines such as this can be very helpful," commented

Dr. Norman Edelman, a pulmonologist and senior consultant for scientific affairs for the American Lung Association.


The guidelines were issued by the European Society for Clinical Microbiology and Infectious Diseases in cooperation with the European Confederation of Medical Mycology and the European Respiratory Society (Eur Respir J. 2015. doi: 10.1183/13993003.00583-2015).

The most recent U.S. guidelines, issued under the aegis of the Infectious Diseases Society of America (IDSA) in 2000 and revised in 2008 (CID 2008;46:327-360), differ from the European recommendations in their level of detail, explained Prof. David W. Denning, professor of infectious diseases in global health at the University of Manchester (England) and lead author of the European guide-

Continued on following page

Sustained effect. Control over 12 months.^{1,4}

Improvement in 1-hour postdose FEV₁ over the 12-month study⁴



- SYMBICORT 160/4.5 significantly improved predose FEV₁ averaged over the course of the study compared to placebo and formoterol, a coprimary endpoint¹

COMPARATOR ARMS: Mean improvement in 1-hour postdose FEV₁ (mL%) over 12 months

1 month: SYMBICORT 160/4.5 mcg (220 mL/21%), formoterol 4.5 mcg (170 mL/17%), placebo (10 mL/1%).
6 months: SYMBICORT 160/4.5 mcg (220 mL/21%), formoterol 4.5 mcg (190 mL/18%), placebo (30 mL/3%).
End of treatment: SYMBICORT 160/4.5 mcg (200 mL/20%), formoterol 4.5 mcg (170 mL/17%), placebo (10 mL/1%).
SYMBICORT 160/4.5 mcg[†] (n=494), formoterol 4.5 mcg[†] (n=495), placebo[†] (n=479).

*Baseline is defined as the predose FEV₁ value on the day of randomization.

[†]Month 12, last observation carried forward (LOCF).

[‡]Administered as 2 inhalations twice daily.

- ▶ The most common adverse reactions ≥3% reported in asthma clinical trials included nasopharyngitis, headache, upper respiratory tract infection, pharyngolaryngeal pain, sinusitis, influenza, back pain, nasal congestion, stomach discomfort, vomiting, and oral candidiasis
- ▶ The most common adverse reactions ≥3% reported in COPD clinical trials included nasopharyngitis, oral candidiasis, bronchitis, sinusitis, and upper respiratory tract infection
- ▶ SYMBICORT should be administered with caution to patients being treated with MAO inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents
- ▶ Beta-blockers may not only block the pulmonary effect of beta-agonists, such as formoterol, but may produce severe bronchospasm in patients with asthma
- ▶ ECG changes and/or hypokalemia associated with nonpotassium-sparing diuretics may worsen with concomitant beta-agonists. Use caution with the coadministration of SYMBICORT

INDICATIONS

- ▶ SYMBICORT is indicated for the treatment of asthma in patients 12 years and older (also see Boxed WARNING on front cover)
- ▶ SYMBICORT 160/4.5 is indicated for the maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema
- ▶ SYMBICORT is NOT indicated for the relief of acute bronchospasm

References: 1. Rennard SI, Tashkin DP, McElhatten J, et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial. *Drugs*. 2009;69(5):549-565. 2. SYMBICORT [package insert]. Wilmington, DE: AstraZeneca; 2012. 3. Data on File, 3088224, AZPLP. 4. Data on File, 1084400, AZPLP. 5. 2015 Express Scripts Preferred Drug List.

Symbicort
 (budesonide/formoterol fumarate dihydrate)
 Inhalation Aerosol

AstraZeneca

Please see Brief Summary of full Prescribing Information, including Boxed WARNING, on following pages.

SYMBICORT is a registered trademark of the AstraZeneca group of companies. Express Scripts is a registered trademark of the Express Scripts Holding Company. ©2015 AstraZeneca. All rights reserved. 3171924 9/15

Continued from previous page

lines. “The IDSA guidelines assume that you know how to make the diagnosis, but actually for chronic pulmonary aspergillosis that’s not so easy,” he said in an interview. “The European ones go into in great detail about the diagnosis, the radiology, whether

this test is better than that test, how they all add up.” The guidelines recommend duration of therapy and comment on the use of steroids and interferon-gamma immunotherapy.

Diagnostic criteria

The European guidelines categorize Aspergillus infections according to

differences in clinical management:

- **Simple aspergilloma.** A single pulmonary cavity containing a fungal ball, supported by serologic or microbiologic evidence of infections with *Aspergillus* species in patients who are not immunocompromised and are asymptomatic or have only minor symptoms and no radiographic

evidence of progression for at least 3 months.

- **Chronic cavitary pulmonary aspergillosis (CCPA).** The presence of one or more pulmonary cavities that may contain one or more aspergillomas or irregular intraluminal material, evidence of *Aspergillus* species, significant pulmonary/systemic

SYMBICORT® 80/4.5

(budesonide 80 mcg and formoterol fumarate dihydrate 4.5 mcg)

Inhalation Aerosol

SYMBICORT® 160/4.5

(budesonide 160 mcg and formoterol fumarate dihydrate 4.5 mcg)

Inhalation Aerosol

For Oral Inhalation Only
Rx only

WARNING: ASTHMA RELATED DEATH

Long-acting beta₂-adrenergic agonists (LABA), such as formoterol one of the active ingredients in SYMBICORT, increase the risk of asthma-related death. Data from a large placebo-controlled U.S. study that compared the safety of another long-acting beta₂-adrenergic agonist (salmeterol) or placebo added to usual asthma therapy showed an increase in asthma-related deaths in patients receiving salmeterol. This finding with salmeterol is considered a class effect of the LABA, including formoterol. Currently available data are inadequate to determine whether concurrent use of inhaled corticosteroids or other long-term asthma control drugs mitigates the increased risk of asthma-related death from LABA. Available data from controlled clinical trials suggest that LABA increase the risk of asthma-related hospitalization in pediatric and adolescent patients. Therefore, when treating patients with asthma, SYMBICORT should only be used for patients not adequately controlled on a long-term asthma control medication, such as an inhaled corticosteroid or whose disease severity clearly warrants initiation of treatment with both an inhaled corticosteroid and LABA. Once asthma control is achieved and maintained, assess the patient at regular intervals and step down therapy (e.g., discontinue SYMBICORT) if possible without loss of asthma control and maintain the patient on a long-term asthma control medication, such as an inhaled corticosteroid. Do not use SYMBICORT for patients whose asthma is adequately controlled on low or medium dose inhaled corticosteroids [see WARNINGS AND PRECAUTIONS].

BRIEF SUMMARY

Before prescribing, please see full Prescribing Information for SYMBICORT® (budesonide/formoterol fumarate dihydrate).

INDICATIONS AND USAGE

Treatment of Asthma

SYMBICORT is indicated for the treatment of asthma in patients 12 years of age and older.

Long-acting beta₂-adrenergic agonists, such as formoterol one of the active ingredients in SYMBICORT, increase the risk of asthma-related death. Available data from controlled clinical trials suggest that LABA increase the risk of asthma-related hospitalization in pediatric and adolescent patients [see WARNINGS AND PRECAUTIONS]. Therefore, when treating patients with asthma, SYMBICORT should only be used for patients not adequately controlled on a long-term asthma-control medication such as an inhaled corticosteroid or whose disease severity clearly warrants initiation of treatment with both an inhaled corticosteroid and LABA. Once asthma control is achieved and maintained, assess the patient at regular intervals and step down therapy (e.g., discontinue SYMBICORT) if possible without loss of asthma control, and maintain the patient on a long-term asthma control medication, such as inhaled corticosteroid. Do not use SYMBICORT for patients whose asthma is adequately controlled on low or medium dose inhaled corticosteroids.

Important Limitations of Use:

- SYMBICORT is NOT indicated for the relief of acute bronchospasm.

Maintenance Treatment of Chronic Obstructive Pulmonary Disease (COPD)

SYMBICORT 160/4.5 is indicated for the twice daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD) including chronic bronchitis and emphysema. SYMBICORT 160/4.5 is the only approved dosage for the treatment of airflow obstruction in COPD.

Important Limitations of Use: SYMBICORT is not indicated for the relief of acute bronchospasm.

DOSAGE AND ADMINISTRATION

SYMBICORT should be administered twice daily every day by the orally inhaled route only. After inhalation, the patient should rinse the mouth with water without swallowing [see PATIENT COUNSELING INFORMATION in full Prescribing Information (17.4)].

Prime SYMBICORT before using for the first time by releasing two test sprays into the air away from the face, shaking well for 5 seconds before each spray. In cases where the inhaler has not been used for more than 7 days or when it has been dropped, prime the inhaler again by shaking well before each spray and releasing two test sprays into the air away from the face.

More frequent administration or a higher number of inhalations (more than 2 inhalations twice daily) of the prescribed strength of SYMBICORT is not recommended as some patients are more likely to experience adverse effects with higher doses of formoterol. Patients using SYMBICORT should not use additional long-acting beta₂-agonists for any reason [see WARNINGS AND PRECAUTIONS].

Asthma

If asthma symptoms arise in the period between doses, an inhaled, short-acting beta₂-agonist should be taken for immediate relief.

Adult and Adolescent Patients 12 Years of Age and Older: For patients 12 years of age and older, the dosage is 2 inhalations twice daily (morning and evening, approximately 12 hours apart).

The recommended starting dosages for SYMBICORT for patients 12 years of age and older are based upon patients' asthma severity.

The maximum recommended dosage is SYMBICORT 160/4.5 mcg twice daily.

Improvement in asthma control following inhaled administration of SYMBICORT can occur within 15 minutes of beginning treatment, although maximum benefit may not be achieved for 2 weeks or longer after beginning treatment. Individual patients will experience a variable time to onset and degree of symptom relief.

For patients who do not respond adequately to the starting dose after 1-2 weeks of therapy with SYMBICORT 80/4.5, replacement with SYMBICORT 160/4.5 may provide additional asthma control.

If a previously effective dosage regimen of SYMBICORT fails to provide adequate control of asthma, the therapeutic regimen should be re-evaluated and additional therapeutic options, (e.g., replacing the lower strength of SYMBICORT with the higher strength, adding additional inhaled corticosteroid, or initiating oral corticosteroids) should be considered.

Chronic Obstructive Pulmonary Disease (COPD)

For patients with COPD the recommended dose is SYMBICORT 160/4.5, two inhalations twice daily.

If shortness of breath occurs in the period between doses, an inhaled, short-acting beta₂-agonist should be taken for immediate relief.

CONTRAINDICATIONS

The use of SYMBICORT is contraindicated in the following conditions:

- Primary treatment of status asthmaticus or other acute episodes of asthma or COPD where intensive measures are required.
- Hypersensitivity to any of the ingredients in SYMBICORT.

WARNINGS AND PRECAUTIONS

Asthma-Related Death

Long-acting beta₂-adrenergic agonists, such as formoterol, one of the active ingredients in SYMBICORT, increase the risk of asthma-related death. Currently available data are inadequate to determine whether concurrent use of inhaled corticosteroids or other long-term asthma control drugs mitigates the increased risk of asthma-related death from LABA. Available data from controlled clinical trials suggest that LABA increase the risk of asthma-related hospitalization in pediatric and adolescent patients. Therefore, when treating patients with asthma, SYMBICORT should only be used for patients not adequately controlled on a long-term asthma-control medication, such as an inhaled corticosteroid or whose disease severity clearly warrants initiation of treatment with both an inhaled corticosteroid and LABA. Once asthma control is achieved and maintained, assess the patient at regular intervals and step down therapy (e.g., discontinue SYMBICORT) if possible without loss of asthma control, and maintain the patient on a long-term asthma control medication, such as an inhaled corticosteroid. Do not use SYMBICORT for patients whose asthma is adequately controlled on low or medium dose inhaled corticosteroids.

A 28-week, placebo controlled US study comparing the safety of salmeterol with placebo, each added to usual asthma therapy, showed an increase in asthma-related deaths in patients receiving salmeterol (13/13,176 in patients treated with salmeterol vs 3/13,179 in patients treated with placebo; RR 4.37, 95% CI 1.25, 15.34). This finding with salmeterol is considered a class effect of the LABA, including formoterol, one of the active ingredients in SYMBICORT. No study adequate to determine whether the rate of asthma-related death is increased with SYMBICORT has been conducted.

Clinical studies with formoterol suggested a higher incidence of serious asthma exacerbations in patients who received formoterol than in those who received placebo. The sizes of these studies were not adequate to precisely quantify the differences in serious asthma exacerbation rates between treatment groups.

Deterioration of Disease and Acute Episodes

SYMBICORT should not be initiated in patients during rapidly deteriorating or potentially life-threatening episodes of asthma or COPD. SYMBICORT has not been studied in patients with acutely deteriorating asthma or COPD. The initiation of SYMBICORT in this setting is not appropriate.

Increasing use of inhaled, short-acting beta₂-agonists is a marker of deteriorating asthma. In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of SYMBICORT with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. Patients should not use more than 2 inhalations twice daily (morning and evening) of SYMBICORT.

SYMBICORT should not be used for the relief of acute symptoms, i.e., as rescue therapy for the treatment of acute episodes of bronchospasm. An inhaled, short-acting beta₂-agonist, not SYMBICORT, should be used to relieve acute symptoms such as shortness of breath. When prescribing SYMBICORT, the physician must also provide the patient with an inhaled, short-acting beta₂-agonist (e.g., albuterol) for treatment of acute symptoms, despite regular twice-daily (morning and evening) use of SYMBICORT.

When beginning treatment with SYMBICORT, patients who have been taking oral or inhaled, short-acting beta₂-agonists on a regular basis (e.g., 4 times a day) should be instructed to discontinue the regular use of these drugs.

Excessive Use of SYMBICORT and Use with Other Long-Acting Beta₂-Agonists

As with other inhaled drugs containing beta₂-adrenergic agents, SYMBICORT should not be used more often than recommended, at higher doses than recommended, or in conjunction with other medications containing long-acting beta₂-agonists, as an overdose may result. Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. Patients using SYMBICORT should not use an additional long-acting beta₂-agonist (e.g., salmeterol, formoterol fumarate, arformoterol tartrate) for any reason, including prevention of exercise-induced bronchospasm (EIB) or the treatment of asthma or COPD.

Local Effects

In clinical studies, the development of localized infections of the mouth and pharynx with *Candida albicans* has occurred in patients treated with SYMBICORT. When such an infection develops, it should be treated with appropriate local or systemic (i.e., oral antifungal) therapy while treatment with SYMBICORT continues, but at times therapy with SYMBICORT may need to be interrupted. Patients should rinse the mouth after inhalation of SYMBICORT.

Pneumonia and Other Lower Respiratory Tract Infections

Physicians should remain vigilant for the possible development of pneumonia in patients with COPD as the clinical features of pneumonia and exacerbations frequently overlap. Lower respiratory tract infections, including pneumonia, have been reported following the inhaled administration of corticosteroids.

In a 6 month study of 1,704 patients with COPD, there was a higher incidence of lung infections other than pneumonia (e.g., bronchitis, viral lower respiratory tract infections, etc.) in patients receiving SYMBICORT 160/4.5 (7.6%) than in those receiving SYMBICORT 80/4.5 (3.2%), formoterol 4.5 mcg (4.6%) or placebo (3.3%). Pneumonia did not occur with greater incidence in the SYMBICORT 160/4.5 group (1.1 %) compared with placebo (1.3%). In a 12-month study of 1,964 patients with COPD, there was also a higher incidence of lung infections other than pneumonia in patients receiving SYMBICORT 160/4.5 (8.1%) than in those receiving SYMBICORT 80/4.5 (6.9%), formoterol 4.5 mcg (7.1%) or placebo (6.2%). Similar to the 6 month study, pneumonia did not occur with greater incidence in the SYMBICORT 160/4.5 group (4.0%) compared with placebo (5.0%).

Immunosuppression

Patients who are on drugs that suppress the immune system are more susceptible to infection than healthy individuals. Chicken pox and measles, for example, can have a more serious or even fatal course in susceptible children or adults using corticosteroids. In such children or adults who have not had these diseases or been properly immunized, particular care should be taken to avoid exposure. How the dose, route, and duration of corticosteroid administration affects the risk of developing a disseminated infection is not known. The contribution of the underlying disease and/or prior corticosteroid treatment to the risk is also not known. If exposed, therapy with varicella zoster immune globulin (VZIG) or pooled intravenous immunoglobulin (IVIG), as appropriate, may be indicated. If exposed to measles, prophylaxis with pooled intramuscular immunoglobulin (IG) may be indicated. (See the respective package inserts for complete VZIG and IG prescribing information.) If chicken pox develops, treatment with antiviral agents may be considered. The immune responsiveness to varicella vaccine was evaluated in pediatric patients with asthma ages 12 months to 8 years with budesonide inhalation suspension.

An open-label, nonrandomized clinical study examined the immune responsiveness to varicella vaccine in 243 asthma patients 12 months to 8 years of age who were treated with budesonide inhalation suspension 0.25 mg to 1 mg daily (n=151) or noncorticosteroid asthma therapy (n=92) (i.e., beta₂-agonists, leukotriene receptor antagonists, cromones). The percentage of patients developing a seroprotective antibody titer of ≥5.0 (gpELISA value) in response to the vaccination was similar in patients treated with budesonide inhalation suspension (85%), compared to patients treated with noncorticosteroid asthma therapy (90%). No patient treated with budesonide inhalation suspension developed chicken pox as a result of vaccination.

Inhaled corticosteroids should be used with caution, if at all, in patients with active or quiescent tuberculosis infections of the respiratory tract; untreated systemic fungal, bacterial, viral, or parasitic infections; or ocular herpes simplex.

Transferring Patients From Systemic Corticosteroid Therapy

Particular care is needed for patients who have been transferred from systemically active corticosteroids to inhaled corticosteroids because deaths due to adrenal insufficiency have occurred in patients with asthma during and after transfer from systemic corticosteroids to less systemically available inhaled corticosteroids. After withdrawal from systemic corticosteroids, a number of months are required for recovery of hypothalamic-pituitary-adrenal (HPA) function.

Patients who have been previously maintained on 20 mg or more per day of prednisone (or its equivalent) may be most susceptible, particularly when their systemic corticosteroids have been almost completely withdrawn. During this period of HPA suppression, patients may exhibit signs and symptoms of adrenal insufficiency when exposed to trauma, surgery, or infection (particularly gastroenteritis) or other conditions associated with severe electrolyte loss. Although SYMBICORT may provide control of asthma symptoms during these episodes, in recommended doses it supplies less than normal physiological amounts of glucocorticoid systemically and does NOT provide the mineralocorticoid activity that is necessary for coping with these emergencies.

During periods of stress or a severe asthma attack, patients who have been withdrawn from systemic corticosteroids should be instructed to resume oral corticosteroids (in large doses) immediately and to contact their physicians for further instruction. These patients should also be instructed to carry a warning card indicating that they may need supplementary systemic corticosteroids during periods of stress or a severe asthma attack.

Patients requiring oral corticosteroids should be weaned slowly from systemic corticosteroid use after transferring to SYMBICORT. Prednisone reduction can be accomplished by reducing the daily prednisone dose by 2.5 mg on a weekly basis during therapy with SYMBICORT. Lung function (mean forced expiratory volume in 1 second [FEV₁] or morning peak expiratory flow [PEF], beta-agonist use, and asthma symptoms should be carefully monitored during withdrawal of oral corticosteroids. In addition to monitoring asthma signs and symptoms, patients should be observed for signs and symptoms of adrenal insufficiency, such as fatigue, lassitude, weakness, nausea and vomiting, and hypotension.

Transfer of patients from systemic corticosteroid therapy to inhaled corticosteroids or SYMBICORT may unmask conditions previously suppressed by the systemic corticosteroid therapy (e.g., rinitis, conjunctivitis, eczema, arthritis, eosinophilic conditions). Some patients may experience symptoms of systemically active corticosteroid withdrawal (e.g., joint and/or muscular pain, lassitude, depression) despite maintenance or even improvement of respiratory function.

Hypocorticism and Adrenal Suppression

Budesonide, a component of SYMBICORT, will often help control asthma symptoms with less suppression of HPA function than therapeutically equivalent oral doses of prednisone. Since budesonide is absorbed into the circulation and can be systemically active at higher doses, the beneficial effects of SYMBICORT in minimizing HPA dysfunction may be expected only when recommended dosages are not exceeded and individual patients are titrated to the lowest effective dose.

Because of the possibility of systemic absorption of inhaled corticosteroids, patients treated with SYMBICORT should be

symptoms, and overt progression on radiography over 3 or more months.

- **Chronic fibrosing pulmonary aspergillosis (CFPA).** Severe, fibrotic destruction of at least two lung lobes as a complication of CCPA, causing a major loss of lung function. Destruction of a single lobe is designated as CCPA of that lobe.

- **Aspergillus nodules.** This unusual presentation is marked by the presence of one or more nodules that may or may not cavitate.

The nodules may resemble tuberculoma, carcinoma of the lung, or coccidioidomycosis; histology is required to make an accurate diagnosis.

- **Subacute invasive aspergillosis (SAIA).** This can occur over the course of 1-3 months in patients who are mildly immunocompromised. Radiologic features can vary, and may include cavitation, the presence of nodules, and progressive consolidation with the appearance of abscess formation. Fungal hyphae (filaments)

can be seen in biopsied lung tissues, and there may be evidence of Aspergillus galactomannan antigen in respiratory fluids or blood.

Treatment

The guidelines note that most of the evidence for managing CPA is based

Continued on following page

SYMBICORT® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol

2

observed carefully for any evidence of systemic corticosteroid effects. Particular care should be taken in observing patients postoperatively or during periods of stress for evidence of inadequate adrenal response.

It is possible that systemic corticosteroid effects such as hypercorticism and adrenal suppression (including adrenal crisis) may appear in a small number of patients, particularly when budesonide is administered at higher than recommended doses over prolonged periods of time. If such effects occur, the dosage of SYMBICORT should be reduced slowly, consistent with accepted procedures for reducing systemic corticosteroids and for management of asthma symptoms.

Drug Interactions With Strong Cytochrome P450 3A4 Inhibitors

Caution should be exercised when considering the coadministration of SYMBICORT with ketoconazole, and other known strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin) because adverse effects related to increased systemic exposure to budesonide may occur [see **DRUG INTERACTIONS** and **CLINICAL PHARMACOLOGY** in full Prescribing Information (12.3)].

Paradoxical Bronchospasm and Upper Airway Symptoms

As with other inhaled medications, SYMBICORT can produce paradoxical bronchospasm, which may be life threatening. If paradoxical bronchospasm occurs following dosing with SYMBICORT, it should be treated immediately with an inhaled, short-acting bronchodilator, SYMBICORT should be discontinued immediately, and alternative therapy should be instituted.

Immediate Hypersensitivity Reactions

Immediate hypersensitivity reactions may occur after administration of SYMBICORT, as demonstrated by cases of urticaria, angioedema, rash, and bronchospasm.

Cardiovascular and Central Nervous System Effects

Excessive beta-adrenergic stimulation has been associated with seizures, angina, hypertension or hypotension, tachycardia with rates up to 200 beats/min, arrhythmias, nervousness, headache, tremor, palpitation, nausea, dizziness, fatigue, malaise, and insomnia [see **OVERDOSAGE**]. Therefore, SYMBICORT, like all products containing sympathomimetic amines, should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension.

Formoterol, a component of SYMBICORT, can produce a clinically significant cardiovascular effect in some patients as measured by pulse rate, blood pressure, and/or symptoms. Although such effects are uncommon after administration of formoterol at recommended doses, if they occur, the drug may need to be discontinued. In addition, beta-agonists have been reported to produce ECG changes, such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The clinical significance of these findings is unknown. Fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs.

Reduction in Bone Mineral Density

Decreases in bone mineral density (BMD) have been observed with long-term administration of products containing inhaled corticosteroids. The clinical significance of small changes in BMD with regard to long-term consequences such as fracture is unknown. Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. Since patients with COPD often have multiple risk factors for reduced BMD, assessment of BMD is recommended prior to initiating SYMBICORT and periodically thereafter. If significant reductions in BMD are seen and SYMBICORT is still considered medically important for that patient's COPD therapy, use of medication to treat or prevent osteoporosis should be strongly considered.

Effects of treatment with SYMBICORT 160/4.5, SYMBICORT 80/4.5, formoterol 4.5, or placebo on BMD was evaluated in a subset of 326 patients (females and males 41 to 88 years of age) with COPD in the 12-month study. BMD evaluations of the hip and lumbar spine regions were conducted at baseline and 52 weeks using dual energy x-ray absorptiometry (DEXA) scans. Mean changes in BMD from baseline to end of treatment were small (mean changes ranged from -0.01 - 0.01 g/cm²). ANCOVA results for total spine and total hip BMD based on the end of treatment time point showed that all geometric LS Mean ratios for the pairwise treatment group comparisons were close to 1, indicating that overall, bone mineral density for total hip and total spine regions for the 12 month time point were stable over the entire treatment period.

Effect on Growth

Orally inhaled corticosteroids may cause a reduction in growth velocity when administered to pediatric patients. Monitor the growth of pediatric patients receiving SYMBICORT routinely (e.g., via stadiometry). To minimize the systemic effects of orally inhaled corticosteroids, including SYMBICORT, titrate each patient's dose to the lowest dosage that effectively controls his/her symptoms [see **DOSE AND ADMINISTRATION** and **USE IN SPECIFIC POPULATIONS**].

Glaucoma and Cataracts

Glaucoma, increased intraocular pressure, and cataracts have been reported in patients with asthma and COPD following the long-term administration of inhaled corticosteroids, including budesonide, a component of SYMBICORT. Therefore, close monitoring is warranted in patients with a change in vision or with history of increased intraocular pressure, glaucoma, and/or cataracts.

Effects of treatment with SYMBICORT 160/4.5, SYMBICORT 80/4.5, formoterol 4.5, or placebo on development of cataracts or glaucoma were evaluated in a subset of 461 patients with COPD in the 12-month study. Ophthalmic examinations were conducted at baseline, 24 weeks, and 52 weeks. There were 26 subjects (6%) with an increase in posterior subcapsular score from baseline to maximum value (>0.7) during the randomized treatment period. Changes in posterior subcapsular scores of >0.7 from baseline to treatment maximum occurred in 11 patients (9.0%) in the SYMBICORT 160/4.5 group, 4 patients (3.8%) in the SYMBICORT 80/4.5 group, 5 patients (4.2%) in the formoterol group, and 6 patients (5.2%) in the placebo group.

Eosinophilic Conditions and Churg-Strauss Syndrome

In rare cases, patients on inhaled corticosteroids may present with systemic eosinophilic conditions. Some of these patients have clinical features of vasculitis consistent with Churg-Strauss syndrome, a condition that is often treated with systemic corticosteroid therapy. These events usually, but not always, have been associated with the reduction and/or withdrawal of oral corticosteroid therapy following the introduction of inhaled corticosteroids. Physicians should be alert to eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy presenting in their patients. A causal relationship between budesonide and these underlying conditions has not been established.

Coexisting Conditions

SYMBICORT, like all medications containing sympathomimetic amines, should be used with caution in patients with convulsive disorders or thyrotoxicosis and in those who are unusually responsive to sympathomimetic amines. Doses of the related beta₂-adrenoceptor agonist albuterol, when administered intravenously, have been reported to aggravate preexisting diabetes mellitus and ketoacidosis.

Hypokalemia and Hyperglycemia

Beta-adrenergic agonist medications may produce significant hypokalemia in some patients, possibly through intracellular shunting, which has the potential to produce adverse cardiovascular effects [see **CLINICAL PHARMACOLOGY** in full Prescribing Information (12.2)]. The decrease in serum potassium is usually transient, not requiring supplementation. Clinically significant changes in blood glucose and/or serum potassium were seen infrequently during clinical studies with SYMBICORT at recommended doses.

ADVERSE REACTIONS

Long-acting beta₂-adrenergic agonists, such as formoterol one of the active ingredients in SYMBICORT, increase the risk of asthma-related death. Currently available data are inadequate to determine whether concurrent use of inhaled corticosteroids or other long-term asthma control drugs mitigates the increased risk of asthma-related death from LABA. Available data from controlled clinical trials suggest that LABA increase the risk of asthma-related hospitalization in pediatric and adolescent patients. Data from a large placebo-controlled US study that compared the safety of another long-acting beta₂-adrenergic agonist (salmeterol) or placebo added to usual asthma therapy showed an increase in asthma-related deaths in patients receiving salmeterol [see **WARNINGS AND PRECAUTIONS**].

Systemic and inhaled corticosteroid use may result in the following:

- *Candida albicans* infection [see **WARNINGS AND PRECAUTIONS**]
- Pneumonia or lower respiratory tract infections in patients with COPD [see **WARNINGS AND PRECAUTIONS**]
- Immunosuppression [see **WARNINGS AND PRECAUTIONS**]
- Hypercorticism and adrenal suppression [see **WARNINGS AND PRECAUTIONS**]
- Growth effects in pediatric patients [see **WARNINGS AND PRECAUTIONS**]
- Glaucoma and cataracts [see **WARNINGS AND PRECAUTIONS**]

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Clinical Trials Experience in Asthma

Patients 12 years and older

The overall safety data in adults and adolescents are based upon 10 active- and placebo-controlled clinical trials in which 3393 patients ages 12 years and older (2052 females and 1341 males) with asthma of varying severity were treated with SYMBICORT 80/4.5 or 160/4.5 mcg taken two inhalations once or twice daily for 12 to 52 weeks. In these trials, the patients on SYMBICORT had a mean age of 38 years and were predominantly Caucasian (82%).

The incidence of common adverse events in Table 1 below is based upon pooled data from three 12-week, double-blind, placebo-controlled clinical studies in which 401 adult and adolescent patients (148 males and 253 females) age 12 years and older were treated with two inhalations of SYMBICORT 80/4.5 or SYMBICORT 160/4.5 twice daily. The SYMBICORT group was composed of mostly Caucasian (84%) patients with a mean age of 38 years, and a mean percent predicted FEV₁ at baseline of 76 and 68 for the 80/4.5 mcg and 160/4.5 mcg treatment groups, respectively. Control arms for comparison included two inhalations of budesonide HFA metered dose inhaler (MDI) 80 or 160 mcg, formoterol dry powder inhaler (DPI) 4.5 mcg, or placebo (MDI and DPI) twice daily. Table 1 includes all adverse events that occurred at an incidence of ≥3% in any one SYMBICORT group and more commonly than in the placebo group with twice-daily dosing. In considering these data, the increased average duration of patient exposure for SYMBICORT patients should be taken into account, as incidences are not adjusted for an imbalance of treatment duration.

Table 1 Adverse reactions occurring at an incidence of ≥3% and more commonly than placebo in the SYMBICORT groups: pooled data from three 12-week, double-blind, placebo-controlled clinical asthma trials in patients 12 years and older

Treatment*	SYMBICORT		Budesonide		Formoterol	Placebo
	80/4.5 mcg N = 277	160/4.5 mcg N = 124	80 mcg N = 121	160 mcg N = 109	4.5 mcg N = 237	N = 400
Adverse Event	%	%	%	%	%	%
Nasopharyngitis	10.5	9.7	14.0	11.0	10.1	9.0
Headache	6.5	11.3	11.6	12.8	8.9	6.5
Upper respiratory tract infection	7.6	10.5	8.3	9.2	7.6	7.8
Pharyngolaryngeal pain	6.1	8.9	5.0	7.3	3.0	4.8
Sinusitis	5.8	4.8	5.8	2.8	6.3	4.8
Influenza	3.2	2.4	6.6	0.9	3.0	1.3
Back pain	3.2	1.6	2.5	5.5	2.1	0.8
Nasal congestion	2.5	3.2	2.5	3.7	1.3	1.0
Stomach discomfort	1.1	6.5	2.5	4.6	1.3	1.8
Vomiting	1.4	3.2	0.8	2.8	1.7	1.0
Oral Candidiasis	1.4	3.2	0	0	0	0.8
Average Duration of Exposure (days)	77.7	73.8	77.0	71.4	62.4	55.9

* All treatments were administered as two inhalations twice daily.

Long-term safety - asthma clinical trials in patients 12 years and older

Long-term safety studies in adolescent and adult patients 12 years of age and older, treated for up to 1 year at doses up to 1280/36 mcg/day (640/18 mcg twice daily), revealed neither clinically important changes in the incidence nor new types of adverse events emerging after longer periods of treatment. Similarly, no significant or unexpected patterns of abnormalities were observed for up to 1 year in safety measures including chemistry, hematology, ECG, Holter monitor, and HPA-axis assessments.

Clinical Trials Experience in Chronic Obstructive Pulmonary Disease

The incidence of common adverse events in Table 2 below is based upon pooled data from two double-blind, placebo-controlled clinical studies (6 and 12 months in duration) in which 771 adult COPD patients (496 males and 275 females) 40 years of age and older were treated with SYMBICORT 160/4.5, two inhalations twice daily. Of these patients 651 were treated for 6 months and 366 were treated for 12 months. The SYMBICORT group was composed of mostly Caucasian (93%) patients with a mean age of 63 years, and a mean percent predicted FEV₁ at baseline of 33%. Control arms for comparison included two inhalations of budesonide HFA (MDI) 160 mcg, formoterol (DPI) 4.5 mcg or placebo (MDI and DPI) twice daily. Table 2 includes all adverse events that occurred at an incidence of ≥3% in the SYMBICORT group and more commonly than in the placebo group. In considering these data, the increased average duration of patient exposure to SYMBICORT should be taken into account, as incidences are not adjusted for an imbalance of treatment duration.

Table 2 Adverse reactions occurring at an incidence of ≥3% and more commonly than placebo in the SYMBICORT group: pooled data from two double-blind, placebo-controlled clinical COPD trials

Treatment*	SYMBICORT	Budesonide	Formoterol	Placebo
	160/4.5 mcg N = 771	160 mcg N = 275	4.5 mcg N = 779	N = 781
Adverse Event	%	%	%	%
Nasopharyngitis	7.3	3.3	5.8	4.9
Oral candidiasis	6.0	4.4	1.2	1.8
Bronchitis	5.4	4.7	4.5	3.5
Sinusitis	3.5	1.5	3.1	1.8
Upper respiratory tract infection viral	3.5	1.8	3.6	2.7
Average Duration of Exposure (days)	255.2	157.1	240.3	223.7

* All treatments were administered as two inhalations twice daily.

Lung infections other than pneumonia (mostly bronchitis) occurred in a greater percentage of subjects treated with SYMBICORT 160/4.5 compared with placebo (7.9% vs. 5.1%, respectively). There were no clinically important or unexpected patterns of abnormalities observed for up to 1 year in chemistry, haematology, ECG, ECG (Holter) monitoring, HPA-axis, bone mineral density and ophthalmology assessments.

Postmarketing Experience

The following adverse reactions have been reported during post-approval use of SYMBICORT. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Some of these adverse reactions may also have been observed in clinical studies with SYMBICORT.

Cardiac disorders: angina pectoris, tachycardia, atrial and ventricular tachyarrhythmias, atrial fibrillation, extrasystoles, palpitations

Endocrine disorders: hypercorticism, growth velocity reduction in pediatric patients

Eye disorders: cataract, glaucoma, increased intraocular pressure

Gastrointestinal disorders: oropharyngeal candidiasis, nausea

Immune system disorders: immediate and delayed hypersensitivity reactions, such as anaphylactic reaction, angioedema, bronchospasm, urticaria, exanthema, dermatitis, pruritus

Metabolic and nutrition disorders: hyperglycemia, hypokalemia

Musculoskeletal, connective tissue, and bone disorders: muscle cramps

Nervous system disorders: tremor, dizziness

Psychiatric disorders: behavior disturbances, sleep disturbances, nervousness, agitation, depression, restlessness

Respiratory, thoracic, and mediastinal disorders: dysphonia, cough, throat irritation

Skin and subcutaneous tissue disorders: skin bruising

Vascular disorders: hypotension, hypertension

DRUG INTERACTIONS

In clinical studies, concurrent administration of SYMBICORT and other drugs, such as short-acting beta₂-agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. No formal drug interaction studies have been performed with SYMBICORT.

Continued from previous page

on cohort studies and case reports, and that there have been no head-to-head trials comparing oral triazoles.

For treatment of CPA, the European guidelines recommend:

- Itraconazole 200 mg twice daily, with therapeutic drug monitoring

and dose adjustment as necessary (Grade A [strong] recommendation).

- Voriconazole 150-200 mg twice daily, with monitoring and dose adjustment. The guidelines recommend lower doses for patients older than 70 years, those with low body weight, significant liver disease, and/or those of Northeast Asian descent, who

may be genetically inclined to slow drug metabolism (Grade A).

- Posaconazole liquid 400 mg twice daily, or tablets 300 mg once daily (Grade B [moderate] recommendation).

In general, the recommended duration of therapy for control of infection in patients with CPA or curative intent for patients with SAIA

or chronic necrotizing pulmonary aspergillosis is 6 months or more, depending on patient status and drug tolerance.

For patients with CPA with progressive disease, those whom therapy has failed, or those who are intolerant of or have disease resistant to triazoles, intravenous therapy with micafungin, 150 mg day (Grade B); amphotericin B deoxycholate, 0.7-1.0 mg/kg per day (Grade C [marginal] recommendation); liposomal amphotericin B, 3 mg/kg per day (Grade B); or caspofungin, 50-70 mg/day (Grade C) are recommended.

The guidelines also recommend surgical excision of simple aspergilloma, preferably by a video-assisted thoracic surgery technique, if technically feasible. "In my own experience, we resort to surgery infrequently," Dr. Edelman said.

He noted that it would be helpful if the guidelines had also allergic bronchopulmonary aspergillosis as a separate entity.

Ideal not always achievable

Prof. Denning points out that the optimum therapies and practices described in the guidelines can't always be implemented.

Worldwide, he said, antifungal therapy is not widely available, with the exception of fluconazole, which has no activity against *Aspergillus*, and is inferior to itraconazole and other extended azoles for other fungal diseases such as histoplasmosis, blastomycosis, and paracoccidiodomycosis.

The price of antifungal therapies can also be a barrier to effective treatment in many parts of the world.

"If you're having to pay for your medicines and you're living on \$5 or \$10 a day in Kenya, say, you can't afford to buy them. So even if the drugs are physically there, it may not be really affordable for a course of therapy for these patients, and there's some advocacy to be done around that for the whole world," he said.

The guidelines were funded primarily by grants from ESCMID and ERS with additional support from ECMM. Authors' travel expenses were funded jointly by ESCMID and ERS. Dr. Denning has received grant support and founder shares in F2G, and has received grants from the Fungal Research Trust, Wellcome Trust, Moulton Trust, Medical Research Council, Chronic Granulomatous Disease Research Trust, National Institute of Allergy and Infectious Diseases, National Institute of Health Research and the European Union, and AstraZeneca. Dr. Edelman reported no relevant disclosures.

SYMBICORT® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol

3

Inhibitors of Cytochrome P450 3A4

The main route of metabolism of corticosteroids, including budesonide, a component of SYMBICORT, is via cytochrome P450 (CYP) isoenzyme 3A4 (CYP3A4). After oral administration of ketoconazole, a strong inhibitor of CYP3A4, the mean plasma concentration of orally administered budesonide increased. Concomitant administration of CYP3A4 may inhibit the metabolism of, and increase the systemic exposure to, budesonide. Caution should be exercised when considering the coadministration of SYMBICORT with long-term ketoconazole and other known strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin) [see **WARNINGS AND PRECAUTIONS**].

Monoamine Oxidase Inhibitors and Tricyclic Antidepressants

SYMBICORT should be administered with caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, because the action of formoterol, a component of SYMBICORT, on the vascular system may be potentiated by these agents. In clinical trials with SYMBICORT, a limited number of COPD and asthma patients received tricyclic antidepressants, and, therefore, no clinically meaningful conclusions on adverse events can be made.

Beta-Adrenergic Receptor Blocking Agents

Beta-blockers (including eye drops) may not only block the pulmonary effect of beta-agonists, such as formoterol, a component of SYMBICORT, but may produce severe bronchospasm in patients with asthma. Therefore, patients with asthma should not normally be treated with beta-blockers. However, under certain circumstances, there may be no acceptable alternatives to the use of beta-adrenergic blocking agents in patients with asthma. In this setting, cardioselective beta-blockers could be considered, although they should be administered with caution.

Diuretics

The ECG changes and/or hypokalemia that may result from the administration of non-potassium-sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. Although the clinical significance of these effects is not known, caution is advised in the coadministration of SYMBICORT with non-potassium-sparing diuretics.

USE IN SPECIFIC POPULATIONS

Pregnancy

Teratogenic Effects: Pregnancy Category C.

There are no adequate and well-controlled studies of SYMBICORT in pregnant women. SYMBICORT was teratogenic and embryocidal in rats. Budesonide alone was teratogenic and embryocidal in rats and rabbits, but not in humans at therapeutic doses. Formoterol fumarate alone was teratogenic in rats and rabbits. Formoterol fumarate was also embryocidal, increased pup loss at birth and during lactation, and decreased pup weight in rats. SYMBICORT should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

SYMBICORT

In a reproduction study in rats, budesonide combined with formoterol fumarate by the inhalation route at doses approximately 1/7 and 1/3, respectively, the maximum recommended human daily inhalation dose on a mg/m² basis produced umbilical hernia. No teratogenic or embryocidal effects were detected with budesonide combined with formoterol fumarate by the inhalation route at doses approximately 1/32 and 1/16, respectively, the maximum recommended human daily inhalation dose on a mg/m² basis.

Budesonide

Studies of pregnant women have not shown that inhaled budesonide increases the risk of abnormalities when administered during pregnancy. The results from a large population-based prospective cohort epidemiological study reviewing data from three Swedish registries covering approximately 99% of the pregnancies from 1995-1997 (ie, Swedish Medical Birth Registry; Registry of Congenital Malformations; Child Cardiology Registry) indicate no increased risk for congenital malformations from the use of inhaled budesonide during early pregnancy. Congenital malformations were studied in 2014 infants born to mothers reporting the use of inhaled budesonide for asthma in early pregnancy (usually 10-12 weeks after the last menstrual period), the period when most major organ malformations occur. The rate of recorded congenital malformations was similar compared to the general population rate (3.8% vs 3.5%, respectively). In addition, after exposure to inhaled budesonide, the number of infants born with orofacial clefts was similar to the expected number in the normal population (4 children vs 3.3, respectively).

These same data were utilized in a second study bringing the total to 2534 infants whose mothers were exposed to inhaled budesonide. In this study, the rate of congenital malformations among infants whose mothers were exposed to inhaled budesonide during early pregnancy was not different from the rate for all newborn babies during the same period (3.6%).

Budesonide produced fetal loss, decreased pup weight, and skeletal abnormalities at subcutaneous doses in rabbits less than the maximum recommended human daily inhalation dose on a mcg/m² basis and in rats at doses approximately 6 times the maximum recommended human daily inhalation dose on a mcg/m² basis. In another study in rats, no teratogenic or embryocidal effects were seen at inhalation doses up to 3 times the maximum recommended human daily inhalation dose on a mcg/m² basis.

Experience with oral corticosteroids since their introduction in pharmacologic as opposed to physiologic doses suggests that rodents are more prone to teratogenic effects from corticosteroids than humans.

Formoterol

Formoterol fumarate has been shown to be teratogenic, embryocidal, to increase pup loss at birth and during lactation, and to decrease pup weights in rats when given at oral doses 1400 times and greater the maximum recommended human daily inhalation dose on a mcg/m² basis. Umbilical hernia was observed in rat fetuses at oral doses 1400 times and greater the maximum recommended human daily inhalation dose on a mcg/m² basis. Brachygnathia was observed in rat fetuses at an oral dose 7000 times the maximum recommended human daily inhalation dose on a mcg/m² basis. Pregnancy was prolonged at an oral dose 7000 times the maximum recommended human daily inhalation dose on a mcg/m² basis. In another study in rats, no teratogenic effects were seen at inhalation doses up to 500 times the maximum recommended human daily inhalation dose on a mcg/m² basis.

Subcapsular cysts on the liver were observed in rabbit fetuses at an oral dose 54,000 times the maximum recommended human daily inhalation dose on a mcg/m² basis. No teratogenic effects were observed at oral doses up to 3200 times the maximum recommended human daily inhalation dose on a mcg/m² basis.

Nonteratogenic Effects

Hypoadrenalism may occur in infants born of mothers receiving corticosteroids during pregnancy. Such infants should be carefully observed.

Labor and Delivery

There are no well-controlled human studies that have investigated the effects of SYMBICORT on preterm labor or labor at term. Because of the potential for beta-agonist interference with uterine contractility, use of SYMBICORT for management of asthma during labor should be restricted to those patients in whom the benefits clearly outweigh the risks.

Nursing Mothers

Since there are no data from controlled trials on the use of SYMBICORT by nursing mothers, a decision should be made whether to discontinue nursing or to discontinue SYMBICORT, taking into account the importance of SYMBICORT to the mother. Budesonide, like other corticosteroids, is secreted in human milk. Data with budesonide delivered via dry powder inhaler indicates that the total daily oral dose of budesonide available in breast milk to the infant is approximately 0.3% to 1% of the dose inhaled by the mother [see **CLINICAL PHARMACOLOGY, Pharmacokinetics** in full Prescribing Information (12.3)]. For SYMBICORT, the dose of budesonide available to the infant in breast milk, as a percentage of the maternal dose, would be expected to be similar.

In reproductive studies in rats, formoterol was excreted in the milk. It is not known whether formoterol is excreted in human milk.

Pediatric Use

Safety and effectiveness of SYMBICORT in asthma patients 12 years of age and older have been established in studies up to 12 months. In the two 12-week, double-blind, placebo-controlled US pivotal studies 25 patients 12 to 17 years of age were treated with SYMBICORT twice daily [see **CLINICAL STUDIES** in full Prescribing Information (14.1)]. Efficacy results in this age group were similar to those observed in patients 18 years and older. There were no obvious differences in the type or frequency of adverse events reported in this age group compared with patients 18 years of age and older.

The safety and effectiveness of SYMBICORT in asthma patients 6 to <12 years of age has not been established. Overall 1447 asthma patients 6 to <12 years of age participated in placebo- and active-controlled SYMBICORT studies. Of these 1447 patients, 539 received SYMBICORT twice daily. The overall safety profile of these patients was similar to that observed in patients ≥12 years of age who also received SYMBICORT twice daily in studies of similar design.

Controlled clinical studies have shown that orally inhaled corticosteroids including budesonide, a component of SYMBICORT, may cause a reduction in growth velocity in pediatric patients. This effect has been observed in the absence of laboratory evidence of HPA-axis suppression, suggesting that growth velocity is a more sensitive indicator of systemic corticosteroid exposure in pediatric patients than some commonly used tests of HPA-axis function. The long-term effect of this reduction in growth velocity associated with orally inhaled corticosteroids, including the impact on final height are unknown. The potential for "catch-up" growth following discontinuation of treatment with orally inhaled corticosteroids has not been adequately studied.

In a study of asthmatic children 5-12 years of age, those treated with budesonide DPI 200 mcg twice daily (n=311) had a 1.1 centimeter reduction in growth compared with those receiving placebo (n=418) at the end of one year; the difference between these two treatment groups did not increase further over three years of additional treatment. By the end of 4 years, children treated with budesonide DPI and children treated with placebo had similar growth velocities. Conclusions drawn from this study may be confounded by the unequal use of corticosteroids in the treatment groups and inclusion of data from patients attaining puberty during the course of the study.

The growth of pediatric patients receiving orally inhaled corticosteroids, including SYMBICORT, should be monitored. If a child or adolescent on any corticosteroid appears to have growth suppression, the possibility that he/she is particularly sensitive to this effect should be considered. The potential growth effects of prolonged treatment should be weighed against the clinical benefits obtained. To minimize the systemic effects of orally inhaled corticosteroids, including SYMBICORT, each patient should be titrated to the lowest strength that effectively controls his/her asthma [see **DOSE AND ADMINISTRATION**].

Geriatric Use

Of the total number of patients in asthma clinical studies treated with SYMBICORT twice daily, 149 were 65 years of age or older, of whom 25 were 75 years of age or older.

In the COPD studies of 6 to 12 months duration, 349 patients treated with SYMBICORT 160/4.5 twice daily were 65 years old and above and of those, 73 patients were 75 years of age and older. No overall differences in safety or effectiveness were observed between these patients and younger patients, and other reported clinical experience has not identified differences in responses between the elderly and younger patients.

As with other products containing beta₂-agonists, special caution should be observed when using SYMBICORT in geriatric patients who have concomitant cardiovascular disease that could be adversely affected by beta₂-agonists.

Based on available data for SYMBICORT or its active components, no adjustment of dosage of SYMBICORT in geriatric patients is warranted.

Hepatic Impairment

Formal pharmacokinetic studies using SYMBICORT have not been conducted in patients with hepatic impairment. However, since both budesonide and formoterol fumarate are predominantly cleared by hepatic metabolism, impairment of liver function may lead to accumulation of budesonide and formoterol fumarate in plasma. Therefore, patients with hepatic disease should be closely monitored.

Renal Impairment

Formal pharmacokinetic studies using SYMBICORT have not been conducted in patients with renal impairment.

OVERDOSAGE

SYMBICORT

SYMBICORT contains both budesonide and formoterol; therefore, the risks associated with overdosage for the individual components described below apply to SYMBICORT. In pharmacokinetic studies, single doses of 960/54 mcg (12 actuations of SYMBICORT 80/4.5) and 1280/36 mcg (8 actuations of 160/4.5), were administered to patients with COPD. A total of 1920/54 mcg (12 actuations of SYMBICORT 160/4.5) was administered as a single dose to both healthy subjects and patients with asthma. In a long-term active-controlled safety study in asthma patients, SYMBICORT 160/4.5 was administered for up to 12 months at doses up to twice the highest recommended daily dose. There were no clinically significant adverse reactions observed in any of these studies.

Clinical signs in dogs that received a single inhalation dose of SYMBICORT (a combination of budesonide and formoterol) in a dry powder included tremor, mucosal redness, nasal catarrh, redness of intact skin, abdominal respiration, vomiting, and salivation; in the rat, the only clinical sign observed was increased respiratory rate in the first hour after dosing. No deaths occurred in rats given a combination of budesonide and formoterol at acute inhalation doses of 97 and 3 mg/kg, respectively (approximately 1200 and 1350 times the maximum recommended human daily inhalation dose on a mcg/m² basis). No deaths occurred in dogs given a combination of budesonide and formoterol at the acute inhalation doses of 732 and 22 mcg/kg, respectively (approximately 30 times the maximum recommended human daily inhalation dose of budesonide and formoterol on a mcg/m² basis).

Budesonide

The potential for acute toxic effects following overdose of budesonide is low. If used at excessive doses for prolonged periods, systemic corticosteroid effects such as hypercorticism may occur [see **WARNINGS AND PRECAUTIONS**]. Budesonide at five times the highest recommended dose (3200 mcg daily) administered to humans for 6 weeks caused a significant reduction (27%) in the plasma cortisol response to a 6-hour infusion of ACTH compared with placebo (+1%). The corresponding effect of 10 mg prednisone daily was a 35% reduction in the plasma cortisol response to ACTH.

In mice, the minimal inhalation lethal dose was 100 mg/kg (approximately 600 times the maximum recommended human daily inhalation dose on a mcg/m² basis). In rats, there were no deaths following the administration of an inhalation dose of 68 mg/kg (approximately 900 times the maximum recommended human daily inhalation dose on a mcg/m² basis). The minimal oral lethal dose in mice was 200 mg/kg (approximately 1300 times the maximum recommended human daily inhalation dose on a mcg/m² basis) and less than 100 mg/kg in rats (approximately 1300 times the maximum recommended human daily inhalation dose on a mcg/m² basis).

Formoterol

An overdose of formoterol would likely lead to an exaggeration of effects that are typical for beta₂-agonists: seizures, angina, hypertension, hypotension, tachycardia, atrial and ventricular tachyarrhythmias, nervousness, headache, tremor, palpitations, muscle cramps, nausea, dizziness, sleep disturbances, metabolic acidosis, hyperglycemia, hypokalemia. As with all sympathomimetic medications, cardiac arrest and even death may be associated with abuse of formoterol. No clinically significant adverse reactions were seen when formoterol was delivered to adult patients with acute bronchoconstriction at a dose of 90 mcg/day over 3 hours or to stable asthmatics 3 times a day at a total dose of 54 mcg/day for 3 days.

Treatment of formoterol overdose consists of discontinuation of the medication together with institution of appropriate symptomatic and/or supportive therapy. The judicious use of a cardioselective beta-receptor blocker may be considered, bearing in mind that such medication can produce bronchospasm. There is insufficient evidence to determine if dialysis is beneficial for overdosage of formoterol. Cardiac monitoring is recommended in cases of overdosage.

No deaths were seen in mice given formoterol at an inhalation dose of 276 mg/kg (more than 62,200 times the maximum recommended human daily inhalation dose on a mcg/m² basis). In rats, the minimum lethal inhalation dose was 40 mg/kg (approximately 18,000 times the maximum recommended human daily inhalation dose on a mcg/m² basis). No deaths were seen in mice that received an oral dose of 2000 mg/kg (more than 450,000 times the maximum recommended human daily inhalation dose on a mcg/m² basis). Maximum nonlethal oral doses were 252 mg/kg in young rats and 1500 mg/kg in adult rats (approximately 114,000 times and 675,000 times the maximum recommended human inhalation dose on a mcg/m² basis).

SYMBICORT is a trademark of the AstraZeneca group of companies.

© AstraZeneca 2008, 2009, 2010, 2012

Manufactured for: AstraZeneca LP, Wilmington, DE 19850

By: AstraZeneca Dunkerque Production, Dunkerque, France

Product of France

Rev. 5/12 2839500 8/13

AstraZeneca

Using the new game-changing heart failure drugs

BY BRUCE JANCIN
Frontline Medical News

SNOWMASS, COLO. – Ivabradine and sacubitril/valsartan are paradigm-changing drugs approved last year for the treatment of heart failure with reduced ejection fraction – and it's entirely reasonable to begin using them now in the appropriate patients, Dr. Akshay S. Desai said at the Annual Cardiovascular Conference at Snowmass.

The impressive positive results seen in the pivotal trials for these novel agents – the SHIFT trial for ivabradine (Corlanor) and PARADIGM-HF for sacubitril/valsartan (Entresto) – have rocked the heart failure world.

The studies showed that, in the right patients, these two medications improve heart failure morbidity and mortality significantly beyond what's achievable with the current gold standard, guideline-directed medical therapy.

That's exciting because even though great therapeutic strides have been made during the past 15 years, symptomatic patients with heart failure with reduced ejection fraction (HFrEF) treated with optimal guideline-directed pharmacotherapy still have substantial residual risk for heart failure hospitalization and death, noted Dr. Desai, director of heart failure disease management at Brigham and Women's Hospital in Boston.

The U.S. heart failure guidelines panel hasn't yet addressed the use of either of these recently approved drugs, but Dr. Desai provided his best sense of the data and how to start using them now.

Ivabradine and sacubitril/valsartan are first-in-class agents with novel mechanisms. Ivabradine's demonstrated safety and efficacy in the SHIFT trial confirmed the hypothesis that elevated heart rate is a legitimate therapeutic target in HFrEF.

Sacubitril/valsartan, an angiotensin II receptor/neprilysin inhibitor, provides what is to date a unique ability to enhance the activity of endogenous vasoactive peptides, including natriuretic peptides, bradykinin, substance P, adrenomedullin, and calcitonin gene-related peptide.

These peptides are antifibrotic, antihypertrophic, and they promote vasodilation and diuresis, thus counteracting the adverse effects of neurohormonal activation. But in HFrEF, these vasoactive peptides are less active and patients are less sensitive to them.

Ivabradine

This selective sinus node inhibitor decreases heart rate and has essentially no other effects. The drug has been available for years in Europe, and the European Society of Cardiology (ESC) has had sufficient time to integrate ivabradine into its guidelines for pharmacotherapy in HFrEF.

The ESC treatment algorithm for HFrEF (Eur Heart J. 2012 Jul;33[14]:1787-847) is built upon a foundation of thiazide diuretics to relieve signs and symptoms of congestion along with a beta-blocker and an ACE inhibitor or angiotensin receptor blocker (ARB). In a patient who still has New York Heart Association class II-IV symptoms after those drugs are titrated to guideline-recommended target levels or maximally tolerated doses, a mineralocorticoid receptor antagonist – either spironolactone or eplerenone – is added. And, in a patient who still remains symptomatic, has a left ventricular ejection fraction of 35% or less, is in sinus rhythm, and has a heart rate of 70 beats per minute or more, it's time to consider adding ivabradine.

"This is how our own guidelines may elect to incorporate ivabradine, but of course, we don't know yet," Dr. Desai observed.

In the randomized, double-blind SHIFT trial involving 6,558 HFrEF patients who fit the description of ivabradine candidates described in the ESC guidelines, those who received ivabradine titrated to a maximum of 7.5 mg twice daily experienced a 26% reduction in hospital admissions for worsening heart failure, compared with placebo, a 26% reduction in deaths from heart failure, and fewer adverse events than the control group (Lancet. 2010 Sep 11;376[9744]:875-85).

The important question is who should get ivabradine and who should just get a little more beta-blocker in order to slow the heart rate. The fact is, many heart failure patients simply can't tolerate the guideline-recommended target dose of beta-blocker therapy, which is 12.5 mg twice daily of carvedilol or its equivalent. Indeed, only 26% of SHIFT participants were able to do so.

"My interpretation of the SHIFT trial is that the goal is to reduce heart rate by any means necessary; preferentially, with a beta-blocker, and with ivabradine as an adjunct in patients who can't get to target doses," the cardiologist said.

Sacubitril/valsartan

In the landmark double-blind, 8,442-patient PARADIGM-HF trial, the group randomized to sacubitril/valsartan had a 20% reduction in the primary endpoint of cardiovascular death or heart failure hospitalization over 27 months of follow-up, compared with controls on enalapril at the guideline-recommended dose of 10 mg twice a day. The number needed to treat (NNT) was 21. Moreover, all-cause mortality was reduced by 16% (N Engl J Med. 2014 Sep 11;37[11]:993-1004).

In a recent follow-up cause of death analysis, Dr. Desai and his co-investigators reported that 81% of all deaths in PARADIGM-HF were cardiovascular in nature. The NNT for sacubitril/valsartan in order to prevent one cardiovascular death was 32. The risk of sudden cardiac death



Lower heart rate; preferentially, with a beta-blocker, and with ivabradine as an adjunct if needed.

DR. DESAI

was reduced by 80%, while the risk of death due to worsening heart failure was decreased by 21% (Eur Heart J 2015 Aug 7;36[30]:1990-7).

In another secondary analysis from the PARADIGM-HF investigators, the use of the angiotensin receptor/neprilysin inhibitor was shown to prevent clinical progression of surviving patients with heart failure much more effectively than enalapril. The sacubitril/valsartan group was 34% less likely to have an emergency department visit for worsening heart failure, 18% less likely to require intensive care, and 22% less likely to receive an implantable heart failure device or undergo cardiac transplantation. The reduction in the rate of heart failure hospitalization became significant within the first 30 days (Circulation. 2015 Jan 6;131[1]:54-61).

Moreover, the absolute benefit of sacubitril/valsartan in PARADIGM-HF was consistent across the full spectrum of patient risk (J Am Coll Cardiol. 2015 Nov 10;66[19]:2059-71).

To put this into perspective, Dr. Desai continued, for every 1,000 HFrEF patients switched from an ACE inhibitor or ARB to sacubitril/valsartan, the absolute benefit over the course of 27 months includes 31

fewer cardiovascular deaths, 28 fewer hospitalizations for heart failure, and 37 fewer hospitalizations for any reason.

"This is potent therapy for patients with HFrEF who have the right phenotype," he observed.

While substitution of sacubitril/valsartan for an ACE inhibitor or ARB may be appropriate in many patients with chronic HFrEF who continue to have NYHA Class II-IV symptoms on guideline-directed medical therapy, several caveats apply, according to Dr. Desai.

It's important to be aware of the PARADIGM-HF eligibility criteria, because it's only in patients who fit that profile that sacubitril/valsartan provides evidence-based therapy. There are as yet no data to support the drug's use in patients with new-onset HFrEF, acute decompensated HFrEF, in patients who are immediately post-MI, or in those with advanced chronic kidney disease, he emphasized.

"I think you have to be mindful of eligibility because the label that's applied to this drug is basically 'patients with HFrEF who are treated with guideline-directed medical therapy.' There's no specific requirement that you follow the detailed eligibility criteria of the PARADIGM-HF trial, but you should realize that the drug is known to be effective only in patients who fit the PARADIGM-HF eligibility profile," he said.

Dr. Desai gave a few clinical pearls for prescribing sacubitril/valsartan.

For most patients, the initial recommended dose is 49/51 mg twice daily. In those with low baseline blood pressure and tenuous hemodynamics, it's appropriate to initiate therapy at 24/26 mg BID.

It's important to halt ACE inhibitor therapy 36 hours prior to starting sacubitril/valsartan so as to avoid overlap and consequent increased risk of angioedema.

And while serum n-terminal pro-hormone brain natriuretic peptide (NT-proBNP) remains a useful biomarker to monitor heart rate severity and response to treatment while a patient is on sacubitril/valsartan, BNP is not because serum levels of that biomarker rise with neprilysin inhibition.

Dr. Desai reported receiving research support from Novartis and St. Jude Medical and serving as a consultant to those companies as well as Merck and Relaysa.

BE IN THE




What is the role of nitric oxide (NO) in PAH and CTEPH?

- PAH and CTEPH are associated with **impaired synthesis of NO**, endothelial dysfunction, and insufficient stimulation of the NO-sGC-cGMP pathway
- **Intracellular cyclic guanosine monophosphate (cGMP)** plays an important role in regulating processes that influence vascular tone, proliferation, fibrosis, and inflammation

Adempas stimulates sGC regardless of NO level to produce more cGMP

- Adempas **sensitizes** soluble guanylate cyclase (sGC) to endogenous NO by stabilizing sGC-NO binding
- Adempas directly **stimulates** sGC independently of NO via a different binding site
- Increased cGMP leads to **vasodilation**



INDICATIONS

- Adempas (riociguat) tablets are indicated for the treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH), (WHO Group 4) after surgical treatment, or inoperable CTEPH, to improve exercise capacity and WHO functional class.
- Adempas is indicated for the treatment of adults with pulmonary arterial hypertension (PAH), (WHO Group 1), to improve exercise capacity, WHO functional class and to delay clinical worsening.*

Efficacy was shown in patients on Adempas monotherapy or in combination with endothelin receptor antagonists or prostanoids. Studies establishing effectiveness included predominantly patients with WHO functional class II–III and etiologies of idiopathic or heritable PAH (61%) or PAH associated with connective tissue diseases (25%).

*Time to clinical worsening was a combined endpoint defined as death (all-cause mortality), heart/lung transplantation, atrial septostomy, hospitalization due to persistent worsening of pulmonary hypertension, start of new PAH-specific treatment, persistent decrease in 6MWD and persistent worsening of WHO functional class.

IMPORTANT SAFETY INFORMATION

WARNING: EMBRYO-FETAL TOXICITY

Do not administer Adempas (riociguat) tablets to a pregnant female because it may cause fetal harm.

Females of reproductive potential: Exclude pregnancy before the start of treatment, monthly during treatment, and 1 month after stopping treatment. Prevent pregnancy during treatment and for one month after stopping treatment by using acceptable methods of contraception.

For all female patients, Adempas is available only through a restricted program called the Adempas Risk Evaluation and Mitigation Strategy (REMS) Program.

CONTRAINDICATIONS

Adempas is contraindicated in:

- Pregnancy. Adempas may cause fetal harm when administered to a pregnant woman. Adempas was consistently shown to have teratogenic effects when administered to animals. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus
- Co-administration with nitrates or nitric oxide donors (such as amyl nitrite) in any form.

Please see additional Important Safety Information, including Boxed Warning, throughout and Brief Summary of Prescribing Information at end of advertisement.

Take your PAH and CTEPH patients farther with Adempas



In pulmonary arterial hypertension (PAH), (WHO Group 1)

36m improvement (mean) in 6-minute walk distance (6MWD) over placebo at Week 12 (95% Confidence Interval (CI): 20m-52m; $p < 0.0001$)

Randomized, multicenter, placebo-controlled clinical study of 443 adult PAH patients with predominantly WHO Functional Class II-III. The primary endpoint was change from baseline in 6MWD at 12 weeks.

In inoperable and persistent/recurrent chronic thromboembolic hypertension (CTEPH), (WHO Group 4)

46m improvement (mean) in 6MWD over placebo at Week 16 (95% CI: 25m-67m; $p < 0.0001$)

Randomized, multicenter, placebo-controlled clinical study of 261 adult patients with persistent/recurrent CTEPH after surgery or who were inoperable. The primary endpoint was change from baseline in 6MWD at 16 weeks.

CONTRAINDICATIONS (continued)

- Concomitant administration with specific phosphodiesterase-5 (PDE-5) inhibitors (such as sildenafil, tadalafil, or vardenafil) or nonspecific PDE inhibitors (such as dipyridamole or theophylline).

WARNINGS AND PRECAUTIONS

Embryo-Fetal Toxicity. Adempas may cause fetal harm when administered during pregnancy and is contraindicated for use in women who are pregnant. In females of reproductive potential, exclude pregnancy prior to initiation of therapy, advise use of acceptable contraception and obtain monthly pregnancy tests. For females, Adempas is only available through a restricted program under the Adempas REMS Program.

Adempas REMS Program. Females can only receive Adempas through the Adempas REMS Program, a restricted distribution program.

Important requirements of the Adempas REMS program include the following:

- Prescribers must be certified with the program by enrolling and completing training.
- All females, regardless of reproductive potential, must enroll in the Adempas REMS Program prior to initiating Adempas. Male patients are not enrolled in the Adempas REMS Program.
- Female patients of reproductive potential must comply with the pregnancy testing and contraception requirements.
- Pharmacies must be certified with the program and must only dispense to patients who are authorized to receive Adempas.

Further information, including a list of certified pharmacies, is available at www.AdempasREMS.com or 1-855-4ADEMPAS.

Hypotension. Adempas reduces blood pressure. Consider the potential for symptomatic hypotension or ischemia in patients with hypovolemia, severe left ventricular outflow obstruction, resting hypotension, autonomic dysfunction, or concomitant treatment with antihypertensives or strong CYP and P-gp/BCRP inhibitors. Consider a dose reduction if patient develops signs or symptoms of hypotension.

BAYER, the Bayer Cross, and Adempas are registered trademarks of Bayer.



Bayer HealthCare LLC
100 Bayer Boulevard, Whippany, NJ 07981 USA
©2015 Bayer HealthCare Inc.
PP-400-US-1777 May 2015

Bleeding. In the placebo-controlled clinical trials, serious bleeding occurred in 2.4% of patients taking Adempas compared to 0% of placebo patients. Serious hemoptysis occurred in 5 (1%) patients taking Adempas compared to 0 placebo patients, including one event with fatal outcome. Serious hemorrhagic events also included 2 patients with vaginal hemorrhage, 2 with catheter site hemorrhage, and 1 each with subdural hematoma, hematemesis, and intra-abdominal hemorrhage.

Pulmonary Veno-Occlusive Disease. Pulmonary vasodilators may significantly worsen the cardiovascular status of patients with pulmonary veno-occlusive disease (PVOD). Therefore, administration of Adempas to such patients is not recommended. Should signs of pulmonary edema occur, the possibility of associated PVOD should be considered and if confirmed, discontinue treatment with Adempas.

MOST COMMON ADVERSE REACTIONS

- The most common adverse reactions occurring more frequently ($\geq 3\%$) on Adempas than placebo were headache (27% vs 18%), dyspepsia/gastritis (21% vs 8%), dizziness (20% vs 13%), nausea (14% vs 11%), diarrhea (12% vs 8%), hypotension (10% vs 4%), vomiting (10% vs 7%), anemia (7% vs 2%), gastroesophageal reflux disease (5% vs 2%), and constipation (5% vs 1%).
- Other events that were seen more frequently in Adempas compared to placebo and potentially related to treatment were: palpitations, nasal congestion, epistaxis, dysphagia, abdominal distension and peripheral edema.

For important risk and use information, please see the Brief Summary of the full Prescribing Information, including Boxed Warning, on the next page.

Visit Adempas-US.com



ADEMPAS (riociguat) tablets, for oral use

Initial U.S. Approval: 2013

BRIEF SUMMARY of PRESCRIBING INFORMATION

For additional information, please see the full Prescribing Information at www.adempas-us.com.

WARNING: EMBRYO-FETAL TOXICITY

See full prescribing information for complete boxed warning

- Do not administer Adempas to a pregnant female because it may cause fetal harm. (4.1, 5.1, 8.1)
- Females of reproductive potential: Exclude pregnancy before start of treatment, monthly during treatment, and 1 month after treatment discontinuation. Prevent pregnancy during treatment and for one month after treatment discontinuation by use of acceptable methods of contraception. (2.3, 5.1, 5.2, 8.6)
- For females, Adempas is available only through a restricted program called the Adempas REMS Program. (5.1, 5.2).

1 INDICATIONS AND USAGE

1.1 Chronic-Thromboembolic Pulmonary Hypertension

Adempas is indicated for the treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH), (WHO Group 4) after surgical treatment, or inoperable CTEPH, to improve exercise capacity and WHO functional class [see Clinical Studies (14.1)].

1.2 Pulmonary Arterial Hypertension

Adempas is indicated for the treatment of adults with pulmonary arterial hypertension (PAH), (WHO Group 1), to improve exercise capacity, WHO functional class and to delay clinical worsening.

Efficacy was shown in patients on Adempas monotherapy or in combination with endothelin receptor antagonists or prostanoids. Studies establishing effectiveness included predominately patients with WHO functional class II–III and etiologies of idiopathic or heritable PAH (61%) or PAH associated with connective tissue diseases (25%) [see Clinical Studies (14.2)].

4 CONTRAINDICATIONS

4.1 Pregnancy

Adempas may cause fetal harm when administered to a pregnant woman. Adempas is contraindicated in females who are pregnant. Adempas was consistently shown to have teratogenic effects when administered to animals. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus [see Use in Specific Populations (8.1)].

4.2 Nitrates and Nitric Oxide Donors

Co-administration of Adempas with nitrates or nitric oxide donors (such as amyl nitrite) in any form is contraindicated [see Drug Interactions (7.1) and Clinical Pharmacology (12.2)].

4.3 Phosphodiesterase Inhibitors

Concomitant administration of Adempas with specific PDE-5 inhibitors (such as sildenafil, tadalafil, or vardenafil) or nonspecific PDE inhibitors (such as dipyridamole or theophylline) is contraindicated [see Drug Interactions (7.1) and Clinical Pharmacology (12.2)].

5 WARNINGS AND PRECAUTIONS

5.1 Embryo-Fetal Toxicity

Adempas may cause fetal harm when administered during pregnancy and is contraindicated for use in women who are pregnant. In females of reproductive potential, exclude pregnancy prior to initiation of therapy, advise use of acceptable contraception and obtain monthly pregnancy tests. For females, Adempas is only available through a restricted program under the Adempas REMS Program [see Dosage and Administration (2.3), Warnings and Precautions (5.2) and Use in Specific Populations (8.1, 8.6)].

5.2 Adempas REMS Program

Females can only receive Adempas through the Adempas Risk Evaluation and Mitigation Strategy (REMS) Program, a restricted distribution program [see Warnings and Precautions (5.1)].

Important requirements of the Adempas REMS Program include the following:

- Prescribers must be certified with the program by enrolling and completing training.
- All females, regardless of reproductive potential, must enroll in the Adempas REMS Program prior to initiating Adempas. Male patients are not enrolled in the Adempas REMS Program.
- Female patients of reproductive potential must comply with the pregnancy testing and contraception requirements [see Use in Specific Populations (8.6)].
- Pharmacies must be certified with the program and must only dispense to patients who are authorized to receive Adempas.

Further information, including a list of certified pharmacies, is available at www.AdempasREMS.com or 1-855-4 ADEMPAS.

5.3 Hypotension

Adempas reduces blood pressure. Consider the potential for symptomatic hypotension or ischemia in patients with hypovolemia, severe left ventricular

outflow obstruction, resting hypotension, autonomic dysfunction, or concomitant treatment with antihypertensives or strong CYP and P-gp/BCRP inhibitors [see Drug Interactions (7.2) and Clinical Pharmacology (12.3)]. Consider a dose reduction if patient develops signs or symptoms of hypotension.

5.4 Bleeding

In the placebo-controlled clinical trials, serious bleeding occurred in 2.4% of patients taking Adempas compared to 0% of placebo patients. Serious hemoptysis occurred in 5 (1%) patients taking Adempas compared to 0 placebo patients, including one event with fatal outcome. Serious hemorrhagic events also included 2 patients with vaginal hemorrhage, 2 with catheter site hemorrhage, and 1 each with subdural hematoma, hematemesis, and intra-abdominal hemorrhage.

5.5 Pulmonary Veno-Occlusive Disease

Pulmonary vasodilators may significantly worsen the cardiovascular status of patients with pulmonary veno-occlusive disease (PVOD). Therefore, administration of Adempas to such patients is not recommended. Should signs of pulmonary edema occur, the possibility of associated PVOD should be considered and, if confirmed, discontinue treatment with Adempas.

6 ADVERSE REACTIONS

The following serious adverse reactions are discussed elsewhere in the labeling:

- Embryo-Fetal Toxicity [see Warnings and Precautions (5.1)]
- Hypotension [see Warnings and Precautions (5.3)]
- Bleeding [see Warnings and Precautions (5.4)]

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety data described below reflect exposure to Adempas in two, randomized, double blind, placebo-controlled trials in patients with inoperable or recurrent/persistent CTEPH (CHEST-1) and treatment naive or pre-treated PAH patients (PATENT-1). The population (Adempas: n = 490; Placebo: n = 214) was between the age of 18 and 80 years [See Clinical Studies (14.1, 14.2)].

The safety profile of Adempas in patients with inoperable or recurrent/persistent CTEPH (CHEST-1) and treatment naive or pre-treated PAH (PATENT-1) were similar. Therefore, adverse drug reactions (ADRs) identified from the 12 and 16 week placebo-controlled trials for PAH and CTEPH respectively were pooled, and those occurring more frequently on Adempas than placebo ($\geq 3\%$) are displayed in Table 1 below. Most adverse reactions in Table 1 can be ascribed to the vasodilatory mechanism of action of Adempas.

The overall rates of discontinuation due to an adverse event in the pivotal placebo-controlled trials were 2.9% for Adempas and 5.1% for placebo (pooled data).

Table 1: Adverse Reactions Occurring More Frequently ($\geq 3\%$) on Adempas than Placebo (Pooled from CHEST-1 and PATENT-1)

Adverse Reactions	Adempas % (n=490)	Placebo % (n=214)
Headache	27	18
Dyspepsia and Gastritis	21	8
Dizziness	20	13
Nausea	14	11
Diarrhea	12	8
Hypotension	10	4
Vomiting	10	7
Anemia (including laboratory parameters)	7	2
Gastroesophageal reflux disease	5	2
Constipation	5	1

Other events that were seen more frequently in Adempas compared to placebo and potentially related to treatment were: palpitations, nasal congestion, epistaxis, dysphagia, abdominal distension and peripheral edema. With longer observation in uncontrolled long-term extension studies the safety profile was similar to that observed in the placebo controlled phase 3 trials.

7 DRUG INTERACTIONS

7.1 Pharmacodynamic Interactions with Adempas

Nitrates: Co-administration of Adempas with nitrates or nitric oxide donors (such as amyl nitrite) in any form is contraindicated because of hypotension [see Contraindications (4.2) and Clinical Pharmacology (12.2)].

PDE Inhibitors: Co-administration of Adempas with specific PDE-5 inhibitors (such as sildenafil, tadalafil, or vardenafil) and nonspecific PDE inhibitors (such as dipyridamole or theophylline), is contraindicated because of hypotension [see Contraindications (4.3) and Clinical Pharmacology (12.2)]. Clinical experience with co-administration of Adempas and

other phosphodiesterase inhibitors (for example, milrinone, cilostazole, roflumilast) is limited.

7.2 Pharmacokinetic Interactions with Adempas

Smoking: Plasma concentrations in smokers are reduced by 50-60% compared to nonsmokers. Based on pharmacokinetic modeling, for patients who are smokers, doses higher than 2.5 mg three times a day may be considered in order to match exposure seen in nonsmoking patients. Safety and effectiveness of Adempas doses higher than 2.5 mg three times a day have not been established. A dose reduction should be considered in patients who stop smoking [see *Dosage and Administration (2.4)* and *Clinical Pharmacology (12.3)*].

Strong CYP and P-gp/BCRP inhibitors: Concomitant use of riociguat with strong cytochrome CYP inhibitors and P-gp/BCRP inhibitors such as azole antimycotics (for example, ketoconazole, itraconazole) or HIV protease inhibitors (such as ritonavir) increase riociguat exposure and may result in hypotension. Consider a starting dose of 0.5 mg 3 times a day when initiating Adempas in patients receiving strong CYP and P-gp/BCRP inhibitors. Monitor for signs and symptoms of hypotension on initiation and on treatment with strong CYP and P-gp/BCRP inhibitors. A dose reduction should be considered in patients who may not tolerate the hypotensive effect of riociguat [see *Dosage and Administration (2.5)*, *Warnings and Precautions (5.3)* and *Clinical Pharmacology (12.3)*].

Strong CYP3A inducers: Strong inducers of CYP3A (for example, rifampin, phenytoin, carbamazepine, phenobarbital or St. John's Wort) may significantly reduce riociguat exposure. Data are not available to guide dosing of riociguat when strong CYP3A inducers are co-administered [see *Clinical Pharmacology (12.3)*].

Antacids: Antacids such as aluminum hydroxide/magnesium hydroxide decrease riociguat absorption and should not be taken within 1 hour of taking Adempas [see *Clinical Pharmacology (12.3)*].

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Pregnancy Category X

Risk Summary

Adempas may cause fetal harm when administered to a pregnant woman and is contraindicated during pregnancy. Adempas was teratogenic and embryotoxic in rats at doses with exposures to unbound drug that were approximately 8 times and 2 times, respectively, the human exposure. In rabbits, riociguat led to abortions at 4 times the human exposure and fetal toxicity with exposures approximately 13 times the human exposure. If Adempas is used in pregnancy, or if the patient becomes pregnant while taking this drug, apprise the patient of the potential hazard to the fetus [see *Boxed Warning and Contraindications (4.1)*].

Animal Data

In rats administered riociguat orally (1, 5, and 25 mg/kg/day) throughout organogenesis, an increased rate of cardiac ventricular-septal defect was observed at the highest dose tested. The highest dose produced evidence of maternal toxicity (reduced body weight). Post-implantation loss was statistically significantly increased from the mid-dose of 5 mg/kg/day. Plasma exposure at the lowest dose in which no adverse effects were observed is approximately 0.4 times that in humans at the maximally recommended human dose (MRHD) of 2.5 mg three times a day based on area under the time-concentration curve (AUC) for unbound drug in rat and humans. Plasma exposure at the highest dose (25 mg/kg/day) is approximately 8 times that in humans at the MRHD while exposure at the mid-dose (5 mg/kg/day) is approximately 2 times that in humans at the MRHD. In rabbits given doses of 0.5, 1.5 and 5 mg/kg/day, an increase in spontaneous abortions was observed starting at the middle dose of 1.5 mg/kg, and an increase in resorptions was observed at 5 mg/kg/day. Plasma exposures at these doses were 4 times and 13 times, respectively, the human exposure at the MRHD.

8.3 Nursing Mothers

It is not known if Adempas is present in human milk. Riociguat or its metabolites were present in the milk of rats. Because many drugs are present in human milk and because of the potential for serious adverse reactions in nursing infants from riociguat, discontinue nursing or Adempas.

8.4 Pediatric Use

Safety and effectiveness of Adempas in pediatric patients have not been established [see *Nonclinical Toxicology (13.2)*].

8.5 Geriatric Use

Of the total number of subjects in clinical studies of Adempas, 23% were 65 and over, and 6% were 75 and over [see *Clinical Studies (14)*]. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

Elderly patients showed a higher exposure to Adempas [see *Clinical Pharmacology (12.3)*].

8.6 Females and Males of Reproductive Potential

Pregnancy Testing: Female patients of reproductive potential must have a negative pregnancy test prior to starting treatment with Adempas, monthly during treatment, and one month after discontinuation of treatment with

Adempas. Advise patients to contact their healthcare provider if they become pregnant or suspect they may be pregnant. Counsel patients on the risk to the fetus [see *Boxed Warning, Dosage and Administration (2.3)* and *Use in Specific Populations (8.1)*].

Contraception: Female patients of reproductive potential must use acceptable methods of contraception during treatment with Adempas and for 1 month after treatment with Adempas. Patients may choose one highly effective form of contraception (intrauterine devices [IUD], contraceptive implants or tubal sterilization) or a combination of methods (hormone method with a barrier method or two barrier methods). If a partner's vasectomy is the chosen method of contraception, a hormone or barrier method must be used along with this method. Counsel patients on pregnancy planning and prevention, including emergency contraception, or designate counseling by another healthcare provider trained in contraceptive counseling [see *Boxed Warning*].

8.7 Renal Impairment

Safety and efficacy have not been demonstrated in patients with creatinine clearance <15 mL/min or on dialysis [see *Clinical Pharmacology (12.3)*].

8.8 Hepatic Impairment

Safety and efficacy have not been demonstrated in patients with severe hepatic impairment (Child Pugh C) [see *Clinical Pharmacology (12.3)*].

10 OVERDOSAGE

In cases of overdose, blood pressure should be closely monitored and supported as appropriate. Based on extensive plasma protein binding, riociguat is not expected to be dialyzable.

17 PATIENT COUNSELING INFORMATION

See FDA-approved patient labeling (Medication Guide).

Embryo-Fetal Toxicity

Instruct patients on the risk of fetal harm when Adempas is used during pregnancy [see *Warnings and Precautions (5.1)* and *Use in Specific Populations (8.1)*]. Instruct females of reproductive potential to use effective contraception and to contact her physician immediately if they suspect they may be pregnant. Female patients must enroll in the Adempas REMS Program.

Adempas REMS Program

For female patients, Adempas is available only through a restricted program called the Adempas REMS Program [see *Warnings and Precautions (5.2)*]. Male patients are not enrolled in the Adempas REMS Program.

Inform female patients (and their guardians, if applicable) of the following important requirements:

- All female patients must sign an enrollment form.
- Advise female patients of reproductive potential that she must comply with the pregnancy testing and contraception requirements [see *Use in Specific Populations (8.6)*].
- Educate and counsel females of reproductive potential on the use of emergency contraception in the event of unprotected sex or contraceptive failure.
- Advise pre-pubertal females to report any changes in their reproductive status immediately to her prescriber.

Review the Medication Guide and REMS educational materials with female patients.

Other Risks Associated with Adempas

- Inform patients of the contraindication of Adempas with nitrates or nitric oxide donors or PDE-5 inhibitors.
- Advise patients about the potential risks/signs of hemoptysis and to report any potential signs of hemoptysis to their physicians.
- Instruct patients on the dosing, titration, and maintenance of Adempas.
- Advise patients regarding activities that may impact the pharmacology of Adempas (strong multi pathway CYP inhibitors and P-gp/BCRP inhibitors and smoking). Patients should report all current medications and new medications to their physician.
- Advise patients that antacids should not be taken within 1 hour of taking Adempas.
- Inform patients that Adempas can cause dizziness, which can affect the ability to drive and use machines [see *Adverse Reactions (6.1)*]. They should be aware of how they react to Adempas, before driving or operating machinery and if needed, consult their physician.

Manufactured for:



Bayer HealthCare

Bayer HealthCare Pharmaceuticals Inc.
Whippany, NJ 07981

Manufactured in Germany

Issued May 2014

©2013 Bayer HealthCare Pharmaceuticals Inc.

6710501BS

SLEEP STRATEGIES: The sleep apnea care delivery paradigm

BY DR. VAISHNAVI KUNDEL AND DR. NEOMI SHAH, MPH

Epidemiology and diagnostics of OSA

Sleep disorders are increasingly prevalent in the United States and are associated with reduced quality of life, increased health-care utilization, and numerous medical and psychiatric disorders (Edinger et al. *Sleep*. 2016;39[1]:237). The most common sleep disorder in the United States is obstructive sleep apnea (OSA). The major risk factor for OSA is obesity. As the obesity epidemic has grown, the prevalence of OSA has also increased (Romero-Corral et al. *Chest*. 2010;137[3]:711), and the need for sleep testing has, therefore, risen dramatically. OSA is traditionally diagnosed using attended in-laboratory polysomnography (PSG) conducted overnight. It requires special equipment, dedicated software for data processing, and trained technicians to conduct and later score the sleep study. A trained sleep medicine physician then interprets the data and provides a diagnosis.



DR. KUNDEL



DR. SHAH

A brief overview of the ACA


The Affordable Care Act (ACA) strives to provide high quality, affordable health care to all Americans. In our current health-care delivery model, primary care providers (PCPs) are often not involved with subspecialists in a coordinated process. This has resulted in fragmented patient care, leading to increased health-care delivery costs. In contrast, the ACA is gearing toward the patient-centered medical home (PCMH) model, where PCPs are at the heart of health-care deliv-

ery and provide comprehensive, patient-centered, coordinated care (Davis et al. *J Gen Intern Med*. 2011;26[10]:1201). The expression “medical neighborhood” is increasingly more popular where the PCMH is surrounded by specialty clinics and ancillary service providers with primary care at the core (Huang et al. *N Engl J Med*. 2014;370[15]:1376). Therefore, it is obvious that primary care will be an integral part of health-care delivery in the years to come, as opposed to current circumstances where primary care accounts for only 6% to 7% of total health-care spending (Phillips et al. *Health Affairs*. 2010;29[5]:806).

Impact of the ACA on sleep medicine delivery

With the provisions of the ACA now in place, its impact on sleep medicine delivery is substantial. Despite the increasing prevalence of sleep disorders, the sleep medicine field faces numerous challenges in sleep disorders diagnostics and management. It has confronted implementation of sizeable cuts in reimbursement rates for in-lab PSG. As a result, use of home sleep testing (HST) has increased rapidly. HST is a cost-effective alternative to in-lab testing and provides an expedited route of care for patients who usually have to wait months for in-lab PSG appointments in sleep centers (Masa et al. *Sleep*. 2013;36[12]:1799). The American Academy of Sleep Medicine (AASM) has endorsed HST as an alternative method to diagnosing OSA among appropriately screened individuals; however, it must be conducted in conjunction with a comprehensive clinical sleep assessment (Collop et al. *J Clin Sleep Med*. 2007;3[7]:737). Therefore, having a sleep program at the center of this process (vs independent

Patient-centered medical home model for integrated sleep care



FRONTLINE MEDICAL NEWS

referrals to home sleep testing companies) is crucial for enforcement of the HST parameters established by the AASM.

Yet, PCPs – in order to comply with insurance company requirements – often refer patients needing evaluation for OSA for HST via an independent HST company that does not have a comprehensive sleep program. These patients are then prescribed automated treatment devices without appropriate education or access to follow-up with experienced sleep providers. This leaves PCPs, who often have limited training and access to sleep medicine resources, to manage problems with sleep apnea treatment devices, subsequently resulting in poor compliance to treatment and fragmented care (Pack. *Chest*. 2015;148[2]:306). Therefore, it is imperative to identify segments in our current sleep practice model that require restructuring, and provide a model inspired by ACA provisions to improve sleep care delivery.

Why move toward the PCMH?

Several studies have shown that primary care-led care for moderate to severe sleep apnea is not inferior when compared with care provided by sleep specialists. In one study (Antic et al. *Am J Respir Crit Care Med*. 2009;179:501), patients with suspected moderate-to-severe OSA were assigned to receive care from an experienced nurse, specialized in sleep disorders management, vs sleep-physician-directed care and laboratory PSG to confirm the diagnosis of OSA. Results showed that the simplified model of care was not inferior to the specialist sleep physician-led model, with no significant difference in continuous positive airway pressure (CPAP) adherence or Epworth Sleepiness Scale (ESS) score between the two groups. Costs were significantly less in the simplified model. Another study showed that primary care management of OSA in patients with moderate to severe

Continued on page 22



MEGAFLOPP/THINKSTOCK



NOW APPROVED

Nucala[®] 
(mepolizumab)
for Subcutaneous Injection
100 mg/vial

Visit **NUCALAinfo.com**
for additional information,
including full Prescribing Information.

www.GSKSource.com

Continued from page 20

OSA was not inferior to specialist management with regards to the change in ESS and showed no difference in OSA symptoms, adherence to CPAP, patient satisfaction, and health-care costs between the two groups (Chai-Coetzer et al. *JAMA*. 2013;309[10]:997). It is crucial to note, however, that although PCPs and community nurses were encouraged to take primary responsibility for patient management, prior experience, training, and education in sleep disorders management, as well as access to sleep specialists, were imperative in producing good outcomes in these studies.

A more recent study tested a collaborative care model, integrating sleep specialists with PCPs to enhance patients' sleep disorders management. Patients with sleep complaints in the intervention group underwent a one-time consultation with a sleep specialist who provided diagnostic feedback and treatment recommendations to the patient and his/her PCP, in contrast to the control group consisting of usual primary care (UPC). Results showed that provider-initiated sleep-focused interventions were significantly higher in the inter-

vention group for PSG and mental health clinic referrals. Intervention recipients also showed increases in sleep efficiency and improved ESS scores at the 10-month follow-up. This demonstrates that a one-time sleep consultation, with access to, and oversight from, a specialist sleep center can serve to increase health-care providers' attention to sleep problems. Subsequently, it increases sleep disorders screening and diagnosis and results in benefits to patients' sleep/wake symptoms (Edinger et al. *Sleep*. 2016;39[1]:237).

Integration of sleep centers and primary care

As noted above, the quality of sleep medicine-related care that patients are receiving under our current model is suboptimal. In order to better fit the requirements of the ACA and provide integrated and coordinated sleep medicine care for our patients, we must consider refining our model of sleep medicine delivery by taking the steps below:

- Encourage partnership of sleep centers with primary care services to develop an integrated care paradigm for sleep medicine by placing PCPs at the center of our sleep care delivery model.
- Educate PCPs on the importance

of sleep health, and provide them with appropriate access to resources for sleep testing.

- Allow PCPs to refer patients to a comprehensive sleep program that will be integrated in a PCMH model, providing HST, which will discourage referrals to independent home testing companies that do not offer comprehensive care.

- Strengthen and expand our sleep medicine teams within sleep centers and primary care centers by integrating trained nurse practitioners and physician assistants, who can serve as a resource for PCPs, and reduce fragmentation of care, thereby reducing costs of unnecessary testing.

Conclusions

In summary, the ACA has and will continue to impact sleep care delivery in the United States. An integrated sleep care model will result in not only meaningful improvements in the quality of sleep disorders care, but it will also help diagnose a vastly underdiagnosed condition. It will do so via a PCP-based model, providing access to sleep providers and sleep testing, yet it will encourage and educate the PCP to screen and treat noncomplex sleep disorders in their own practices. Below, we provide an example of this model. Patients via

this model will have appropriate access to comprehensive sleep care that will reduce fragmentation of care. This PCMH sleep model is necessary in this post-ACA era that demands primary care provider-based, coordinated, high quality care.

Dr. Kundel and Dr. Shah are with the Division of Pulmonary, Critical Care, and Sleep Medicine, Icahn School of Medicine at Mount Sinai, New York, NY; and Dr. Shah is with the Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY.

It's a Brand New Day for CHEST Logo Products



> Purchase at: chestcollection.com





AVAILABLE NOW

New Coding Resource



An updated edition of *Coding for Chest Medicine*



New in the 2016 edition:


- Complex Chronic Care Services
- Examples With ICD-10-CM coding
- Advance Care Planning Services
- EBUS Services
- ECMO Services
- Clarification for 94640 inhalation treatments

Coding for Chest Medicine 2016 is an ideal resource for physicians, nonphysician providers, practice administrators/managers, office managers, and business managers, and this edition will contain important updates for pulmonologists, pediatricians, and interventional bronchoscopists.



Expand Your Ultrasonography Skills

Innovation, Simulation, and Training Center
Glenview, Illinois



Build your critical care ultrasonography skills with courses designed to help you in diagnosis and management of critically ill patients. Advance your practice, and enhance patient care through hands-on training by experts in the field of ultrasonography.

Ultrasonography: Essentials in Critical Care

December 3-5, 2015 • March 11-13, 2016

Discover key elements of critical care ultrasonography in this intensive 3-day course. Practice image acquisition with human models using high quality ultrasound machines.

Critical Care Ultrasonography: Integration Into Clinical Practice

May 5-7, 2016

Study whole body ultrasonography for diagnosis and management of the critical ill patient in a hands-on learning environment using human models and state-of-the-art simulators.

Advanced Critical Care Echocardiography

June 2-4, 2016

Focus on practical elements of advanced critical care echocardiography through hands-on training. Learn practical measurement skills relevant to the diagnosis and management of patients with cardiopulmonary failure.

NEW! Transesophageal Echocardiography

June 5, 2016

Learn critical care transesophageal echocardiography (TEE) image acquisition through the use of high fidelity TEE simulators in small group training sessions.



> Register Now chestnet.org/live-learning

Who Should Attend?

Frontline intensivists, pulmonary/critical care specialists, and fellows; hospitalists; emergency medicine/critical care, anesthesia/critical care, and surgical/critical care fellows; physicians; nurse practitioners; and physician assistants are encouraged to attend.

Prenatal vitamin D failed to prevent wheezing

BY MARY ANN MOON
Frontline Medical News

Among pregnant women at high risk for having a child with asthma, high doses of vitamin D administered during the third trimester failed to prevent persistent wheezing illness in their children at age 3, according to two separate reports published online Jan. 26 in JAMA.

Both studies were conducted because vitamin D insufficiency during pregnancy is commonplace and is thought to affect fetal immune programming and to contribute to asthma pathogenesis. In addition, observational studies have found an association between low levels of vitamin D in cord blood and later asthma in the child.

The two randomized, double-blind placebo-controlled clinical trials found that neither 2,800 IU/day nor 4,400 IU/day of vitamin D significantly reduced the risk of persistent

The percentage of women with sufficient levels of vitamin D after the intervention was 81% in the vitamin D group, compared with 44% in the control group.

wheeze in the offspring through 3 years of age. However, both research groups noted that their studies may have been underpowered to detect a clinically important protective effect, and both recommended longer-term observation of their study participants, as well as further studies using larger sample sizes, higher doses of vitamin D, administration earlier in pregnancy, and postnatal supplementation to establish a definitive result.

In the first study – conducted as part of the Copenhagen Prospective Studies on Asthma in Childhood 2010 cohort – 623 Danish women already taking the standard 400 IU of vitamin D₃ during pregnancy were randomly assigned to receive an additional 2,400 IU (315 women) or a matching placebo (308 women) from 22 to 26 weeks' gestation until delivery. After exclusions, researchers analyzed data on 581 children.

Maternal serum vitamin D levels increased markedly in the active-treatment group. The percentage of women with sufficient levels of vitamin D (greater than 30 ng/mL) after the intervention was 81% in the vitamin D group, compared with

44% in the control group, wrote Dr. Bo L. Chawes of Copenhagen Prospective Studies on Asthma in Childhood, University of Copenhagen, and his associates.

Persistent wheeze developed in 104 (18%) of the 581 children: 47 (16%) in the vitamin D group and 57 (20%) in the control group, a nonsignificant difference.

Similarly, asthma was diagnosed in 79 children: 32 (12%) in the vitamin D group and 47 (14%) in the control group, another nonsignificant difference.

Vitamin D supplementation also made no difference in infants' levels of C-reactive protein, interleukin-6, tumor necrosis factor- α , or CXCL8, nor in the number of upper respiratory tract infections (5.2 per year vs 5.3 per year), the number of lower respiratory tract infections (32% vs 33%), the risk of allergic sensitization as measured by skin prick test or specific IgE level, or the development of eczema (23% vs 25%).

However, the risk of persistent wheeze was higher in children whose mothers' vitamin D levels were lowest, compared with those whose mothers' vitamin D levels were in the middle and upper tertiles. And high-dose vitamin D was protective with regard to some secondary endpoints, such as preventing more episodes of "troublesome lung symptoms" (5.9 vs. 7.2).

This finding, together with the study's somewhat reduced statistical power, mean that a clinically important protective effect cannot be ruled out.

In addition, the supplementation dose may have been too low or may have been given too late in the course of pregnancy to produce a significant effect, Dr. Chawes and his associates wrote (JAMA. 2016;315[4]:353-61. doi: 10.1001/jama.2015.18318).

In the second study – the Vitamin D Antenatal Asthma Reduction Trial – 876 pregnant women in Boston, St. Louis, and San Diego who were already taking the standard 400 IU of vitamin D were randomly assigned to receive either an additional 4,000 IU/day (440 participants) or a matching placebo (436 participants).

Maternal levels of vitamin D rose markedly in the active-treatment group (mean, 39.2 ng/mL), compared with the control group (mean, 26.8 ng/mL), and the proportion of women who achieved higher than "inadequate" levels was much greater (74.9% vs 34.0%), reported Dr.



VIEW ON THE NEWS

Sobering results

These are sobering findings. Even if we assume that prenatal vitamin D supplementation will prove more protective as the children in these studies grow older, vitamin D insufficiency still would explain only a small portion of the current asthma epidemic.

But neither study showed any unwanted effects from supplementation, so it seems reasonable for clinicians to prescribe vitamin D to mothers at high risk of having children with asthma by virtue of their own asthma, eczema, or allergic rhinitis – especially if those mothers are deficient in vitamin D. However, the data in these two

clinical trials do not support the use of very high-dose vitamin D, since any beneficial effects achieved with 4,400 IU/day were identical to those achieved with approximately half as high a dose.

Dr. Erika von Mutius is at Ludwig Maximilians University, Munich. Dr. Fernando D. Martinez is at the asthma and airway disease research center and the department of pediatrics at the University of Arizona, Tucson. Both reported having no relevant financial disclosures. Their remarks are adapted from an editorial accompanying the two reports (JAMA 2016;315[4]:347-8.).

Augusto A. Litonjua of Brigham and Women's Hospital, Boston, and his associates.

A total of 24.3% of the vitamin D group and 30.4% of the control group developed asthma or recurrent wheeze by age 3 years, a nonsignificant difference. However, the incidence of asthma was so much lower than anticipated in both study groups that the study may have lost statistical power to detect a clinically meaningful difference, according to the investigators (JAMA. 2016;315[4]:362-70. doi: 10.1001/jama.2015.18589).

It remains unclear whether vitamin D supplementation during pregnancy will reduce asthma and persistent wheezing in the offspring. "Larger studies and longer follow-up of the children in this study will be needed to answer the question," the investi-

gators wrote. "If additional studies identify a significant effect, given the high prevalence of low vitamin D levels in pregnant women, the effect of this inexpensive intervention on child health could be substantial."

The first study was supported by the Copenhagen Prospective Study on Asthma in Childhood, which is funded by private and public research groups. One of the coauthors reported receiving consulting fees from Chiesi. The Vitamin D Antenatal Asthma Reduction Trial was supported by the U.S. National Heart, Lung, and Blood Institute and the National Centers for Advancing Translational Sciences. The lead author, Dr. Litonjua, reported receiving personal fees from UpToDate and Springer Humana Press; his associates reported ties to numerous industry sources.

For reducing the risk of exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations

BEFORE ONE EXACERBATION CAN LEAD TO ANOTHER, ADD DALIRESP



INDICATION AND USAGE

DALIRESP® (roflumilast) is indicated as a treatment to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations. DALIRESP is not a bronchodilator and is not indicated for the relief of acute bronchospasm.

IMPORTANT SAFETY INFORMATION

Contraindications

DALIRESP® (roflumilast) is contraindicated in patients with moderate to severe liver impairment (Child-Pugh B or C).

Warnings and Precautions

- DALIRESP is not a bronchodilator and should not be used for the relief of acute bronchospasm
- Prescribers should advise patients, their caregivers, and families to be alert for the emergence or worsening of insomnia, anxiety, depression, suicidal thoughts or other mood changes, and if such changes occur, to contact their healthcare provider. Prescribers should carefully evaluate the risks and benefits of continuing treatment if such events occur. Before using

DALIRESP in patients with a history of depression and/or suicidal thoughts or behavior, prescribers should carefully weigh the risks and benefits of treatment with DALIRESP


- Treatment with DALIRESP is associated with an increase in psychiatric adverse reactions. In controlled clinical trials 5.9% of patients treated with DALIRESP reported psychiatric adverse reactions vs 3.3% treated with placebo. The most common psychiatric adverse reactions were insomnia (2.4% vs 1.0%), anxiety (1.4% vs 0.9%), and depression (1.2% vs 0.9%). Three patients treated with DALIRESP experienced suicide-related adverse reactions (one completed suicide and two suicide attempts) compared to one patient (suicidal ideation) treated with placebo
- Patients should have their weight monitored regularly. If unexplained or clinically significant weight loss occurs, weight loss should be evaluated and treatment discontinuation considered
 - In addition to weight loss being reported as a common adverse reaction (7.5% of patients treated with DALIRESP vs 2.1% placebo), weight was prospectively assessed in two 1-year clinical trials. In these studies that compared DALIRESP to placebo, 20% vs 7% experienced moderate

The first and only once-daily tablet to provide enhanced protection against COPD exacerbations*²

- DALIRESP is not a bronchodilator and should not be used for the relief of acute bronchospasm

In the two 1-year pivotal studies:

Significantly reduced the rate of moderate or severe exacerbations[†] on top of current bronchodilator therapy^{‡3}



weight loss (5-10% of body weight) and 7% vs 2% experienced severe weight loss (>10% body weight). During the follow-up period after discontinuing DALIRESP, the majority of patients regained some of the weight they had lost

- Use with strong cytochrome P450 enzyme inducers (eg, rifampicin, phenobarbital, carbamazepine, phenytoin) is not recommended, as they decrease the exposure and may reduce the therapeutic effectiveness of DALIRESP

Adverse Reactions

In clinical trials, the most common adverse reactions ($\geq 2\%$ and greater than placebo) were diarrhea (9.5% vs 2.7%), weight loss (7.5% vs 2.1%), nausea (4.7% vs 1.4%), headache (4.4% vs 2.1%), back pain (3.2% vs 2.2%), influenza (2.8% vs 2.7%), insomnia (2.4% vs 1.0%), dizziness (2.1% vs 1.1%), and decreased appetite (2.1% vs 0.4%).

Please see Brief Summary on the following page.

* In the two 1-year pivotal studies, DALIRESP was added to bronchodilators, including long-acting β_2 agonists (LABA), or short-acting muscarinic antagonists (SAMA), and short-acting β_2 agonists (SABA).

[†] Moderate exacerbations were defined as those requiring treatment with systemic corticosteroids, and severe exacerbations were defined as those resulting in hospitalization or death.

[‡] Patients were allowed to be on LABA or SAMA at stable doses. SABA was allowed for rescue use. In the pooled analysis, the use of concomitant bronchodilators in the placebo group vs DALIRESP group were: LABA (51% vs 49%), SAMA (37% vs 35%), and SABA (99% vs 100%).

Study design: A pooled analysis of two identical, 1-year, double-blind, placebo-controlled studies of 3091 patients with severe COPD associated with chronic bronchitis and a history of exacerbations compared DALIRESP (n=1537) and placebo (n=1554). Subjects were current or ex-smokers with a smoking history of >20 pack-years, aged >40 with a clinical diagnosis of COPD with chronic cough and sputum production. The study included a 4-week run-in period followed by a 1-year treatment period. Subjects could use SABAs as needed and could continue treatment with LABAs or SAMAs at stable doses. The studies were designed to assess the rate of moderate or severe COPD exacerbations and the change from baseline in pre-bronchodilator FEV₁.

References: 1. Hurst JR, Donaldson GC, Quint JK, Goldring JJP, Baghai-Ravary R, Wedzicha JA. Temporal clustering of exacerbations in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med.* 2009;179:369-374. 2. DALIRESP Prescribing Information. Wilmington, DE; AstraZeneca Pharmaceuticals LP; November 2015. 3. Calverley PMA, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ; for the M2-124 and M2-125 Study Groups. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. *Lancet.* 2009;374:685-694.


Daliresp
 (roflumilast) tablets
 500 mcg

DALIRESP® (roflumilast) tablets

Brief Summary of Prescribing Information.

For complete prescribing information consult official package insert.

INDICATIONS AND USAGE

DALIRESP® is indicated as a treatment to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations.

Limitations of Use

DALIRESP is not a bronchodilator and is not indicated for the relief of acute bronchospasm.

DOSAGE AND ADMINISTRATION

The recommended dose of DALIRESP is one 500 microgram (mcg) tablet per day, with or without food.

CONTRAINDICATIONS

The use of DALIRESP is contraindicated in the following condition:

Moderate to severe liver impairment (Child-Pugh B or C) [*see Clinical Pharmacology (12.3) and Use in Specific Populations (8.6) in the full Prescribing Information*].

WARNINGS AND PRECAUTIONS

Treatment of Acute Bronchospasm

DALIRESP is not a bronchodilator and should not be used for the relief of acute bronchospasm.

Psychiatric Events including Suicidality

Treatment with DALIRESP is associated with an increase in psychiatric adverse reactions. In 8 controlled clinical trials 5.9% (263) of patients treated with DALIRESP 500 mcg daily reported psychiatric adverse reactions compared to 3.3% (137) treated with placebo. The most commonly reported psychiatric adverse reactions were insomnia, anxiety, and depression which were reported at higher rates in those treated with DALIRESP 500 mcg daily (2.4%, 1.4%, and 1.2% for DALIRESP versus 1.0%, 0.9%, and 0.9% for placebo, respectively) [*see Adverse Reactions (6.1) in the full Prescribing Information*]. Instances of suicidal ideation and behavior, including completed suicide, have been observed in clinical trials. Three patients experienced suicide-related adverse reactions (one completed suicide and two suicide attempts) while receiving DALIRESP compared to one patient (suicidal ideation) who received placebo. Cases of suicidal ideation and behavior, including completed suicide, have been observed in the post-marketing setting in patients with or without a history of depression.

Before using DALIRESP in patients with a history of depression and/or suicidal thoughts or behavior, prescribers should carefully weigh the risks and benefits of treatment with DALIRESP in such patients. Patients, their caregivers, and families should be advised of the need to be alert for the emergence or worsening of insomnia, anxiety, depression, suicidal thoughts or other mood changes, and if such changes occur to contact their healthcare provider. Prescribers should carefully evaluate the risks and benefits of continuing treatment with DALIRESP if such events occur.

Weight Decrease

Weight loss was a common adverse reaction in DALIRESP clinical trials and was reported in 7.5% (331) of patients treated with DALIRESP 500 mcg once daily compared to 2.1% (89) treated with placebo [*see Adverse Reactions (6.1) in the full Prescribing Information*]. In addition to being reported as adverse reactions, weight was prospectively assessed in two placebo-controlled clinical trials of one year duration. In these studies, 20% of patients receiving roflumilast experienced moderate weight loss (defined as between 5–10% of body weight) compared to 7% of patients who received placebo. In addition, 7% of patients who received roflumilast compared to 2% of patients receiving placebo experienced severe (>10% body weight) weight loss. During follow-up after treatment discontinuation, the majority of patients with weight loss regained some of the weight they had lost while receiving DALIRESP. Patients treated with DALIRESP should have their weight monitored regularly. If unexplained or clinically significant weight loss occurs, weight loss should be evaluated, and discontinuation of DALIRESP should be considered.

Drug Interactions

A major step in roflumilast metabolism is the N-oxidation of roflumilast to roflumilast N-oxide by CYP3A4 and CYP1A2. The administration of the cytochrome P450 enzyme inducer rifampicin resulted in a reduction in exposure, which may result in a decrease in the therapeutic effectiveness of DALIRESP. Therefore, the use of strong cytochrome P450 enzyme inducers (e.g. rifampicin, phenobarbital, carbamazepine, phenytoin) with DALIRESP is not recommended [*see Drugs that Induce Cytochrome P450 (CYP) Enzymes (7.1) and Clinical Pharmacology (12.3) in the full Prescribing Information*].

ADVERSE REACTIONS

The following adverse reactions are described in greater detail in other sections:

- Psychiatric Events Including Suicidality [*see Warnings and Precautions (5.2) in the full Prescribing Information*]
- Weight Decrease [*see Warnings and Precautions (5.3) in the full Prescribing Information*]

Adverse Reactions in Clinical Studies

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety data described below reflect exposure of 4438 patients to DALIRESP 500 mcg once daily in four 1-year placebo-controlled trials, two 6-month placebo-controlled trials, and two 6-month drug add-on trials [*see Clinical Studies (14.1)*]. In these trials, 3136 and 1232 COPD patients were exposed to DALIRESP 500 mcg once daily for 6 months and 1-year, respectively.

The population had a median age of 64 years (range 40–91), 73% were male, 92.9% were Caucasian, and had COPD with a mean pre-bronchodilator forced expiratory volume in one second (FEV₁) of 8.9 to 89.1% predicted. In these trials, 68.5% of the patients treated with DALIRESP reported an adverse reaction compared with 65.3% treated with placebo.

The proportion of patients who discontinued treatment due to adverse reaction was 14.8% for DALIRESP-treated patients and 9.9% for placebo-treated patients. The most common adverse reactions that led to discontinuation of DALIRESP were diarrhea (2.4%) and nausea (1.6%).

Serious adverse reactions, whether considered drug-related or not by the investigators, which occurred more frequently in DALIRESP-treated patients include diarrhea, atrial fibrillation, lung cancer, prostate cancer, acute pancreatitis, and acute renal failure.

Table 1 summarizes the adverse reactions reported by ≥2% of patients in the DALIRESP group in 8 controlled COPD clinical trials.

Table 1: Adverse Reactions Reported by ≥2% of Patients Treated with DALIRESP 500 mcg daily and Greater Than Placebo

Adverse Reactions (Preferred Term)	Treatment	
	DALIRESP (N=4438)	Placebo (N=4192)
	n (%)	n (%)
Diarrhea	420 (9.5)	113 (2.7)
Weight decreased	331 (7.5)	89 (2.1)
Nausea	209 (4.7)	60 (1.4)
Headache	195 (4.4)	87 (2.1)
Back pain	142 (3.2)	92 (2.2)
Influenza	124 (2.8)	112 (2.7)
Insomnia	105 (2.4)	41 (1.0)
Dizziness	92 (2.1)	45 (1.1)
Decreased appetite	91 (2.1)	15 (0.4)

Adverse reactions that occurred in the DALIRESP group at a frequency of 1 to 2% where rates exceeded that in the placebo group include: Gastrointestinal disorders - abdominal pain, dyspepsia, gastritis, vomiting
Infections and infestations - rhinitis, sinusitis, urinary tract infection
Musculoskeletal and connective tissue disorders - muscle spasms
Nervous system disorders - tremor
Psychiatric disorders - anxiety, depression

Postmarketing Experience

The following adverse reactions have been identified from spontaneous reports of DALIRESP received worldwide and have not been listed elsewhere. These adverse reactions have been chosen for inclusion due to a combination of seriousness, frequency of reporting or potential causal connection to DALIRESP. Because these adverse reactions were reported voluntarily from a population of uncertain size, it is not possible to estimate their frequency or establish a causal relationship to DALIRESP exposure: hypersensitivity reactions (including angioedema, urticaria and rash), gynecomastia.

DRUG INTERACTIONS

A major step in roflumilast metabolism is the N-oxidation of roflumilast to roflumilast N-oxide by CYP3A4 and CYP1A2 [*see Clinical Pharmacology (12.3) in the full Prescribing Information*].

Drugs that Induce Cytochrome P450 (CYP) Enzymes

Strong cytochrome P450 enzyme inducers decrease systemic exposure to roflumilast and may reduce the therapeutic effectiveness of DALIRESP. Therefore the use of strong cytochrome P450 inducers (e.g., rifampicin, phenobarbital, carbamazepine, and phenytoin) with DALIRESP is not recommended [*see Drug Interactions (5.4) and Clinical Pharmacology (12.3) in the full Prescribing Information*].

Drugs that Inhibit Cytochrome P450 (CYP) Enzymes

The co-administration of DALIRESP (500 mcg) with CYP3A4 inhibitors or dual inhibitors that inhibit both CYP3A4 and CYP1A2 simultaneously (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) may increase roflumilast systemic exposure and may result in increased adverse reactions. The risk of such concurrent use should be weighed carefully against benefit [*see Clinical Pharmacology (12.3) in the full Prescribing Information*].

Oral Contraceptives Containing Gestodene and Ethinyl Estradiol

The co-administration of DALIRESP (500 mcg) with oral contraceptives containing gestodene and ethinyl estradiol may increase roflumilast systemic exposure and may result in increased side effects. The risk of such concurrent use should be weighed carefully against benefit [*see Clinical Pharmacology (12.3) in the full Prescribing Information*].

USE IN SPECIFIC POPULATIONS

Pregnancy

Teratogenic effects: Pregnancy Category C: There are no adequate and well controlled studies of DALIRESP in pregnant women. DALIRESP was not teratogenic in mice, rats, or rabbits. DALIRESP should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

DALIRESP induced stillbirth and decreased pup viability in mice at doses corresponding to approximately 16 and 49 times, respectively, the maximum recommended human dose (MRHD) (on a mg/m² basis at maternal doses >2 mg/kg/day and 6 mg/kg/day, respectively). DALIRESP induced post-implantation loss in rats at doses greater than or equal to approximately 10 times the MRHD (on a mg/m² basis at maternal doses ≥0.6 mg/kg/day). No treatment-related effects on embryo-fetal development were observed in mice, rats, and rabbits at approximately 12, 3, and 26 times the MRHD, respectively (on a mg/m² basis at maternal doses of 1.5, 0.2, and 0.8 mg/kg/day, respectively).

Nonteratogenic effects: DALIRESP has been shown to adversely affect pup post-natal development when dams were treated with the drug during pregnancy and lactation periods in mice. These studies found that DALIRESP decreased pup rearing frequencies at approximately 49 times the MRHD (on a mg/mg² basis at a maternal dose of 6 mg/kg/day) during pregnancy and lactation. DALIRESP also decreased survival and forelimb grip reflex and delayed pinna detachment in mouse pups at approximately 97 times the MRHD (on a mg/m² basis at a maternal dose of 12 mg/kg/day) during pregnancy and lactation.

Labor and Delivery

DALIRESP should not be used during labor and delivery. There are no human studies that have investigated effects of DALIRESP on preterm labor or labor at term; however, animal studies showed that DALIRESP disrupted the labor and delivery process in mice. DALIRESP induced delivery retardation in pregnant mice at doses greater than or equal to approximately 16 times the MRHD (on a mg/m² basis at a maternal dose of >2 mg/kg/day).

Nursing Mothers

Roflumilast and/or its metabolites are excreted into the milk of lactating rats. Excretion of roflumilast and/or its metabolites into human milk is probable. There are no human studies that have investigated effects of DALIRESP on breast-fed infants. DALIRESP should not be used by women who are nursing.

Pediatric Use

COPD does not normally occur in children. The safety and effectiveness of DALIRESP in pediatric patients have not been established.

Geriatric Use

Of the 4438 COPD subjects exposed to DALIRESP for up to 12 months in 8 controlled clinical trials, 2022 were >65 years of age and 471 were >75 years of age. No overall differences in safety or effectiveness were observed between these subjects and younger subjects and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. Based on available data for roflumilast, no adjustment of dosage in geriatric patients is warranted [*see Clinical Pharmacology (12.3) in the full Prescribing Information*].

Hepatic Impairment

Roflumilast 250 mcg once daily for 14 days was studied in subjects with mild-to-moderate hepatic impairment classified as Child-Pugh A and B (8 subjects in each group). The AUCs of roflumilast and roflumilast N-oxide were increased by 51% and 24%, respectively in Child-Pugh A subjects and by 92% and 41%, respectively in Child-Pugh B subjects, as compared to age-, weight- and gender-matched healthy subjects. The C_{max} of roflumilast and roflumilast N-oxide were increased by 3% and 26%, respectively in Child-Pugh A subjects and by 26% and 40%, respectively in Child-Pugh B subjects, as compared to healthy subjects. DALIRESP 500 mcg has not been studied in hepatically impaired patients. Clinicians should consider the risk-benefit of administering DALIRESP to patients who have mild liver impairment (Child-Pugh A). DALIRESP is not recommended for use in patients with moderate or severe liver impairment (Child-Pugh B or C) [*see Contraindications (4) and Clinical Pharmacology (12.3) in the full Prescribing Information*].

Renal Impairment

In twelve subjects with severe renal impairment administered a single dose of 500 mcg roflumilast, the AUCs of roflumilast and roflumilast N-oxide were decreased by 21% and 7%, respectively and C_{max} were reduced by 16% and 12%, respectively. No dosage adjustment is necessary for patients with renal impairment [*see Clinical Pharmacology (12.3) in the full Prescribing Information*].

OVERDOSAGE

Human Experience

No case of overdose has been reported in clinical studies with DALIRESP. During the Phase I studies of DALIRESP, the following symptoms were observed at an increased rate after a single oral dose of 2500 mcg and a single dose of 5000 mcg: headache, gastrointestinal disorders, dizziness, palpitations, lightheadedness, clamminess and arterial hypotension.

Management of Overdose

In case of overdose, patients should seek immediate medical help. Appropriate supportive medical care should be provided. Since roflumilast is highly protein bound, hemodialysis is not likely to be an efficient method of drug removal. It is not known whether roflumilast is dialyzable by peritoneal dialysis.

PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

Distributed by:

AstraZeneca Pharmaceuticals LP, Wilmington, DE 19850

Under license of Takeda GmbH

Daliresp® is a registered trademark of Takeda GmbH.

© AstraZeneca 2015

3217200 1/16

Iss.11/15

Technology could boost cystic fibrosis screening

BY BARBARA FEDER OSTROV,
KAISER HEALTH NEWS

Stanford University scientists say they've devised a more accurate and comprehensive DNA test to screen newborns for cystic fibrosis.

Every state screens newborns for cystic fibrosis, but the current sequence of tests can miss cases. The new method, presented in a study published Feb. 1 in the *Journal of Molecular Diagnostics*, promises to be more efficient and cost effective, researchers said. It may also improve screening for nonwhite babies, for whom cystic fibrosis is rarer and harder to diagnose.

The test "offers the promise of potentially eliminating the false negative results that lead to miss ed cases," said Dr. Philip Farrell, a former dean of the University of Wisconsin School of Medicine and Public Health, Madison.

The new test uses "next generation" DNA sequencing that can quickly and more cheaply look at the entire CFTR gene, not just selected mutations. It does not require an extra blood sample. Rather, it uses blood drawn from the common newborn heel stick test that's already used to screen for a number of diseases, including cystic fibrosis. The advance can enable testing labs to review many newborn samples at a time and reduce costs, allowing a technology previously used to diagnose only individual cases to be applied to a large population.

"Next generation" DNA sequencing is only now becoming cheap and fast enough to even be considered for large-scale population screening. Scientists from Stanford, the California Department of Public Health, and the University of Texas at Austin conducted the research. Other U.S. scientists have been working on similar newborn screening approaches using next-generation DNA sequencing.

The test is not only quicker and cheaper, but also "very accurate," said Dr. Iris Schrijver, a Stanford University Medical School pathology professor who is one of the study's authors. "We can look at the entire gene and assess ... all kinds of mutations in this single test," possibly in half the time of a current DNA test.

A spokesman for the California Department of Public Health, which oversees newborn screenings, said the current cost, including DNA testing, is approximately \$113 per newborn, which is typically covered by insurers. In general, the spokesman

noted, the agency's newborn screening program evaluates potential new testing methods for effectiveness and cost. "Historically, changes to existing testing methods have been rare, so the department cannot speculate

on a timeline for this process," the spokesman wrote in an email.

A Stanford spokeswoman said its laboratory is running side-by-side comparisons of the new test and the current one, and its lab physicians ex-

pect to meet with public state health officials soon to discuss next steps.

This story was produced by Kaiser Health News, which publishes California Healthline, a service of the California Health Care Foundation.

Avycaz[®]
ceftazidime and avibactam
for injection (2.5 g)

VISIT WWW.AVYCAZ.COM

Please contact
your Actavis representative
for more information

 **Allergan**

Allergan[®] and its design are trademarks of Allergan, Inc.

AVYCAZ[®] and its design are trademarks of Forest Laboratories, LLC, an Allergan affiliate.
© 2016 Allergan. All rights reserved. AVY41771 01/16
Actavis Pharma, Inc., an Allergan affiliate.

ICU care bundle cut delirium, in-hospital deaths

BY KARI OAKES
Frontline Medical News

ORLANDO – Implementing an ICU care plan got patients moving and breathing on their own sooner. The interventions resulted in significantly less delirium and better in-hospital survival in 6,000 patients treated at seven community hospitals, according to data presented at the Critical Care Congress, sponsored by the Society for Critical Care Medicine.

The care bundle focused on minimizing sedation and maximizing patient mobilization. For each 10% increase in compliance with the care plan, community ICUs saw a 15% increase in delirium-free ICU days. In-hospital survival also increased by 15% for every 10% increase in implementation.

The ICU Liberation project set forward the ABCDEF care bundle to operationalize the Society for Critical Care Medicine (SCCM) 2012 guidelines regarding pain, agitation, and delirium in the ICU.

“It’s never quite clear whether guidelines, which are developed from randomized controlled trials in academic university hospitals, can be implemented in the community hospital setting. And as we know, the majority of critical care in our country is provided in the community hospital setting,” said Mary Ann Barnes-Daly, an RN who is the regional clinical initiative lead for ICU Liberation at Sutter Health in Sacramento, Calif.

The care bundle calls for all ICU patients to have daily assessments for pain and delirium, sponta-

neous awakening and breathing trials, minimal sedation, early mobilization and exercise, and family involvement as part of the care team.

A dedicated RN, whose sole responsibility was to implement the ICU Liberation program, led the on-site teams. Other team members were an administrative RN, a pharmacist, a physical therapist, a respiratory care practitioner, and an ICU physician. In some hospitals, the physician was an intensivist, while in others, a hospitalist provided ICU care.

“We provided clinical education, and more importantly, interprofessional team education, where the teams learned to work together,” said Ms. Barnes-Daly. Rounds were audited and audit results, along with ongoing data collection and reporting, were the basis for ongoing reporting and process improvement.

The mantra for care bundle implementation was “every patient, every day,” said Ms. Barnes-Daly. Patient exclusions were based on safety and included such factors as hemodynamic, respiratory, or neurologic instability; open abdomen; active alcohol withdrawal; and new coronary ischemia.

Altogether, 6,064 patients were involved in the program; about one in four patients received mechanical ventilation during their stay. When patients were mechanically ventilated, all aspects of the care bundle were to be implemented. When patients were not receiving mechanical ventilation, only four aspects of the bundle applied and were measured. Overall, patients were mechanically ventilated for about 20% of the days observed.

Compliance with the care bundle was measured in two ways, said Ms. Barnes-Daly: One analysis was all-or-none, measuring the proportion of a patient’s ICU stay for which all applicable bundle elements were implemented. The other measure allowed partial compliance; dose compliance was calculated by averaging the proportion of care bundle compliance for each day over the patient’s ICU stay. This second analysis proved more sensitive in assessing the effects of the care bundle.

A dose-response ratio was noted between the number of delirium-free and coma-free days and the number of care bundle components delivered (P less than .001). Similarly, hospital survival also increased as bundle delivery increased, with each 10% increase in compliance associated with a 15% increase in hospital survival (P less than .001). When palliative care patients were removed from data analysis, hospital survival increased by 23% with each 10% increase in bundle compliance, said Ms. Barnes-Daly.

The study’s strengths include “the large sample size, and the fact that we adjusted for age, Apache score, and mechanical ventilation,” said Ms. Barnes-Daly. The limitations are that this was not a randomized controlled trial, and data were initially collected by the nurse team leader. Data collection was subsequently switched to the electronic ICU team.

The QI program was sponsored by the Society for Critical Care Medicine, and conducted at Sutter Health community Hospitals. Ms. Barnes-Daly reported receiving honoraria from the Society for Critical Care Medicine.

koakes@frontlinemedcom.com
On Twitter @karioakes

Each 10% increase in compliance with the care bundle was associated with a 15% increase in hospital survival.

AWS patients may not need pre-emptive intubation

BY NICOLA GARRETT
Frontline Medical News

FROM ANNALS OF THE AMERICAN
THORACIC SOCIETY

People hospitalized with alcohol withdrawal syndrome (AWS) and treated with continuously infused high dose sedatives may not need to be intubated, as long as they are monitored for signs of worsening gas exchange and aspiration, suggests a single-center retrospective study.

Standard practice is to treat AWS patients with sedating drugs in order to mitigate the catecholamine storm and agitation. Even at low doses, these medications can cause cardiorespiratory instability and the issue of when to secure the airways of these patients has remained a clinical question.

In their study, (Ann Am Thorac Soc. 2016 Feb 1. 13[2],162-4) Dr. Robert Stewart of Texas A&M University,

College Station, and his colleagues described the outcomes of 188 patients with AWS given lorazepam as a continuous infusion up to 1.2 mg per hour with intermittent boluses of 1-2 mg when their Clinical Institute Withdrawal Assessment Score was greater than 6.

Transfer to the ICU was initiated only as clinically indicated or when higher doses of continuous hypnotics were needed. For instance, 170 of the patients also received midazolam, all but 2 by continuous intravenous infusion (median total dose, 527 mg; all administered in ICU); 19 received propofol (median total dose, 6,000 mg); and 19 received dexmedetomidine (median total dose, 1,075 mg).

All patients were monitored by continuous pulse oximetry and nasal capnography and were only intubated when gas exchange worsened or

Continued on following page



Continued from previous page

macro-aspiration was observed.

No explicit criteria mandated intubation and clinicians, most of whom were ICU residents, were required to determine ad hoc the degree of gas exchange failure or apparent aspiration that warranted intubation.

Overall, 36 (19%) of the 188 patients required intubation. These patients tended to have a higher APACHE II score (greater than 10) and to receive substantially more benzodiazepine than non-intubated patients (761 mg of lorazepam equivalent vs 229 mg; P less than 0.0001).

Intubated patients also had longer hospital lengths of stays (median, 14.7 vs. 6.0 days; P less than 0.0001) and more pneumonias (58.3% vs. 5.9%; P less than 0.0001). One patient died, and had been intubated.

“Our study adds to those cited previously suggesting that high doses of sedatives can be given

without mandatory intubation, provided patients are closely monitored,” the researchers said. “Whether this practice is safer and more effective than pre-emptive intubation for such patients remains an open question.”

The researchers declared no relevant conflicts of interest.

VIEW ON THE NEWS

Not every drip needs a plumber

Many clinicians feel comfortable administering benzodiazepines by intravenous bolus to patients without high levels of monitoring, yet will use continuous infusions only in more monitored settings such as an ICU in patients with “protected airways” via intubation and mechanical ventilation. The current study forces critical care clinicians to question the status quo.

Are we really helping patients by racing to intubate those we deem in need of continuous sedative infusions for AWS for fear of what might happen, when we know intubation and mechanical ventilation have their own risks?

Mechanical ventilation can be associated with pneumonia, weakness, and delirium. Further, patients with alcohol withdrawal syndrome who receive invasive mechanical ventilation are more likely to have poor outcomes.

The current study illustrated the use of low-dose continuous benzodiazepines (lorazepam) on the general hospital wards and deferred intubation. Nevertheless, there were limitations to the study stemming from its design as a retrospective analysis of a single center’s experience. Also, it was not clear how safe or effective a similar protocol of continuous benzodiazepine infusions coupled with delayed intubation might be in a setting in which practitioners are less comfortable with the complications of AWS and its treatments and have less access to continuous end-tidal carbon dioxide measurements.

Dr. Hayley B. Gershengorn is with the Albert Einstein College of Medicine, New York. She made her remarks in an editorial (Ann Am Thorac Soc. 2016 Feb 1, 13[2], 162–4) that accompanied the study.

OFEV IS RECOMMENDED* FOR THE TREATMENT OF IPF BY THE ATS/ERS/JRS/ALAT GUIDELINES¹

SLOW THE PATH OF IPF PROGRESSION

OFEV (nintedanib) has demonstrated reproducible reductions in the annual rate of FVC decline in 3 clinical trials²

OFEV significantly reduced the risk of first acute IPF exacerbation over 52 weeks compared with placebo in 2 out of 3 clinical trials²

Learn more about OFEV inside.

INDICATION AND USAGE

OFEV is indicated for the treatment of idiopathic pulmonary fibrosis (IPF).

IMPORTANT SAFETY INFORMATION WARNINGS AND PRECAUTIONS

Elevated Liver Enzymes

- OFEV is not recommended in patients with moderate (Child Pugh B) or severe (Child Pugh C) hepatic impairment.
- OFEV was associated with elevations of liver enzymes (ALT, AST, ALKP, and GGT) and bilirubin. Liver enzyme increases were reversible with dose modification or interruption and not associated with clinical signs or symptoms of liver injury. The majority (94%) of patients with ALT and/or AST elevations had elevations <5 times ULN. The majority (95%) of patients with bilirubin elevations had elevations <2 times ULN.
- Conduct liver function tests prior to treatment, monthly for 3 months, and every 3 months thereafter, and as clinically indicated. Monitor for adverse reactions and consider dosage modifications, interruption, or discontinuation as necessary for liver enzyme elevations.

Please see additional Important Safety Information and brief summary for OFEV on the following pages.

*This conditional recommendation means that clinicians are encouraged to discuss preferences with their patients when making treatment decisions as the majority of patients would want treatment, but many would not.¹

ALAT, Latin American Thoracic Association; ATS, American Thoracic Society; ERS, European Respiratory Society; FVC, forced vital capacity; JRS, Japanese Respiratory Society.

 **OFEV**[®]
(nintedanib)
capsules 150mg

TREAT NOW. SLOW PROGRESSION.

A better way to relieve rib fracture pain in the ICU

BY M. ALEXANDER OTTO
Frontline Medical News

AT THE EAST SCIENTIFIC ASSEMBLY

SAN ANTONIO – A new pain relief option for multiple rib fractures

means that you might not have to wait around anymore for anesthesiology to place thoracic epidurals.

It's called posterior paramedian subrhomboidal (PoPS) analgesia. A skin incision is made below the low-


est fractured rib just paramedian to the spinus processes; a tunneling device is then used to work a catheter upwards under the rhomboids just past the highest fractured rib. The catheter has multiple openings along

its length – like a sprinkler hose – so analgesic bathes the intercostal nerves as it runs down from a reservoir into the patient. The reservoir can be set to a desired flow rate or for on-demand use (ON-Q Pain Re-

The totality of the evidence demonstrates that OFEV slows IPF progression²⁻⁶


REPRODUCIBLE REDUCTIONS IN THE ANNUAL RATE OF FVC DECLINE ACROSS 3 TRIALS^{2*}

INPULSIS[®]-1 (Study 2)^{2,7}



- -115 mL/year for OFEV (nintedanib) compared with -240 mL/year for placebo*

INPULSIS[®]-2 (Study 3)^{2,7}



- -114 mL/year for OFEV compared with -207 mL/year for placebo*

TOMORROW (Study 1): OFEV demonstrated a 68% relative reduction in the annual rate of FVC decline compared with placebo (-60 mL/year vs -191 mL/year, respectively; $P = .01$, 95% CI = 27, 235)^{2,8}

CI, confidence interval; HR, hazard ratio.

*The annual rate of decline in FVC (mL/year) was analyzed using a random coefficient regression model.²

IMPORTANT SAFETY INFORMATION WARNINGS AND PRECAUTIONS (CONT'D)

Gastrointestinal Disorders

Diarrhea

- Diarrhea was the most frequent gastrointestinal event reported in 62% versus 18% of patients treated with OFEV and placebo, respectively. Events were primarily mild to moderate intensity and occurred within the first 3 months. Diarrhea led to permanent dose reduction in 11% and discontinuation in 5% of OFEV patients versus 0 and <1% in placebo patients, respectively.
- Dosage modifications or treatment interruptions may be necessary in patients with diarrhea. Treat diarrhea at first signs with adequate hydration and antidiarrheal medication (e.g., loperamide), and consider treatment interruption if diarrhea continues. OFEV treatment may be resumed at the full dosage (150 mg twice daily), or at the reduced dosage (100 mg twice daily), which subsequently may be increased to the full dosage. If severe diarrhea persists, discontinue treatment.

Nausea and Vomiting

- Nausea was reported in 24% versus 7% and vomiting was reported in 12% versus 3% of patients treated with OFEV and placebo, respectively. Events were primarily of mild to moderate intensity. Nausea and vomiting led to discontinuation of OFEV in 2% and 1% of patients, respectively.
- If nausea or vomiting persists despite appropriate supportive care including anti-emetic therapy, consider dose reduction or treatment interruption. OFEV treatment may be resumed at full dosage or at reduced dosage, which subsequently may be increased to full dosage. If severe nausea or vomiting does not resolve, discontinue treatment.

lief System – Halyard).

A pilot study at the University of Kansas, Kansas City, found that pain control from PoPS was at least equivalent to standard thoracic epidural analgesia (TEA), and that the system can be placed by a variety of hospital staff, not just anesthesiologists.

The 11 PoPS patients also used

fewer rescue narcotics than the 19 TEA patients and had less hypotension. Because they weren't at risk for epidural hematomas, they started venous thromboembolism prophylaxis without delay and at full dose.

"Our results are very promising. PoPS provides pain control similar to that of TEA," with several "other

benefits. You are not relying on one specialty for pain control," so patients probably get faster relief. "PoPS can also be placed in patients whose injuries prohibit TEA, such as those with spinal cord injuries or increased intracranial pressure," said investigator Dr. Casey Shelley, a University of

Continued on following page



COURTESY OF DR. MICHAEL TRUITT, METHUENIST DALLAS MEDICAL CENTER

SIGNIFICANT REDUCTION IN THE RISK OF FIRST ACUTE IPF EXACERBATION OVER 52 WEEKS COMPARED WITH PLACEBO IN 2 OUT OF 3 CLINICAL TRIALS²

- **INPULSIS[®]-2** (adjudicated): HR=0.20 (95% CI=0.07, 0.56)
- **TOMORROW** (investigator-reported): HR=0.16 (95% CI=0.04, 0.71)
- **INPULSIS[®]-1** (adjudicated): HR=0.55 (95% CI=0.20, 1.54; not statistically significant)

THE MOST COMMON ADVERSE EVENTS WERE GASTROINTESTINAL IN NATURE AND GENERALLY OF MILD OR MODERATE INTENSITY²

- Diarrhea was reported in 62% of patients receiving OFEV vs 18% on placebo
- Diarrhea can be managed by symptomatic treatment, dose reduction, or treatment interruption until diarrhea resolves to levels that allow continuation of therapy. If severe diarrhea persists despite symptomatic treatment, discontinue OFEV



ONE CAPSULE,
TWICE DAILY WITH FOOD²

Not shown at actual size

Visit hcp.OFEV.com for more information.

IMPORTANT SAFETY INFORMATION WARNINGS AND PRECAUTIONS (CONT'D)

Embryofetal Toxicity: OFEV is Pregnancy category D. It can cause fetal harm when administered to a pregnant woman and patients should be advised of the potential hazard to a fetus. Women should be advised to avoid becoming pregnant while receiving OFEV and to use adequate contraception during treatment and at least 3 months after the last dose of OFEV.

Arterial Thromboembolic Events: Arterial thromboembolic events were reported in 2.5% of OFEV and 0.8% of placebo patients, respectively. Myocardial infarction was the most common arterial thromboembolic event, occurring in 1.5% of OFEV and 0.4% of placebo patients. Use caution when treating patients at higher cardiovascular risk including known coronary artery disease. Consider treatment interruption in patients who develop signs or symptoms of acute myocardial ischemia.

Risk of Bleeding: OFEV may increase the risk of bleeding. Bleeding events were reported in 10% of OFEV versus 7% of placebo patients. Use OFEV in patients with known risk of bleeding only if the anticipated benefit outweighs the potential risk.

Gastrointestinal Perforation: OFEV may increase the risk of gastrointestinal perforation. Gastrointestinal perforation was reported in 0.3% of OFEV versus in 0% placebo patients. Use caution when treating patients who have had recent abdominal surgery. Discontinue therapy with OFEV in patients who develop gastrointestinal perforation. Only use OFEV in patients with known risk of gastrointestinal perforation if the anticipated benefit outweighs the potential risk.

Please see additional Important Safety Information and brief summary for OFEV on the following pages.

 **OFEV[®]**
(nintedanib)
capsules 150mg

TREAT NOW. SLOW PROGRESSION.

Continued from previous page

Kansas general surgery resident.

PoPS was placed in the study either by anesthesiologists or by a trauma surgeon who practiced placement beforehand in the cadaver lab. The do-it-yourself potential for surgeons “is key. Most of us trauma surgeons are sick of begging anesthesiologists to come place thoracic epidurals,” said an

audience member after Dr. Shelley’s presentation at the annual scientific assembly of the Eastern Association for the Surgery of Trauma.

Ropivacaine 0.2% was used in both PoPS and TEA patients, all of whom had at least three broken ribs.

Median pain scores dropped from 8.5 to 2.5 on a 10-point scale an hour after PoPS placement, versus a median drop from 8 to 5 points an hour

after TEA ($P = .03$). Although not statistically significant, median pain scores were about 1.5 points better with PoPS over the next several days, hovering around 3.5 versus around 5 points with TEA. Anesthesiology “usually won’t place high thoracic epidurals. With PoPS, you can tunnel up as far as you need to go to get to higher ribs,” which might explain the better pain control, Dr. Shelley said.

PoPS patients used about 70 mg/day oral mor-

GRANTED BREAKTHROUGH THERAPY DESIGNATION FOR IPF DURING FDA REVIEW⁹

Start your appropriate patients with IPF on OFEV



CONDUCT liver function tests (ALT, AST, and bilirubin) prior to initiating treatment with OFEV (nintedanib)



COMPLETE the OFEV Prescription Form—available at www.hcp.OFEV.com—and fax it to one of the participating specialty pharmacies listed on the form



OFFER enrollment in OPEN DOORS™, a patient support program for patients receiving OFEV

IMPORTANT SAFETY INFORMATION ADVERSE REACTIONS

- Adverse reactions reported in $\geq 5\%$ of OFEV patients included diarrhea, nausea, abdominal pain, liver enzyme elevation, vomiting, decreased appetite, weight decreased, headache, and hypertension.
- The most frequent serious adverse reactions reported in OFEV patients were bronchitis and myocardial infarction. The most common adverse events leading to death in OFEV patients versus placebo were pneumonia (0.7% vs. 0.6%), lung neoplasm malignant (0.3% vs. 0%), and myocardial infarction (0.3% vs. 0.2%). In the predefined category of major adverse cardiovascular events (MACE) including MI, fatal events were reported in 0.6% of OFEV versus 1.8% in placebo patients.

DRUG INTERACTIONS

- **P-glycoprotein (P-gp) and CYP3A4 Inhibitors and Inducers:** Coadministration with oral doses of a P-gp and CYP3A4 inhibitor, ketoconazole, increased exposure to nintedanib by 60%. Concomitant use of potent P-gp and CYP3A4 inhibitors (e.g., erythromycin) with OFEV may increase exposure to nintedanib. In such cases, patients should be monitored closely for tolerability of OFEV. Management of adverse reactions may require

interruption, dose reduction, or discontinuation of therapy with OFEV. Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. Concomitant use of P-gp and CYP3A4 inducers (e.g., carbamazepine, phenytoin, and St. John’s wort) with OFEV should be avoided as these drugs may decrease exposure to nintedanib.

- **Anticoagulants:** Nintedanib may increase the risk of bleeding. Monitor patients on full anticoagulation therapy closely for bleeding and adjust anticoagulation treatment as necessary.

USE IN SPECIFIC POPULATIONS

- **Nursing Mothers:** Excretion of nintedanib and/or its metabolites into human milk is probable. Because of the potential for serious adverse reactions in nursing infants from OFEV, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
- **Smokers:** Smoking was associated with decreased exposure to OFEV, which may affect the efficacy of OFEV. Encourage patients to stop smoking prior to and during treatment.

OFHCPISISEP15

Please see brief summary for OFEV on the following pages.

References: 1. Raghu G et al; on behalf of the ATS, ERS, JRS, and ALAT. *Am J Respir Crit Care Med.* 2015;192(2):238-248. 2. OFEV® (nintedanib) Prescribing Information. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; 2014. 3. Zappala CJ et al. *Eur Respir J.* 2010;35(4):830-836. 4. Schmidt SL et al. *Chest.* 2014;145(3):579-585. 5. du Bois RM et al. *Am J Respir Crit Care Med.* 2011;184(12):1382-1389. 6. Song JW et al. *Eur Respir J.* 2011;37(2):356-363. 7. Richeldi L et al; for the INPULSIS Trial Investigators. *N Engl J Med.* 2014;370(22):2071-2082. 8. Richeldi L et al. *N Engl J Med.* 2011;365(12):1079-1087. 9. US Food and Drug Administration. [http://www.fda.gov/downloads/Regulatory Information/Legislation/FederalFoodDrugandCosmeticActFD-CAct/SignificantAmendmentstotheFDCAAct/FDASIA/UCM380724.pdf](http://www.fda.gov/downloads/Regulatory%20Information/Legislation/FederalFoodDrugandCosmeticActFD-CAct/SignificantAmendmentstotheFDCAAct/FDASIA/UCM380724.pdf). Accessed September 1, 2015.



Copyright ©2015, Boehringer Ingelheim Pharmaceuticals, Inc. All rights reserved. (09/15) PC-OF-0267-PROF



TREAT NOW. SLOW PROGRESSION.

phine equivalents versus about 90 mg/day with TEA through day 6, but again the difference was not statistically significant. Even so, it might explain why six TEA patients (32%) were hypotensive over that time, compared with two PoPS patients (18%).

PoPS patients were a little older on average (mean 63 versus 55 years), with more fractured ribs (mean eight versus seven), and higher Injury

Severity Scale scores (mean 20 versus 16). They were also more likely to have bilateral fractures, longer ICU stays (mean 4.9 versus 3.1 days), and longer overall lengths of stay (mean 14.8 versus 9.8 days), but none of those trends were statistically significant.

Both groups had mean chest Abbreviated Injury Scale scores of 3, and there were no statistical differences in daily spirometry readings. The majority

of patients in both groups were men.

Favorable results were also reported in 2010 for ON-Q rib pain control, but the investigators did not compare the system to TEA (World J Surg. 2010 Oct;34:2359-62).

Dr. Shelley said Halyard was not involved in the study, and that she has no disclosures.

aotto@frontlinemedcom.com

OFEV® (nintedanib) capsules, for oral use

BRIEF SUMMARY OF PRESCRIBING INFORMATION

Please see package insert for full Prescribing Information, including Patient Information

INDICATIONS AND USAGE: OFEV is indicated for the treatment of idiopathic pulmonary fibrosis (IPF).

DOSAGE AND ADMINISTRATION: Testing Prior to OFEV Administration: Conduct liver function tests prior to initiating treatment with OFEV [see Warnings and Precautions]. **Recommended Dosage:** The recommended dosage of OFEV is 150 mg twice daily administered approximately 12 hours apart. OFEV capsules should be taken with food and swallowed whole with liquid. OFEV capsules should not be chewed or crushed because of a bitter taste. The effect of chewing or crushing of the capsule on the pharmacokinetics of nintedanib is not known. If a dose of OFEV is missed, the next dose should be taken at the next scheduled time. Advise the patient to not make up for a missed dose. Do not exceed the recommended maximum daily dosage of 300 mg. **Dosage Modification due to Adverse Reactions:** In addition to symptomatic treatment, if applicable, the management of adverse reactions of OFEV may require dose reduction or temporary interruption until the specific adverse reaction resolves to levels that allow continuation of therapy. OFEV treatment may be resumed at the full dosage (150 mg twice daily), or at the reduced dosage (100 mg twice daily), which subsequently may be increased to the full dosage. If a patient does not tolerate 100 mg twice daily, discontinue treatment with OFEV [see Warnings and Precautions and Adverse Reactions]. Dose modifications or interruptions may be necessary for liver enzyme elevations. For aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >3 times to <5 times the upper limit of normal (ULN) without signs of severe liver damage, interrupt treatment or reduce OFEV to 100 mg twice daily. Once liver enzymes have returned to baseline values, treatment with OFEV may be reintroduced at a reduced dosage (100 mg twice daily), which subsequently may be increased to the full dosage (150 mg twice daily) [see Warnings and Precautions and Adverse Reactions]. Discontinue OFEV for AST or ALT elevations >5 times ULN or >3 times ULN with signs or symptoms of severe liver damage.

CONTRAINDICATIONS: None

WARNINGS AND PRECAUTIONS: Elevated Liver Enzymes: The safety and efficacy of OFEV has not been studied in patients with moderate (Child Pugh B) or severe (Child Pugh C) hepatic impairment. Treatment with OFEV is not recommended in patients with moderate or severe hepatic impairment [see Use in Specific Populations]. In clinical trials, administration of OFEV was associated with elevations of liver enzymes (ALT, AST, ALKP, GGT). Liver enzyme increases were reversible with dose modification or interruption and not associated with clinical signs or symptoms of liver injury. The majority (94%) of patients with ALT and/or AST elevations had elevations <5 times ULN. Administration of OFEV was also associated with elevations of bilirubin. The majority (95%) of patients with bilirubin elevations had elevations <2 times ULN [see Use in Specific Populations]. Conduct liver function tests (ALT, AST, and bilirubin) prior to treatment with OFEV, monthly for 3 months, and every 3 months thereafter, and as clinically indicated. Dosage modifications or interruption may be necessary for liver enzyme elevations. **Gastrointestinal Disorders:** Diarrhea was the most frequent gastrointestinal event reported in 62% versus 18% of patients treated with OFEV and placebo, respectively [see Adverse Reactions]. In most patients, the event was of mild to moderate intensity and occurred within the first 3 months of treatment. Diarrhea led to permanent dose reduction in 11% of patients treated with OFEV compared to 0 placebo-treated patients. Diarrhea led to discontinuation of OFEV in 5% of the patients compared to <1% of placebo-treated patients. Dosage modifications or treatment interruptions may be necessary in patients with adverse reactions of diarrhea. Treat diarrhea at first signs with adequate hydration and antidiarrheal medication (e.g., loperamide), and consider treatment interruption if diarrhea continues. OFEV treatment may be resumed at the full dosage (150 mg twice daily), or at the

reduced dosage (100 mg twice daily), which subsequently may be increased to the full dosage. If severe diarrhea persists despite symptomatic treatment, discontinue treatment with OFEV (nintedanib). **Nausea and Vomiting:** Nausea was reported in 24% versus 7% and vomiting was reported in 12% versus 3% of patients treated with OFEV and placebo, respectively [see Adverse Reactions]. In most patients, these events were of mild to moderate intensity. Nausea led to discontinuation of OFEV in 2% of patients. Vomiting led to discontinuation of OFEV in 1% of the patients. For nausea or vomiting that persists despite appropriate supportive care including anti-emetic therapy, dose reduction or treatment interruption may be required. OFEV treatment may be resumed at the full dosage (150 mg twice daily), or at the reduced dosage (100 mg twice daily), which subsequently may be increased to the full dosage. If severe nausea or vomiting does not resolve, discontinue treatment with OFEV. **Embryofetal Toxicity:** OFEV can cause fetal harm when administered to a pregnant woman. Nintedanib was teratogenic and embryofetotoxic in rats and rabbits at less than and approximately 5 times the maximum recommended human dose (MRHD) in adults (on an AUC basis at oral doses of 2.5 and 15 mg/kg/day in rats and rabbits, respectively). If OFEV is used during pregnancy, or if the patient becomes pregnant while taking OFEV, the patient should be advised of the potential hazard to a fetus. Women of childbearing potential should be advised to avoid becoming pregnant while receiving treatment with OFEV and to use adequate contraception during treatment and at least 3 months after the last dose of OFEV [see Use in Specific Populations].

Arterial Thromboembolic Events: Arterial thromboembolic events have been reported in patients taking OFEV. In clinical trials, arterial thromboembolic events were reported in 2.5% of patients treated with OFEV and 0.8% of placebo-treated patients. Myocardial infarction was the most common adverse reaction under arterial thromboembolic events, occurring in 1.5% of OFEV-treated patients compared to 0.4% of placebo-treated patients. Use caution when treating patients at higher cardiovascular risk including known coronary artery disease. Consider treatment interruption in patients who develop signs or symptoms of acute myocardial ischemia. **Risk of Bleeding:** Based on the mechanism of action (VEGFR inhibition), OFEV may increase the risk of bleeding. In clinical trials, bleeding events were reported in 10% of patients treated with OFEV and in 7% of patients treated with placebo. Use OFEV in patients with known risk of bleeding only if the anticipated benefit outweighs the potential risk. **Gastrointestinal Perforation:** Based on the mechanism of action, OFEV may increase the risk of gastrointestinal perforation. In clinical trials, gastrointestinal perforation was reported in 0.3% of patients treated with OFEV, compared to 0 cases in the placebo-treated patients. Use caution when treating patients who have had recent abdominal surgery. Discontinue therapy with OFEV in patients who develop gastrointestinal perforation. Only use OFEV in patients with known risk of gastrointestinal perforation if the anticipated benefit outweighs the potential risk.

ADVERSE REACTIONS: The following adverse reactions are discussed in greater detail in other sections of the labeling: Liver Enzyme and Bilirubin Elevations [see Warnings and Precautions]; Gastrointestinal Disorders [see Warnings and Precautions]; Embryofetal Toxicity [see Warnings and Precautions]; Arterial Thromboembolic Events [see Warnings and Precautions]; Risk of Bleeding [see Warnings and Precautions]; Gastrointestinal Perforation [see Warnings and Precautions]. **Clinical Trials Experience:** Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety of OFEV was evaluated in over 1000 IPF patients with over 200 patients exposed to OFEV for more than 2 years in clinical trials. OFEV was studied in three randomized, double-blind, placebo-controlled, 52-week trials. In the phase 2 (Study 1) and phase 3 (Studies 2 and 3) trials, 723 patients with IPF received OFEV 150 mg twice daily and 508 patients received placebo. The median duration of exposure was 10 months for patients treated with OFEV and 11 months for patients treated with placebo. Subjects ranged in age from 42 to

89 years (median age of 67 years). Most patients were male (79%) and Caucasian (60%). The most frequent serious adverse reactions reported in patients treated with OFEV (nintedanib), more than placebo, were bronchitis (1.2% vs. 0.8%) and myocardial infarction (1.5% vs. 0.4%). The most common adverse events leading to death in patients treated with OFEV, more than placebo, were pneumonia (0.7% vs. 0.6%), lung neoplasm malignant (0.3% vs. 0%), and myocardial infarction (0.3% vs. 0.2%). In the predefined category of major adverse cardiovascular events (MACE) including MI, fatal events were reported in 0.6% of OFEV-treated patients and 1.8% of placebo-treated patients. Adverse reactions leading to permanent dose reductions were reported in 16% of OFEV-treated patients and 1% of placebo-treated patients. The most frequent adverse reaction that led to permanent dose reduction in the patients treated with OFEV was diarrhea (11%). Adverse reactions leading to discontinuation were reported in 21% of OFEV-treated patients and 15% of placebo-treated patients. The most frequent adverse reactions that led to discontinuation in OFEV-treated patients were diarrhea (5%), nausea (2%), and decreased appetite (2%). The most common adverse reactions with an incidence of ≥5% and more frequent in the OFEV than placebo treatment group are listed in Table 1.

Table 1 Adverse Reactions Occurring in ≥5% of OFEV-treated Patients and More Commonly Than Placebo in Studies 1, 2, and 3

Adverse Reaction	OFEV, 150 mg n=723	Placebo n=508
Gastrointestinal disorders		
Diarrhea	62%	18%
Nausea	24%	7%
Abdominal pain ^a	15%	6%
Vomiting	12%	3%
Hepatobiliary disorders		
Liver enzyme elevation ^b	14%	3%
Metabolism and nutrition disorders		
Decreased appetite	11%	5%
Nervous system disorders		
Headache	8%	5%
Investigations		
Weight decreased	10%	3%
Vascular disorders		
Hypertension ^c	5%	4%

^a Includes abdominal pain, abdominal pain upper, abdominal pain lower, gastrointestinal pain and abdominal tenderness.

^b Includes gamma-glutamyltransferase increased, hepatic enzyme increased, alanine aminotransferase increased, aspartate aminotransferase increased, hepatic function abnormal, liver function test abnormal, transaminase increased, blood alkaline phosphatase-increased, alanine aminotransferase abnormal, aspartate aminotransferase abnormal, and gamma-glutamyltransferase abnormal.

^c Includes hypertension, blood pressure increased, hypertensive crisis, and hypertensive cardiomyopathy.

In addition, hypothyroidism was reported in patients treated with OFEV, more than placebo (1.1% vs. 0.6%).

DRUG INTERACTIONS: P-glycoprotein (P-gp) and CYP3A4 Inhibitors and Inducers: Nintedanib is a substrate of P-gp and, to a minor extent, CYP3A4. Coadministration with oral doses of a P-gp and CYP3A4 inhibitor, ketoconazole, increased exposure to nintedanib by 60%. Concomitant use of P-gp and CYP3A4 inhibitors (e.g., erythromycin) with OFEV may increase exposure to nintedanib. In such cases, patients should be monitored closely for tolerability of OFEV. Management of adverse reactions may require interruption, dose reduction, or discontinuation of therapy with OFEV. Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. Concomitant use of P-gp and CYP3A4 inducers (e.g., carbamazepine, phenytoin, and St. John's wort) with OFEV should be avoided as these drugs may decrease exposure to nintedanib. **Anticoagulants:** Nintedanib is a VEGFR inhibitor, and may increase the risk of bleeding. Monitor patients on full anticoagulation therapy closely for bleeding and adjust

NSQIP calculator fails to stratify stage I NSCLC risk

BY MARK S. LESNEY
Frontline Medical News

A study performed to validate the National Surgical Quality Improvement Program (NSQIP) Surgical Risk Calculator for use in patients receiving surgery

or stereotactic body radiation therapy (SBRT) for stage I non–small cell lung cancer showed the calculator to be inadequate for both classification and risk stratification.

The study was reported in the *Journal of Thoracic and Cardiovascular Surgery* (2016;151;697-705). Dr. Pamela Samson of Washington University in St.

Louis and her colleagues performed a retrospective analysis of 485 patients with clinical stage I NSCLC who underwent either surgery (277) or SBRT (195) from 2009 to 2012. Surgery was either wedge resection (19.3%) or lobectomy (74.5%), with smaller percentages receiving segmentectomy (4.0%), pneumonectomy (1.5%), and bilobectomy (0.7%).

A large majority of surgical patients (84.1%) underwent a video-assisted thoracoscopic surgery (VATS) approach.

The researchers calculated NSQIP complication risk estimates for both surgical and SBRT patients using the NSQIP Surgical Risk Calculator. They compared predicted risk with actual adverse events.

Compared with patients undergoing VATS wedge resection, patients receiving SBRT were older, had larger tumors, lower forced expiratory volume (FEV₁) and diffusing capacity of the lungs for carbon monoxide (DLCO), higher American Society of Anesthesiologist scores, higher rates of dyspnea and higher NSQIP serious complication risk estimates, all significant at *P* less than .05. Similar disparities were seen in comparing patients receiving SBRT vs. VATS lobectomy.

The actual serious complication rate for surgical patients was significantly higher than the NSQIP risk calculator prediction (16.6% vs. 8.8%), as was the rate of pneumonia (6.0% vs. 3.2%), both at *P* less than .05.

Overall, the NSQIP Surgical Risk Calculator provided a fair level of discrimination between VATS lobectomy and SBRT on receiver operating characteristic (ROC) curve analysis, but it was a poor model for differentiating between VATS wedge resection and SBRT.

“Unfortunately, it is this latter population of the highest risk surgical patients (for whom a lobectomy is not a surgical option) where risk models and decision aids are needed most,” Dr. Samson and her colleagues stated.

“Counseling the high-risk but operable patient with clinical stage I NSCLC in regard to lobectomy, sublobar resection, or SBRT is challenging for both the clinician and the patient,” according to the researchers.

“We believe that a model tailored to patients with clinical stage I needs to serve as both an estimator of operative risks and a patient decision aid for surgery versus SBRT, espe-

Continued on following page

anticoagulation treatment as necessary [see *Warnings and Precautions*].

USE IN SPECIFIC POPULATIONS: Pregnancy: *Pregnancy Category D.* [See *Warnings and Precautions*]: OFEV (nintedanib) can cause fetal harm when administered to a pregnant woman. If OFEV is used during pregnancy, or if the patient becomes pregnant while taking OFEV, the patient should be apprised of the potential hazard to a fetus. Women of childbearing potential should be advised to avoid becoming pregnant while receiving treatment with OFEV. In animal reproduction toxicity studies, nintedanib caused embryofetal deaths and teratogenic effects in rats and rabbits at less than and approximately 5 times the maximum recommended human dose (MRHD) in adults (on a plasma AUC basis at maternal oral doses of 2.5 and 15 mg/kg/day in rats and rabbits, respectively). Malformations included abnormalities in the vasculature, urogenital, and skeletal systems. Vasculature anomalies included missing or additional major blood vessels. Skeletal anomalies included abnormalities in the thoracic, lumbar, and caudal vertebrae (e.g., hemivertebra, missing, or asymmetrically ossified), ribs (bifid or fused), and sternbrae (fused, split, or unilaterally ossified). In some fetuses, organs in the urogenital system were missing. In rabbits, a significant change in sex ratio was observed in fetuses (female:male ratio of approximately 71%:29%) at approximately 15 times the MRHD in adults (on an AUC basis at a maternal oral dose of 60 mg/kg/day). Nintedanib decreased post-natal viability of rat pups during the first 4 post-natal days when dams were exposed to less than the MRHD (on an AUC basis at a maternal oral dose of 10 mg/kg/day). **Nursing Mothers:** Nintedanib and/or its metabolites are excreted into the milk of lactating rats. Milk and plasma of lactating rats have similar concentrations of nintedanib and its metabolites. Excretion of nintedanib and/or its metabolites into human milk is probable. There are no human studies that have investigated the effects of OFEV on breast-fed infants. Because of the potential for serious adverse reactions in nursing infants from OFEV, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. **Pediatric Use:** Safety and effectiveness in pediatric patients have not been established. **Geriatric Use:** Of the total number of subjects in phase 2 and 3 clinical studies of OFEV, 60.8% were 65 and over, while 16.3% were 75 and over. In phase 3 studies, no overall differences in effectiveness were observed between subjects who were 65 and over and younger subjects; no overall differences in safety were observed

between subjects who were 65 and over or 75 and over and younger subjects, but greater sensitivity of some older individuals cannot be ruled out. **Hepatic Impairment:** Nintedanib is predominantly eliminated via biliary/fecal excretion (>90%). No dedicated pharmacokinetic (PK) study was performed in patients with hepatic impairment. Monitor for adverse reactions and consider dose modification or discontinuation of OFEV (nintedanib) as needed for patients with mild hepatic impairment (Child Pugh A). The safety and efficacy of nintedanib has not been investigated in patients with hepatic impairment classified as Child Pugh B or C. Therefore, treatment of patients with moderate (Child Pugh B) and severe (Child Pugh C) hepatic impairment with OFEV is not recommended [see *Warnings and Precautions*]. **Renal Impairment:** Based on a single-dose study, less than 1% of the total dose of nintedanib is excreted via the kidney. Adjustment of the starting dose in patients with mild to moderate renal impairment is not required. The safety, efficacy, and pharmacokinetics of nintedanib have not been studied in patients with severe renal impairment (<30 mL/min CrCl) and end-stage renal disease. **Smokers:** Smoking was associated with decreased exposure to OFEV, which may alter the efficacy profile of OFEV. Encourage patients to stop smoking prior to treatment with OFEV and to avoid smoking when using OFEV.

OVERDOSAGE: In the trials, one patient was inadvertently exposed to a dose of 600 mg daily for a total of 21 days. A non-serious adverse event (nasopharyngitis) occurred and resolved during the period of incorrect dosing, with no onset of other reported events. Overdose was also reported in two patients in oncology studies who were exposed to a maximum of 600 mg twice daily for up to 8 days. Adverse events reported were consistent with the existing safety profile of OFEV. Both patients recovered. In case of overdose, interrupt treatment and initiate general supportive measures as appropriate.

PATIENT COUNSELING INFORMATION: Advise the patient to read the FDA-approved patient labeling (*Patient Information*). **Liver Enzyme and Bilirubin Elevations:** Advise patients that they will need to undergo liver function testing periodically. Advise patients to immediately report any symptoms of a liver problem (e.g., skin or the whites of eyes turn yellow, urine turns dark or brown (tea colored), pain on the right side of stomach, bleed or bruise more easily than normal, lethargy) [see *Warnings and Precautions*]. **Gastrointestinal Disorders:** Inform patients that gastrointestinal disorders such as diarrhea, nausea,

and vomiting were the most commonly reported gastrointestinal events occurring in patients who received OFEV (nintedanib). Advise patients that their healthcare provider may recommend hydration, antidiarrheal medications (e.g., loperamide), or anti-emetic medications to treat these side effects. Temporary dosage reductions or discontinuations may be required. Instruct patients to contact their healthcare provider at the first signs of diarrhea or for any severe or persistent diarrhea, nausea, or vomiting [see *Warnings and Precautions and Adverse Reactions*]. **Pregnancy:** Counsel patients on pregnancy planning and prevention. Advise females of childbearing potential of the potential hazard to a fetus and to avoid becoming pregnant while receiving treatment with OFEV. Advise females of childbearing potential to use adequate contraception during treatment, and for at least 3 months after taking the last dose of OFEV. Advise female patients to notify their doctor if they become pregnant during therapy with OFEV [see *Warnings and Precautions and Use in Specific Populations*]. **Arterial Thromboembolic Events:** Advise patients about the signs and symptoms of acute myocardial ischemia and other arterial thromboembolic events and the urgency to seek immediate medical care for these conditions [see *Warnings and Precautions*]. **Risk of Bleeding:** Bleeding events have been reported. Advise patients to report unusual bleeding [see *Warnings and Precautions*]. **Gastrointestinal Perforation:** Serious gastrointestinal perforation events have been reported. Advise patients to report signs and symptoms of gastrointestinal perforation [see *Warnings and Precautions*]. **Nursing Mothers:** Advise patients to discontinue nursing while taking OFEV or discontinue OFEV while nursing [see *Use in Specific Populations*]. **Smokers:** Encourage patients to stop smoking prior to treatment with OFEV and to avoid smoking when using with OFEV. **Administration:** Instruct patients to swallow OFEV capsules whole with liquid and not to chew or crush the capsules due to the bitter taste. Advise patients to not make up for a missed dose [see *Dosage and Administration*].

Copyright © 2014 Boehringer Ingelheim International GmbH

ALL RIGHTS RESERVED

OF-BS-10-14 (10-15) OF629900PROF

Rx only



Poor adherence to quality indicators in NSCLC surgery

BY DOUG BRUNK
Frontline Medical News


PHOENIX – National adherence to quality indicators for surgery in stage I non–small cell lung cancer is suboptimal, results from a large analysis of national data suggest.

“Compliance with such guidelines is a strong predictor of long-term survival, and vigorous efforts should be instituted at the level of national societies to improve such adherence,” researchers led by Dr. Pamela P. Samson wrote in a study presented at the annual meeting of the Society of Thoracic Surgeons.

“National organizations, including the American College of Chest Physicians (CHEST), the National Comprehensive Cancer Network, and the American College of Surgeons Commission on Cancer, have recommended quality standards for surgery in early-stage non–small cell lung cancer (NSCLC). The determinants and outcomes of adherence to these guidelines for early-stage lung cancer patients are largely unknown.”

Dr. Samson, a general surgery resident at Washington University in St. Louis, and her associates used the National Cancer Data Base to evaluate data from 146,908 patients undergoing surgery for clinical stage I NSCLC between 2004 and 2013.

They selected the following four quality measures for evaluation: performing an anatomical pulmonary resection, surgery within 8 weeks of diagnosis, R0 resection, and evaluation of 10 or more lymph nodes. Next, the researchers fitted multivar-



The strongest determinant of long-term overall survival included pathologic upstaging (HR 1.84) and meeting all four quality indicators (HR 0.39). Every additional quality measure met was associated with a significant reduction in overall mortality.

iate models to identify variables independently associated with adherence to quality measures, and created a Cox multivariate model to evaluate long-term overall survival.

Dr. Varun Puri, senior author of the study, presented the findings at the STS meeting on behalf of Dr. Samson.

The researchers found that between 2004 and 2013, nearly 100% of patients met at least one of the four recommended criteria, 95% met two, 69% met three, and 22%

met all four. Sampling of 10 or more lymph nodes was the least frequently met measure, occurring in 31% of surgical patients.

Patient factors associated with a greater likelihood of receiving all four quality measures included average income in ZIP code of at least \$38,000 (odds ratio, 1.20), private insurance (OR, 1.22), or having Medicare (OR, 1.16). Institutional factors associated with a greater likelihood of meeting all four quality measures included higher-volume centers, de-

fining as treating at least 38 cases per year (OR, 1.18), or being an academic institution (OR, 1.31).

At the same time, factors associated with a lower likelihood of recommended surgical care included increasing age (per year increase, OR, 0.99) and a higher Charlson/Deyo comorbidity score (OR, 0.90 for a score of 1 and OR, 0.82 for a score of 2 or more). The strongest determinant of long-term overall survival included pathologic upstaging (HR 1.84) and meeting all four quality indicators (HR 0.39). Every additional quality measure met was associated with a significant reduction in overall mortality.

“We believe this study can be a starting point to draw attention to institution- and surgeon-specific practice patterns that may vary widely,” Dr. Samson said in an interview prior to the meeting. “At our own institution, we are working to decrease time to surgery, as well as implementing quality improvement measures to increase nodal sampling rates. Improving these trends nationally must start at the local level, with a tailored approach.”

Dr. Samson is currently supported by a T32 NIH training grant for research fellows in cardiothoracic surgery. Study coauthor Dr. Bryan Meyers, has received honoraria from Varian Medical Systems and is a consultant/advisory board member of Ethicon. Senior author Dr. Varun Puri is supported by NIH career awards.

dbrunk@frontlinemedcom.com

Continued from previous page

cially with projected increases in the number of early-stage lung cancers as a result of increased lung cancer screening efforts,” they added.

“Our analysis suggests that the NSQIP Surgical Risk Calculator likely does not profile the risk of a patient with lung cancer closely enough to dichotomize surgical and inoperable SBRT cases (especially when patients are being considered for a wedge resection) or adequately estimate a surgical patient’s risk of serious complications,” Dr. Samson and her colleagues concluded.

The study was supported by grants from National Institutes of Health. The authors had no relevant financial disclosures.

mlesney@frontlinemedcom.com

VIEW ON THE NEWS

Risk calculators can be useful, but...

In their reported study, Dr. Samson and her colleagues found that the NSQIP tool underestimated morbidity. They also found that risk predicted by the NSQIP tool was not necessarily aligned with their institution’s actual treatment selection for stage I NSCLC, which they based upon a number of factors. “This study potentially has important clinical implications,” according to Dr. Xiaofei Wang and Dr. Mark F. Berry in their invited commentary (*J Thorac Cardiovasc Surg.* 2016 Mar;151:706-7). “This present study shows that even a robust, well-managed tool from the NSQIP does not adequately stratify surgical risk... Their analysis implies that the treatment decision made by the institutional clinicians is optimal.”

“The lackluster performance of the NSQIP score is understandable, because it was not designed to optimally differentiate patients who benefited most from surgery or SBRT. Randomized clinical trials or

well-controlled prospective observations are needed to develop and validate specific predictive tools for optimal treatment selection. These models must consider not only treatment morbidity, but also the cost of possible recurrence with each therapy,” Dr. Wang and Dr. Berry stated.

“Perhaps the most important conclusion that can be drawn from this present study is that current risk assessment tools can be helpful, but cannot replace evaluation by clinicians for whom all management options are available when therapy is chosen for a specific patient,” they concluded.


Dr. Wang is from the department of biostatistics and bioinformatics at Duke University, Durham, N.C., and Dr. Berry is from the department of cardiothoracic surgery, Stanford University, Stanford, Calif. They had no relevant financial disclosures.



INTRODUCING
AEROSPHERE™
CO-SUSPENSION TECHNOLOGY

THE NEW SCIENCE OF
INTELLIGENT DELIVERY
IN RESPIRATORY MEDICINE

Exploring a new formulation for inhaled drug delivery

*A specially engineered,
phospholipid particle with
multiple drug crystals¹*





Visit Co-SuspensionParticles.com
to Learn More

AEROSPHERE

CO-SUSPENSION TECHNOLOGY

All images are for illustrative purposes only.

Reference: 1. Vehring R, Lechuga-Ballesteros D, Joshi V, Noga B, Dwivedi SK. Cosuspensions of microcrystals and engineered microparticles for uniform and efficient delivery of respiratory therapeutics from pressurized metered dose inhalers. *Langmuir*. 2012;28(42):15015-15023.

Selecting lesions for endoluminal bronchoscopy

BY DOUG BRUNK

Frontline Medical News

PHOENIX – According to Dr. Moishe Liberman, promising lesions for bronchoscopic endoluminal treatment include endobronchial lesions and intraluminal exophytic tumors within the trachea or main bronchus, provided that the distal airway lumen is visible and you can get past the tumor with a flexible endoscope.

“We always teach the fellows that if you get pus back when you’re trying to get around the tumor or play with the tumor, you’re usually going to have a very good result,” said Dr. Liberman, a thoracic surgeon who directs the endoscopic tracheo-bronchial and oesophageal center at the Centre hospitalier de l’Université de Montréal, Quebec, Canada. “If you play with the tumor and you get the tumor out and you get nothing back, usually the CT scan or the X-ray postoperatively is going to look just like it did preoperatively, even though endoscopically you might have a good result.”

Central lesions are also excellent candidates for endoluminal therapy, he said at the meeting.

Distal lesions in the small bronchi “are candidates but are much more difficult and require more specialized tools. The shorter the lesion, the more likely you are to have good success.”

Available options for delivering energy endo-

scopically include electrocautery, argon plasma coagulation, laser, and cryotherapy.

A disadvantage of all of the thermal modalities except for cryotherapy “include the potential for airway fire and you have to work with low FiO₂s [fraction of inspired oxygen],” Dr. Liberman noted. “A lot of these patients need high FiO₂s to saturate, so I think that’s always an issue. We never go on cardiopulmonary bypass to do these cases and we never cannulate patients to do these cases. You also have to worry about gas emboli, especially when you open up big vessels. These modalities can also cause inadvertent airway injury, delayed effects, and bronchoscope damage.”

In general, he continued, laser-tissue interactions depend on the power and the wavelength of the laser as well as the color and the water content of the target tissue.

“The power density of the wavelength you choose determines its ability to cut, coagulate, or vaporize the tissue,” he said. “As the power density increases, the laser fiber approaches the target tissue. Power density is more important than the energy delivered.”

The Nd:YAG (neodymium-doped yttrium aluminium garnet) laser, which causes more destruction in the deep tissue than on the surface, is the most common laser used in interventional airway procedures, he said.

Two other commonly used lasers include the

KTP (potassium titanyl phosphate) and the CO₂.

“I like CO₂ a lot for upper airway and subglottic problems as well as vocal cord problems,” Dr. Liberman said. “It’s very precise and has low penetration. The Nd:YAG is very good for deep penetration. You need familiarity with these. I don’t think you can just take one of these off the shelf if you’ve never used it before. Sometimes your ENT [ear nose and throat] or urology colleagues can help you, because they’re using a lot more of these lasers than we are.”

Contraindications for laser bronchoscopy include operable lesions.

Dr. Liberman said that while he and his associates use lasers in a preoperative setting, “we’re very careful not to damage proximal or distal airway when we know we’re going to do a sleeve resection or pneumonectomy.”

Other contraindications for laser bronchoscopy include patients with a poor short-term prognosis, severe coagulation disorder, extrinsic airway obstruction, tracheoesophageal fistula or T-Med fistula, those with extensive submucosal disease causing obstruction, and those with lesion adjacent to the esophagus or to a major vessel.

Dr. Liberman reported having received research grants from Ethicon, Boston Scientific, Olympus, Covidien, and Baxter.

dbrunk@frontlinemedcom.com

BMI impacts risk for complications after lung resection

BY DOUG BRUNK

Frontline Medical News

PHOENIX – Being underweight is associated with a substantially increased risk of complications following lung resection for cancer, results from a large database study found.

“This is not generally known among surgeons or their patients,” Dr. Trevor Williams said in an interview before the annual meeting of the Society of Thoracic Surgeons. “Studies are conflicting about the relationship of BMI [body mass index] to surgical outcomes. Most of the previous studies simply categorize BMI as overweight or not. We’ve stratified based on World Health Organization categories to get a more precise look at BMI.”



Dr. Williams, a surgeon at the University of Chicago Medical Center, and his associates evaluated 41,446 patients in the STS General Thoracic Surgery Database who underwent elective anatomic lung resection for cancer between 2009 and 2014. Their mean age was 68 years, and 53% were female. The researchers performed multivariable analysis after adjusting for validated STS risk model covariates, including gender and spirometry.

According to WHO criteria for BMI, 3% were underweight (less than 18.5 kg/m²); 33.5% were normal weight (18.5-24.9 kg/m²); 35.4% were

overweight (25-29.9 kg/m²); 18.1% were obese I (30-34.9 kg/m²); 6.4% were obese II (35-39.9 kg/m²), and 3.6% were obese III (40 kg/m² or greater).

Dr. Williams and his associates observed that women were more often underweight, compared with men (4.1% vs. 1.8%, respectively; *P* less than .001), and underweight patients more often had chronic obstructive pulmonary disease (51.7% vs. 35.2%; *P* less than .001). Pulmonary complication

Surprisingly, obese patients have a lower risk of overall complications than ‘normal’-BMI patients.

DR. WILLIAMS

rates were higher among underweight and obese III patients (*P* less than .001), while being underweight was also associated with higher rates of infections and any surgical complications. Multivariable analysis revealed that pulmonary and any postoperative complications were more common among underweight patients (odds ratio, 1.44 and OR, 1.41, respectively), while any major complication was more common among obese III patients (OR, 1.18). Overweight and obese I-II patients were less likely to have any postoperative and pulmonary complications, compared with patients who had a normal BMI.

“The finding of underweight patients being such a high-risk patient population is suggested in the literature but not demonstrated as clearly as in this study,” Dr. Williams said. “A truly surprising finding was that obese patients actually have a lower

risk of pulmonary and overall complications than ‘normal’-BMI patients.”

He concluded that according to the current analysis, “careful risk assessment is appropriate when considering operating on underweight patients. Whether there are interventions that could be instituted to improve an individual’s risk profile has not been determined. Any preconceived notions about not operating on obese patients due to elevated risk appear to be unfounded.”

Dr. Williams reported having no financial disclosures.

dbrunk@frontlinemdcom.com

Enhance your reading experience.

FREE APP DOWNLOAD

Optimized for mobile and tablets.

chestphysician.org


Available for iOS, Android and Amazon Kindle.

CHEST[®] Physician

THE NEWSPAPER OF THE AMERICAN COLLEGE OF CHEST PHYSICIANS

chestphysician.org

THE MORE DIFFICULT THE CASE, THE LESS DIFFICULT THE CHOICE OF HOSPITAL.



The Mount Sinai Hospital - National Jewish Health Respiratory Institute brings together a strong, integrated program for diagnosis and treatment of respiratory illness and lung disease. Our pulmonologists collaborate with specialists in related disciplines and work closely with research scientists on precision medicine, genomics, and data-driven clinical protocols to enhance the quality and outcomes of the respiratory disease practice. Additionally, our experts are on the faculty of the Icahn School of Medicine at Mount Sinai, ranked among the nation's top 20 medical schools by *U.S. News & World Report*.

- Asthma
- Bronchiectasis and NTM
- COPD
- Pulmonary Fibrosis/ILD
- Lung Nodule/Lung Cancer
- Pulmonary Hypertension
- Sarcoidosis
- Sleep Disorders

MOUNT SINAI - NATIONAL JEWISH HEALTH

Respiratory Institute

1-800-MD-SINAI • mountsinai.org/mslung



PRESIDENT'S REPORT: An open letter to President Obama

BY DR. BARBARA A. PHILLIPS, MSPH, FCCP

This month, we sent a letter to President Obama supporting ratification of the Framework Convention on Tobacco Control (FCTC) by the United States. Our goal was to let the President know it is our feeling that now is the right time for the United States to start playing a leading role in world tobacco control based on the scientific support of CHEST. Joining me in sending this letter was Dr. Panagiotis K. Behrakis, FCCP, who serves as a

Regent-at-Large on the CHEST Board of Regents. As President of the Scientific Committee on the European Network of Smoking and Tobacco Prevention and a former Chair of CHEST's Council of Global Governors, Dr. Behrakis has been closely following the history of the FCTC since its beginning more than 10 years ago. He suggested that this open letter to President Obama might be a very effective first step toward the desired ratification of FCTC by the United States. I was happy to join Dr. Behrakis in sending the following letter, on behalf of CHEST.



DR. PHILLIPS



DR. BEHRAKIS



2595 Patriot Boulevard
Glenview, Illinois 60026
USA
224/521-9800
chestnet.org

March 1, 2016

To champion the prevention, diagnosis, and treatment of chest diseases through education, communication, and research.

Board of Regents

Barbara A. Phillips, MD, MSPH, FCCP
President and Chair

Gerard A. Silvestri, MD, FCCP
President-Elect and Vice-Chair

Curtis N. Sessler, MD, FCCP
Immediate Past President

John E. Studdard, MD, FCCP
President-Designate

John A. Howington, MD, FCCP
*CHEST Foundation
President and Trustee*

Executive Vice President and CEO

Paul A. Markowski, CAE
Secretary

Regents-at-Large

Robert Aranson, MD, FCCP
Panagiotis K. Behrakis, MD, FCCP
Jack D. Buckley, MD, FCCP
Clayton T. Cowl, MD, FCCP
Marilyn G. Foreman, MD, FCCP
Burton L. Lesnick, MD, FCCP
Stephanie M. Levine, MD, FCCP
Janet R. Maurer, MD, MBA, FCCP
Atul C. Mehta, MBBS, FCCP
Steven Q. Simpson, MD, FCCP

Francesco de Blasio, MD, FCCP
Chair, Council of Global Governors
David A. Schulman, MD, FCCP
Chair, Council of NetWorks

Ex Officio Members

Islam M. Ibrahim, MD, FCCP
*Vice-Chair, Council of Global
Governors*

Victor J. Test, MD, FCCP
Vice-Chair, Council of NetWorks

Richard S. Irwin, MD, Master FCCP
CHEST, Editor in Chief

The President

The White House
1600 Pennsylvania Avenue NW
Washington, DC 20500

Dear Mr. President,

Addiction to tobacco is the largest preventable cause of death and disability worldwide, expected to cause one billion deaths this century. In addition, passive smoking is estimated to cause over 600,000 deaths annually, 150,000 of which are among children.

These staggering numbers can only be prevented by a global consensus on the protection of public health from tobacco use. A supranational coordination for the solution to the problem is the Framework Convention on Tobacco Control of the World Health Organization (FCTC, WHO). The FCTC is an evidence-based treaty reaffirming the right of all people to the highest standard of health. As stated in its preamble, it seeks "to protect present and future generations from the devastating health, social, environmental and economic consequences of tobacco consumption and exposure to tobacco smoke" by enacting a set of universal standards stating the dangers of tobacco and limiting its use in all forms worldwide. To this end, the treaty's provisions include rules that govern the production, sale, distribution, advertisement, and taxation of tobacco.

The FCTC was adopted as the first global treaty negotiated under the auspices of the WHO by the World Health Assembly in May 2003, entered into force in February 2005, and very soon became one of the most rapidly and widely embraced treaties in the history of the United Nations. Currently, the FCTC has been ratified by 180 countries, corresponding to more than 80% of the world population. Only seven countries, the most prominent of which being the United States of America, have signed but not yet ratified the treaty. Interestingly, the USA played an active role in the long preparatory phase and the signing of the treaty in May 2004 but has not yet ratified the FCTC.

Within the past six Conferences of the Parties (COP) of FCTC, the absence of the USA as an active member results as following:

- The leading role of the USA is absent from the most important efforts of the United Nations toward the protection of public health.
- In the decision-making process of the FCTC, the most powerful nation in the world is silent.
- The excellent national actions to curb the tobacco epidemic in the USA fail to be transferred to the global level.

As an ambassador for the protection of human rights at a global level, the USA's leadership is needed to ensure implementation worldwide of FCTC articles for the protection of children, women, and other vulnerable populations.

(continued)

Page 2

We are reaching out to you on behalf of the American College of Chest Physicians (CHEST). With more than 19,000 members representing 100+ countries around the world, CHEST is the global leader in advancing best patient outcomes through innovative chest medicine education, clinical research, and team-based care. Our mission is to champion the prevention, diagnosis, and treatment of chest diseases through education, communication, and research. Over our 80+ years in existence, CHEST has been active on a global level raising awareness about the dangers of tobacco use and the importance of lung health. We were one of the first medical organizations to recognize the dangers of cigarette smoking and were instrumental in helping pass legislation requiring printing the Surgeon General's warning on cigarette packages. We were also instrumental in the passage of legislation banning smoking on domestic flights.

In light of the above, as a board member and as a board chair and President of CHEST, we feel it is our duty to urge the First Citizen of the strongest nation in the world to take the historic decision of addressing the largest preventable threat to human health and to ratify the WHO Framework Convention on Tobacco Control.

Most Respectfully,

Panagiotis K. Behrakis, MD, PhD (McGill), FCCP, Pulmonologist-Intensivist
Regent-At-Large, Board of Regents, American College of Chest Physicians
Director, Institute of Public Health, the American College of Greece
President, Scientific Committee of European Network of Smoking and Tobacco Prevention
Former Adjunct Professor, School of Public Health, Harvard University
Former Associate Professor of Physiology, School of Medicine, Athens University
panbehrakis@gmail.com

Barbara A. Phillips, MD, MSPH, FCCP
President and Chair of the Board of Regents, American College of Chest Physicians
Professor, Division of Pulmonary, Critical Care and Sleep Medicine
University of Kentucky College of Medicine, Lexington, KY
bphil020@gmail.com

Make plans now to attend CHEST 2016

October 22-26
Los Angeles, California

With mild temperatures and sunshine nearly 300 days a year, Los Angeles is often described as "perfect." And, it's a perfect setting for the CHEST Annual Meeting 2016, where we'll connect a global community in clinical chest medi-

cine. As always, our program will deliver pulmonary, critical care, and sleep medicine topics presented by world-renowned faculty in a variety of innovative instruction formats. Take advantage of these opportunities now:

Call for abstracts

Submission Deadline: April 1

Submit an abstract of your original investigative work for presentation at CHEST 2016. Submission is free, and accepted abstracts become eligible for CHEST Foundation investigative awards. Accepted abstracts will appear in an online supplement to CHEST featuring abstracts and case reports. Two types of abstracts will be considered:

CHEST
Annual Meeting
2016

- Slide Presentations
- Poster Presentations

Learn more and submit at chest-meeting.chestnet.org.

Continued on page 46

In a subset (n=366) of a managed care population with a diagnosis of COPD

81% of patients had moderate or worse COPD at spirometry-confirmed diagnosis¹



Is it time to rethink
how you treat COPD?

BETTER BREATHING *Starts With* ANORO

ANORO is for the once-daily maintenance treatment of airflow obstruction in patients with COPD. ANORO is NOT for the relief of acute bronchospasm or for asthma.

StartWithANORO.com



ANORO[®] ELLIPTA[®]
(umeclidinium 62.5 mcg and vilanterol 25 mcg inhalation powder)

In the study referenced above, COPD severity was based on GOLD classification at time of study: 50% moderate, 26% severe, 5% very severe. COPD=chronic obstructive pulmonary disease; GOLD=Global Initiative for Chronic Obstructive Lung Disease.

Important Safety Information

WARNING: ASTHMA-RELATED DEATH

- Long-acting beta₂-adrenergic agonists (LABA), such as vilanterol, one of the active ingredients in ANORO ELLIPTA, increase the risk of asthma-related death. A placebo-controlled trial with another LABA (salmeterol) showed an increase in asthma-related deaths in subjects receiving salmeterol. This finding with salmeterol is considered a class effect of all LABA, including vilanterol.
- The safety and efficacy of ANORO ELLIPTA in patients with asthma have not been established. ANORO ELLIPTA is not indicated for the treatment of asthma.

CONTRAINDICATIONS

- The use of ANORO ELLIPTA is contraindicated in patients with severe hypersensitivity to milk proteins or who have demonstrated hypersensitivity to umeclidinium, vilanterol, or any of the excipients.

WARNINGS AND PRECAUTIONS

- ANORO ELLIPTA should not be initiated in patients during rapidly deteriorating or potentially life-threatening episodes of COPD.
- ANORO ELLIPTA should not be used for the relief of acute symptoms, ie, as rescue therapy for the treatment of acute episodes of bronchospasm. Acute symptoms should be treated with an inhaled, short-acting beta₂-agonist.

Please see additional Important Safety Information for ANORO ELLIPTA on the following pages.

Please see Brief Summary of Prescribing Information, including Boxed Warning, for ANORO ELLIPTA following this advertisement.





ANORO for the maintenance treatment of COPD

Description of Lung Function Comparison Studies²⁻⁴

The efficacy and safety of a once-daily dose of ANORO ELLIPTA and SPIRIVA® HandiHaler® (tiotropium bromide inhalation powder) were evaluated in 24-week, multicenter, randomized, blinded, active-controlled, double-dummy, parallel-group studies in patients (mean age range: 62 to 65 years) with COPD. At screening, patients had a mean postbronchodilator FEV₁ range of 46.4% to 47.7% predicted (ranges for each study were

within GOLD classification 2, 3, or 4). The studies were not powered to compare the safety profile of ANORO ELLIPTA with that of SPIRIVA HandiHaler.

Primary endpoint: Trough (predose) FEV₁ at Day 169 (defined as the mean of the FEV₁ values obtained 23 and 24 hours after dosing on Day 168).

FEV₁=forced expiratory volume in 1 second.

SPIRIVA and HandiHaler are registered trademarks owned by Boehringer Ingelheim.



Important Safety Information (cont'd)

WARNINGS AND PRECAUTIONS (cont'd)

- ANORO ELLIPTA should not be used more often than recommended, at higher doses than recommended, or in conjunction with other medicines containing LABA, as an overdose may result. Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. Patients using ANORO ELLIPTA should not use another medicine containing a LABA (eg, salmeterol, formoterol fumarate, arformoterol tartrate, indacaterol) for any reason.
- Caution should be exercised when considering the coadministration of ANORO ELLIPTA with long-term ketoconazole and other known strong CYP3A4 inhibitors (eg, ritonavir, clarithromycin, conivaptan, indinavir, itraconazole, lopinavir, nefazodone, nelfinavir, saquinavir, telithromycin, troleandomycin, voriconazole) because increased cardiovascular adverse effects may occur.
- If paradoxical bronchospasm occurs, discontinue ANORO ELLIPTA and institute alternative therapy.
- Vilanterol can produce clinically significant cardiovascular effects in some patients as measured by increases in pulse rate, systolic or diastolic blood pressure, or symptoms. If such effects occur, ANORO ELLIPTA may need to be discontinued. ANORO ELLIPTA should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension.

WARNINGS AND PRECAUTIONS (cont'd)

- Use with caution in patients with convulsive disorders, thyrotoxicosis, diabetes mellitus, and ketoacidosis, and in patients who are unusually responsive to sympathomimetic amines.
- Use with caution in patients with narrow-angle glaucoma. Instruct patients to contact a physician immediately if signs or symptoms of acute narrow-angle glaucoma develop.
- Use with caution in patients with urinary retention, especially in patients with prostatic hyperplasia or bladder-neck obstruction. Instruct patients to contact a physician immediately if signs or symptoms of urinary retention develop.
- Be alert to hypokalemia and hyperglycemia.


ADVERSE REACTIONS

- The most common adverse reactions (≥1% and more common than placebo) reported in four 6-month clinical trials with ANORO ELLIPTA (and placebo) were: pharyngitis, 2% (<1%); sinusitis, 1% (<1%); lower respiratory tract infection, 1% (<1%); constipation, 1% (<1%); diarrhea, 2% (1%); pain in extremity, 2% (1%); muscle spasms, 1% (<1%); neck pain, 1% (<1%); and chest pain, 1% (<1%).
- In addition to the 6-month efficacy trials with ANORO ELLIPTA, a 12-month trial evaluated the safety of umeclidinium/vilanterol 125 mcg/25 mcg in subjects with COPD. Adverse reactions (incidence ≥1% and more common than placebo) in subjects receiving umeclidinium/vilanterol 125 mcg/25 mcg were: headache, back pain, sinusitis, cough, urinary tract infection, arthralgia, nausea, vertigo, abdominal pain, pleuritic pain, viral respiratory tract infection, toothache, and diabetes mellitus.

For patients with moderate or worse COPD

Start with ANORO ELLIPTA instead of SPIRIVA HandiHaler for superior improvement in lung function

ANORO ELLIPTA DELIVERED SIGNIFICANT IMPROVEMENT IN TROUGH FEV₁ vs SPIRIVA HandiHaler AT DAY 169 IN 2 STUDIES^{2,3}



ANORO ELLIPTA is a combination anticholinergic/LABA for the maintenance treatment of airflow obstruction in patients with COPD.

SPIRIVA HandiHaler is an anticholinergic for the maintenance treatment of bronchospasm associated with COPD, and for reducing COPD exacerbations.⁵

In a separate study, ANORO ELLIPTA showed a 60-mL difference* compared with SPIRIVA HandiHaler (208 mL and 149 mL, respectively), but due to testing hierarchy, statistical significance cannot be inferred.²

LS=least squares.

*Reflects rounding.

Important Safety Information (cont'd)

DRUG INTERACTIONS

- Caution should be exercised when considering the coadministration of ANORO ELLIPTA with ketoconazole and other known strong CYP3A4 inhibitors (eg, ritonavir, clarithromycin, conivaptan, indinavir, itraconazole, lopinavir, nefazodone, nelfinavir, saquinavir, telithromycin, troleandomycin, voriconazole) because increased systemic exposure to vilanterol and cardiovascular adverse effects may occur.
- ANORO ELLIPTA should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval, or within 2 weeks of discontinuation of such agents, because the effect of adrenergic agonists, such as vilanterol, on the cardiovascular system may be potentiated by these agents.

DRUG INTERACTIONS (cont'd)

- Use beta-blockers with caution as they not only block the pulmonary effect of beta-agonists, such as vilanterol, but may produce severe bronchospasm in patients with COPD.
- Use with caution in patients taking non-potassium-sparing diuretics, as electrocardiographic changes and/or hypokalemia associated with non-potassium-sparing diuretics may worsen with concomitant beta-agonists.
- Avoid coadministration of ANORO ELLIPTA with other anticholinergic-containing drugs as this may lead to an increase in anticholinergic adverse effects.



Learn more at
StartWithANORO.com

Please see additional Important Safety Information for ANORO ELLIPTA on preceding pages.

Please see Brief Summary of Prescribing Information, including Boxed Warning, for ANORO ELLIPTA on the following pages.

References: 1. Mapel DW, Dalal AA, Blanchette CM, et al. Severity of COPD at initial spirometry-confirmed diagnosis: data from medical charts and administrative claims. *Int J Chron Obstruct Pulmon Dis.* 2011;6:573-581. 2. Decramer M, Anzueto A, Kerwin E, et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. *Lancet Respir Med.* 2014;2(6):472-486. 3. Maleki-Yazdi MR, Kaelin T, Richard N, et al. Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial. *Respir Med.* 2014;108(12):1752-1760. 4. Data on file, GSK. 5. SPIRIVA HandiHaler [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; 2014.



©2015 GSK group of companies.
All rights reserved. Printed in USA. 507614R0 November 2015



ANORO ELLIPTA was developed in collaboration with Theravance

ANORO[®] ELLIPTA[®]
(umeclidinium 62.5 mcg and vilanterol 25 mcg inhalation powder)

BRIEF SUMMARY

ANORO® ELLIPTA® (umeclidinium and vilanterol inhalation powder) FOR ORAL INHALATION USE

The following is a brief summary only; see full prescribing information for complete product information.

WARNING: ASTHMA-RELATED DEATH

Long-acting beta₂-adrenergic agonists (LABA) increase the risk of asthma-related death. Data from a large placebo-controlled US trial that compared the safety of another LABA (salmeterol) with placebo added to usual asthma therapy showed an increase in asthma-related deaths in subjects receiving salmeterol. This finding with salmeterol is considered a class effect of all LABA, including vilanterol, one of the active ingredients in ANORO ELLIPTA [see Warnings and Precautions (5.1)].

The safety and efficacy of ANORO ELLIPTA in patients with asthma have not been established. ANORO ELLIPTA is not indicated for the treatment of asthma.

1 INDICATIONS AND USAGE

ANORO ELLIPTA is a combination anticholinergic/long-acting beta₂-adrenergic agonist (anticholinergic/LABA) indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

Important Limitations of Use: ANORO ELLIPTA is NOT indicated for the relief of acute bronchospasm or for the treatment of asthma.

4 CONTRAINDICATIONS

The use of ANORO ELLIPTA is contraindicated in patients with severe hypersensitivity to milk proteins or who have demonstrated hypersensitivity to umeclidinium, vilanterol, or any of the excipients [see Warnings and Precautions (5.6), Description (11) of full Prescribing Information].

5 WARNINGS AND PRECAUTIONS

5.1 Asthma-Related Death

- Data from a large placebo-controlled trial in subjects with asthma showed that LABA may increase the risk of asthma-related death. Data are not available to determine whether the rate of death in patients with COPD is increased by LABA.
- A 28-week, placebo-controlled, US trial comparing the safety of another LABA (salmeterol) with placebo, each added to usual asthma therapy, showed an increase in asthma-related deaths in subjects receiving salmeterol (13/13,176 in subjects treated with salmeterol vs. 3/13,179 in subjects treated with placebo; relative risk: 4.37 [95% CI: 1.25, 15.34]). The increased risk of asthma-related death is considered a class effect of LABA, including vilanterol, one of the active ingredients in ANORO ELLIPTA.
- No trial adequate to determine whether the rate of asthma-related death is increased in subjects treated with ANORO ELLIPTA has been conducted. The safety and efficacy of ANORO ELLIPTA in patients with asthma have not been established. ANORO ELLIPTA is not indicated for the treatment of asthma.

5.2 Deterioration of Disease and Acute Episodes

ANORO ELLIPTA should not be initiated in patients during rapidly deteriorating or potentially life-threatening episodes of COPD. ANORO ELLIPTA has not been studied in subjects with acutely deteriorating COPD. The initiation of ANORO ELLIPTA in this setting is not appropriate.

ANORO ELLIPTA should not be used for the relief of acute symptoms, i.e., as rescue therapy for the treatment of acute episodes of bronchospasm. ANORO ELLIPTA has not been studied in the relief of acute symptoms and extra doses should not be used for that purpose. Acute symptoms should be treated with an inhaled, short-acting beta₂-agonist. When beginning treatment with ANORO ELLIPTA, patients who have been taking oral or inhaled, short-acting beta₂-agonists on a regular basis (e.g., 4 times a day) should be instructed to discontinue the regular use of these drugs and to use them only for symptomatic relief of acute respiratory symptoms. When prescribing ANORO ELLIPTA, the healthcare provider should also prescribe an inhaled, short-acting beta₂-agonist and instruct the patient on how it should be used. Increasing inhaled, short-acting beta₂-agonist use is a signal of deteriorating disease for which prompt medical attention is indicated.

COPD may deteriorate acutely over a period of hours or chronically over several days or longer. If ANORO ELLIPTA no longer controls symptoms of bronchoconstriction; the patient's inhaled, short-acting beta₂-agonist becomes less effective; or the patient needs more short-acting beta₂-agonist than usual, these may be markers of deterioration of disease. In this setting a re-evaluation of the patient and the COPD treatment regimen should be undertaken at once. Increasing the daily dose of ANORO ELLIPTA beyond the recommended dose is not appropriate in this situation.

5.3 Excessive Use of ANORO ELLIPTA and Use With Other Long-Acting Beta₂-Agonists

ANORO ELLIPTA should not be used more often than recommended, at higher doses than recommended, or in conjunction with other medicines containing LABA, as an overdose may result. Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. Patients using ANORO ELLIPTA should not use another medicine containing a LABA (e.g., salmeterol, formoterol fumarate, arformoterol tartrate, indacaterol) for any reason.

5.4 Drug Interactions With Strong Cytochrome P450 3A4 Inhibitors

Caution should be exercised when considering the coadministration of ANORO ELLIPTA with long-term ketoconazole and other known strong cytochrome P450 3A4 (CYP3A4) inhibitors (e.g., ritonavir, clarithromycin, conivaptan, indinavir, itraconazole, lopinavir, nefazodone, nelfinavir, saquinavir, telithromycin, troleandomycin, voriconazole) because increased cardiovascular adverse effects may occur [see Drug Interactions (7.1), Clinical Pharmacology (12.3) of full Prescribing Information].

5.5 Paradoxical Bronchospasm

As with other inhaled medicines, ANORO ELLIPTA can produce paradoxical bronchospasm, which may be life threatening. If paradoxical bronchospasm occurs following dosing with ANORO ELLIPTA, it should be treated immediately with an inhaled, short-acting bronchodilator; ANORO ELLIPTA should be discontinued immediately; and alternative therapy should be instituted.

5.6 Hypersensitivity Reactions

Hypersensitivity reactions may occur after administration of ANORO ELLIPTA. There have been reports of anaphylactic reactions in patients with severe milk protein allergy after inhalation of other powder products containing lactose; therefore, patients with severe milk protein allergy should not use ANORO ELLIPTA [see Contraindications (4)].

5.7 Cardiovascular Effects

Vilanterol, like other beta₂-agonists, can produce a clinically significant cardiovascular effect in some patients as measured by increases in pulse rate, systolic or diastolic blood pressure, or symptoms [see Clinical Pharmacology (12.2) of full Prescribing Information]. If such effects occur, ANORO ELLIPTA may need to be discontinued. In addition, beta-agonists have been reported to produce electrocardiographic changes, such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression, although the clinical significance of these findings is unknown.

Therefore, ANORO ELLIPTA should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension.

5.8 Coexisting Conditions

ANORO ELLIPTA, like all medicines containing sympathomimetic amines, should be used with caution in patients with convulsive disorders or thyrotoxicosis and in those who are unusually responsive to sympathomimetic amines. Doses of the related beta₂-adrenoceptor agonist albuterol, when administered intravenously, have been reported to aggravate preexisting diabetes mellitus and ketoacidosis.

5.9 Worsening of Narrow-Angle Glaucoma

ANORO ELLIPTA should be used with caution in patients with narrow-angle glaucoma. Prescribers and patients should be alert for signs and symptoms of acute narrow-angle glaucoma (e.g., eye pain or discomfort, blurred vision, visual halos or colored images in association with red eyes from conjunctival congestion and corneal edema). Instruct patients to consult a physician immediately if any of these signs or symptoms develops.

5.10 Worsening of Urinary Retention

ANORO ELLIPTA should be used with caution in patients with urinary retention. Prescribers and patients should be alert for signs and symptoms of urinary retention (e.g., difficulty passing urine, painful urination), especially in patients with prostatic hyperplasia or bladder-neck obstruction. Instruct patients to consult a physician immediately if any of these signs or symptoms develops.

5.11 Hypokalemia and Hyperglycemia

Beta-adrenergic agonist medicines may produce significant hypokalemia in some patients, possibly through intracellular shunting, which has the potential to produce adverse cardiovascular effects. The decrease in serum potassium is usually transient, not requiring supplementation. Beta-agonist medicines may produce transient hyperglycemia in some patients. In 4 clinical trials of 6-month duration evaluating ANORO ELLIPTA in subjects with COPD, there was no evidence of a treatment effect on serum glucose or potassium.

6 ADVERSE REACTIONS

LABA, such as vilanterol, one of the active ingredients in ANORO ELLIPTA, increase the risk of asthma-related death. ANORO ELLIPTA is not indicated for the treatment of asthma. [See Boxed Warning and Warnings and Precautions (5.1).]

The following adverse reactions are described in greater detail in other sections:

- Paradoxical bronchospasm [see Warnings and Precautions (5.5)]
- Cardiovascular effects [see Warnings and Precautions (5.7)]
- Worsening of narrow-angle glaucoma [see Warnings and Precautions (5.9)]
- Worsening of urinary retention [see Warnings and Precautions (5.10)]

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The clinical program for ANORO ELLIPTA included 8,138 subjects with COPD in four 6-month lung function trials, one 12-month long-term safety study, and 9 other trials of shorter duration. A total of 1,124 subjects have received at least 1 dose of ANORO ELLIPTA (umeclidinium/vilanterol 62.5 mcg/25 mcg), and 1,330 subjects have received a higher dose of umeclidinium/vilanterol (125 mcg/25 mcg). The safety data described below are based on the four 6-month and the one 12-month trials. Adverse reactions observed in the other trials were similar to those observed in the confirmatory trials.

6-Month Trials: The incidence of adverse reactions associated with ANORO ELLIPTA in Table 1 is based on four 6-month trials: 2 placebo-controlled trials (Trials 1 and 2; n = 1,532 and n = 1,489, respectively) and 2 active-controlled trials (Trials 3 and 4; n = 843 and n = 869, respectively). Of the 4,733 subjects, 68% were male and 84% were Caucasian. They had a mean age of 63 years and an average smoking history of 45 pack-years, with 50% identified as current smokers. At screening, the mean post-bronchodilator percent predicted forced expiratory volume in 1 second (FEV₁) was 48% (range: 13% to 76%), the mean post-bronchodilator FEV₁/forced vital capacity (FVC) ratio was 0.47 (range: 0.13 to 0.78), and the mean percent reversibility was 14% (range: -45% to 109%). Subjects received 1 dose once daily of the following: ANORO ELLIPTA, umeclidinium/vilanterol 125 mcg/25 mcg, umeclidinium 62.5 mcg, umeclidinium 125 mcg, vilanterol 25 mcg, active control, or placebo.

Table 1. Adverse Reactions With ANORO ELLIPTA With ≥1% Incidence and More Common Than With Placebo in Subjects With Chronic Obstructive Pulmonary Disease

Adverse Reaction	Placebo (n = 555) %	ANORO ELLIPTA (n = 842) %	Umeclidinium 62.5 mcg (n = 418) %	Vilanterol 25 mcg (n = 1,034) %
Infections and infestations				
Pharyngitis	<1	2	1	2
Sinusitis	<1	1	<1	1
Lower respiratory tract infection	<1	1	<1	<1
Gastrointestinal disorders				
Constipation	<1	1	<1	<1
Diarrhea	1	2	<1	2
Musculoskeletal and connective tissue disorders				
Pain in extremity	1	2	<1	2
Muscle spasms	<1	1	<1	<1
Neck pain	<1	1	<1	<1
General disorders and administration site conditions				
Chest pain	<1	1	<1	<1

Other adverse reactions with ANORO ELLIPTA observed with an incidence less than 1% but more common than with placebo included the following: productive cough, dry mouth, dyspepsia, abdominal pain, gastroesophageal reflux disease, vomiting, musculoskeletal chest pain, chest discomfort, asthenia, atrial fibrillation, ventricular extrasystoles, supraventricular extrasystoles, myocardial infarction, pruritus, rash, and conjunctivitis.

12-Month Trial: In a long-term safety trial, 335 subjects were treated for up to 12 months with umeclidinium/vilanterol 125 mcg/25 mcg or placebo. The demographic and baseline characteristics of the long-term safety trial were similar to those of the placebo-controlled efficacy trials described above. Adverse reactions that occurred with a frequency of greater than or equal to 1% in the group receiving umeclidinium/vilanterol 125 mcg/25 mcg that exceeded that in placebo in this trial were: headache, back pain, sinusitis, cough, urinary tract infection, arthralgia, nausea, vertigo, abdominal pain, pleuritic pain, viral respiratory tract infection, toothache, and diabetes mellitus.

7 DRUG INTERACTIONS

7.1 Inhibitors of Cytochrome P450 3A4

Vilanterol, a component of ANORO ELLIPTA, is a substrate of CYP3A4. Concomitant administration of the strong CYP3A4 inhibitor ketoconazole increases the systemic exposure to vilanterol. Caution should be exercised when

considering the coadministration of ANORO ELLIPTA with ketoconazole and other known strong CYP3A4 inhibitors (e.g., ritonavir, clarithromycin, conivaptan, indinavir, itraconazole, lopinavir, nefazodone, nelfinavir, saquinavir, telithromycin, troleanomycin, voriconazole) [see *Warnings and Precautions (5.4), Clinical Pharmacology (12.3) of full Prescribing Information*].

7.2 Monoamine Oxidase Inhibitors and Tricyclic Antidepressants

Vilanterol, like other beta₂-agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval or within 2 weeks of discontinuation of such agents, because the effect of adrenergic agonists on the cardiovascular system may be potentiated by these agents. Drugs that are known to prolong the QTc interval have an increased risk of ventricular arrhythmias.

7.3 Beta-Adrenergic Receptor Blocking Agents

Beta-blockers not only block the pulmonary effect of beta-agonists, such as vilanterol, a component of ANORO ELLIPTA, but may produce severe bronchospasm in patients with COPD. Therefore, patients with COPD should not normally be treated with beta-blockers. However, under certain circumstances, there may be no acceptable alternatives to the use of beta-adrenergic blocking agents for these patients; cardioselective beta-blockers could be considered, although they should be administered with caution.

7.4 Non-Potassium-Sparing Diuretics

The electrocardiographic changes and/or hypokalemia that may result from the administration of non-potassium-sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, such as vilanterol, a component of ANORO ELLIPTA, especially when the recommended dose of the beta-agonist is exceeded. Although the clinical significance of these effects is not known, caution is advised in the coadministration of ANORO ELLIPTA with non-potassium-sparing diuretics.

7.5 Anticholinergics

There is potential for an additive interaction with concomitantly used anticholinergic medicines. Therefore, avoid coadministration of ANORO ELLIPTA with other anticholinergic-containing drugs as this may lead to an increase in anticholinergic adverse effects [see *Warnings and Precautions (5.9, 5.10), Adverse Reactions (6)*].

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Teratogenic Effects: Pregnancy Category C. There are no adequate and well-controlled trials of ANORO ELLIPTA or its individual components, umeclidinium and vilanterol, in pregnant women. Because animal reproduction studies are not always predictive of human response, ANORO ELLIPTA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Women should be advised to contact their physicians if they become pregnant while taking ANORO ELLIPTA.

Umeclidinium: There was no evidence of teratogenic effects in rats and rabbits at approximately 50 and 200 times, respectively, the MRHDID (maximum recommended human daily inhaled dose) in adults (on an AUC basis at maternal inhaled doses up to 278 mcg/kg/day in rats and at maternal subcutaneous doses up to 180 mcg/kg/day in rabbits).

Vilanterol: There were no teratogenic effects in rats and rabbits at approximately 13,000 and 70 times, respectively, the MRHDID in adults (on a mcg/m² basis at maternal inhaled doses up to 33,700 mcg/kg/day in rats and on an AUC basis at maternal inhaled doses up to 591 mcg/kg/day in rabbits). However, fetal skeletal variations were observed in rabbits at approximately 450 times the MRHDID in adults (on an AUC basis at maternal inhaled or subcutaneous doses of 5,740 or 300 mcg/kg/day, respectively). The skeletal variations included decreased or absent ossification in cervical vertebral centrum and metacarpals.

Nonteratogenic Effects: **Umeclidinium:** There were no effects on perinatal and postnatal developments in rats at approximately 80 times the MRHDID in adults (on an AUC basis at maternal subcutaneous doses up to 180 mcg/kg/day).

Vilanterol: There were no effects on perinatal and postnatal developments in rats at approximately 3,900 times the MRHDID in adults (on a mcg/m² basis at maternal oral doses up to 10,000 mcg/kg/day).

8.2 Labor and Delivery

There are no adequate and well-controlled human trials that have investigated the effects of ANORO ELLIPTA during labor and delivery.

Because beta-agonists may potentially interfere with uterine contractility, ANORO ELLIPTA should be used during labor only if the potential benefit justifies the potential risk.

8.3 Nursing Mothers

ANORO ELLIPTA: It is not known whether ANORO ELLIPTA is excreted in human breast milk. Because many drugs are excreted in human milk, caution should be exercised when ANORO ELLIPTA is administered to a nursing woman. Since there are no data from well-controlled human studies on the use of ANORO ELLIPTA by nursing mothers, based on the data for the individual components, a decision should be made whether to discontinue nursing or to discontinue ANORO ELLIPTA, taking into account the importance of ANORO ELLIPTA to the mother.

Umeclidinium: It is not known whether umeclidinium is excreted in human breast milk. However, administration to lactating rats at approximately 25 times the MRHDID in adults resulted in a quantifiable level of umeclidinium in 2 pups, which may indicate transfer of umeclidinium in milk.

Vilanterol: It is not known whether vilanterol is excreted in human breast milk. However, other beta₂-agonists have been detected in human milk.

8.4 Pediatric Use

ANORO ELLIPTA is not indicated for use in children. The safety and efficacy in pediatric patients have not been established.

8.5 Geriatric Use

Based on available data, no adjustment of the dosage of ANORO ELLIPTA in geriatric patients is necessary, but greater sensitivity in some older individuals cannot be ruled out.

Clinical trials of ANORO ELLIPTA for COPD included 2,143 subjects aged 65 and older and, of those, 478 subjects were aged 75 and older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger subjects.

8.6 Hepatic Impairment

Patients with moderate hepatic impairment (Child-Pugh score of 7-9) showed no relevant increases in C_{max} or AUC, nor did protein binding differ between subjects with moderate hepatic impairment and their healthy controls.

Studies in subjects with severe hepatic impairment have not been performed [see *Clinical Pharmacology (12.3) of full Prescribing Information*].

8.7 Renal Impairment

There were no significant increases in either umeclidinium or vilanterol exposure in subjects with severe renal impairment (CrCl < 30 mL/min) compared with healthy subjects. No dosage adjustment is required in patients with renal impairment [see *Clinical Pharmacology (12.3) of full Prescribing Information*].

10 OVERDOSAGE

No case of overdose has been reported with ANORO ELLIPTA.

ANORO ELLIPTA contains both umeclidinium and vilanterol; therefore, the risks associated with overdosage for the individual components described below apply to ANORO ELLIPTA. Treatment of overdosage consists of discontinuation of ANORO ELLIPTA together with institution of appropriate symptomatic and/or supportive therapy. The judicious use of a cardioselective beta-receptor blocker may be considered, bearing in mind that such medicine can produce bronchospasm. Cardiac monitoring is recommended in cases of overdosage.

10.1 Umeclidinium

High doses of umeclidinium may lead to anticholinergic signs and symptoms. However, there were no systemic anticholinergic adverse effects following a once-daily inhaled dose of up to 1,000 mcg umeclidinium (16 times the maximum recommended daily dose) for 14 days in subjects with COPD.

10.2 Vilanterol

The expected signs and symptoms with overdosage of vilanterol are those of excessive beta-adrenergic stimulation and/or occurrence or exaggeration of any of the signs and symptoms of beta-adrenergic stimulation (e.g., angina, hypertension or hypotension, tachycardia with rates up to 200 beats/min, arrhythmias, nervousness, headache, tremor, seizures, muscle cramps, dry mouth, palpitation, nausea, dizziness, fatigue, malaise, insomnia, hyperglycemia, hypokalemia, metabolic acidosis). As with all inhaled sympathomimetic medicines, cardiac arrest and even death may be associated with an overdose of vilanterol.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

ANORO ELLIPTA: No studies of carcinogenicity, mutagenicity, or impairment of fertility were conducted with ANORO ELLIPTA; however, studies are available for individual components, umeclidinium and vilanterol, as described below.

Umeclidinium: Umeclidinium produced no treatment-related increases in the incidence of tumors in 2-year inhalation studies in rats and mice at inhaled doses up to 137 mcg/kg/day and 295/200 mcg/kg/day (male/female), respectively (approximately 20 and 25/20 times the MRHDID in adults on an AUC basis, respectively).

Umeclidinium tested negative in the following genotoxicity assays: the *in vitro* Ames assay, *in vitro* mouse lymphoma assay, and *in vivo* rat bone marrow micronucleus assay.

No evidence of impairment of fertility was observed in male and female rats at subcutaneous doses up to 180 mcg/kg/day and inhaled doses up to 294 mcg/kg/day, respectively (approximately 100 and 50 times, respectively, the MRHDID in adults on an AUC basis).

Vilanterol: In a 2-year carcinogenicity study in mice, vilanterol caused a statistically significant increase in ovarian tubulostromal adenomas in females at an inhalation dose of 29,500 mcg/kg/day (approximately 7,800 times the MRHDID in adults on an AUC basis). No increase in tumors was seen at an inhalation dose of 615 mcg/kg/day (approximately 210 times the MRHDID in adults on an AUC basis).

In a 2-year carcinogenicity study in rats, vilanterol caused statistically significant increases in mesovarian leiomyomas in females and shortening of the latency of pituitary tumors at inhalation doses greater than or equal to 84.4 mcg/kg/day (greater than or equal to approximately 20 times the MRHDID in adults on an AUC basis). No tumors were seen at an inhalation dose of 10.5 mcg/kg/day (approximately 1 time the MRHDID in adults on an AUC basis).

These tumor findings in rodents are similar to those reported previously for other beta-adrenergic agonist drugs. The relevance of these findings to human use is unknown.

Vilanterol tested negative in the following genotoxicity assays: the *in vitro* Ames assay, *in vivo* rat bone marrow micronucleus assay, *in vivo* rat unscheduled DNA synthesis (UDS) assay, and *in vitro* Syrian hamster embryo (SHE) cell assay. Vilanterol tested equivocal in the *in vitro* mouse lymphoma assay.

No evidence of impairment of fertility was observed in reproductive studies conducted in male and female rats at inhaled vilanterol doses up to 31,500 and 37,100 mcg/kg/day, respectively (approximately 12,000 and 14,500 times, respectively, the MRHDID in adults on a mcg/m² basis).

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Medication Guide and Instructions for Use).

Asthma-Related Death: Inform patients that LABA, such as vilanterol, one of the active ingredients in ANORO ELLIPTA, increase the risk of asthma-related death. ANORO ELLIPTA is not indicated for the treatment of asthma.

Not for Acute Symptoms: Inform patients that ANORO ELLIPTA is not meant to relieve acute symptoms of COPD and extra doses should not be used for that purpose. Advise them to treat acute symptoms with a rescue inhaler such as albuterol.

Provide patients with such medicine and instruct them in how it should be used.

Instruct patients to seek medical attention immediately if they experience any of the following:

- Symptoms get worse
 - Need for more inhalations than usual of their rescue inhaler
- Patients should not stop therapy with ANORO ELLIPTA without physician/provider guidance since symptoms may recur after discontinuation.

Do Not Use Additional Long-Acting Beta₂-Agonists: Instruct patients to not use other medicines containing a LABA. Patients should not use more than the recommended once-daily dose of ANORO ELLIPTA.

Instruct patients who have been taking inhaled, short-acting beta₂-agonists on a regular basis to discontinue the regular use of these products and use them only for the symptomatic relief of acute symptoms.

Paradoxical Bronchospasm: As with other inhaled medicines, ANORO ELLIPTA can cause paradoxical bronchospasm. If paradoxical bronchospasm occurs, instruct patients to discontinue ANORO ELLIPTA.

Risks Associated With Beta-Agonist Therapy: Inform patients of adverse effects associated with beta₂-agonists, such as palpitations, chest pain, rapid heart rate, tremor, or nervousness. Instruct patients to consult a physician immediately should any of these signs or symptoms develop.

Worsening of Narrow-Angle Glaucoma: Instruct patients to be alert for signs and symptoms of acute narrow-angle glaucoma (e.g., eye pain or discomfort, blurred vision, visual halos or colored images in association with red eyes from conjunctival congestion and corneal edema). Instruct patients to consult a physician immediately if any of these signs or symptoms develop.

Worsening of Urinary Retention: Instruct patients to be alert for signs and symptoms of urinary retention (e.g., difficulty passing urine, painful urination). Instruct patients to consult a physician immediately if any of these signs or symptoms develop.

ANORO and ELLIPTA are registered trademarks of GSK group of companies.



ANORO ELLIPTA was developed in collaboration with **Theravance**.



GlaxoSmithKline
Research Triangle Park, NC 27709

©2014, the GSK group of companies. All rights reserved.
Revised 05/2014

ANR:2BRS

©2015 GSK group of companies.
All rights reserved. Printed in USA. 507614R0 November 2015

FROM THE EVP/CEO: Focused on our international initiatives

BY PAUL A. MARKOWSKI, CAE

CHEST is committed to being the global leader in clinical chest medicine. Our vision affirms it: CHEST is the global leader in advancing best patient outcomes through innovative chest medicine education, clinical research, and team-based care. Our organization is a diverse community of experts and peers, representing more than 100 countries, giving us ample opportunity to collaborate and advance chest medicine around the world. Recently, we reviewed our international work to ensure we're meeting education needs and fulfilling leadership responsibilities around the world. I'm happy to say we're in good standing on both counts.

To be effective and efficient in our international education offerings, we have identified premier programs and products that readily allow us to share the CHEST brand and reputation across the globe. We offer standardized delivery and execution to ensure everyone receives the same high-quality CHEST experience. These programs include:

- CHEST live learning events, held in international locations
- CHEST journal-branded meetings
- Grant partnerships for international fellows
- Captured content from live events

Our live learning events are scalable to accommodate larger or smaller meetings, enabling them to be delivered across multiple locations and countries. We invite CHEST leadership and faculty to collaborate with local partners to provide expertise and lead sessions.

Similarly, CHEST journal-branded meetings, developed and held in partnership with our journal publisher Elsevier, offer the same value and benefits as our live learning events. Content can focus on a specific disease state or have a broader topic reach. Journal editors or associate editors and top researchers are available to assist by serving as faculty. Both these options mean CHEST-branded education is accessible around the world.

In addition to bringing our programs to international audiences, we're also able to bring inter-



CHEST leaders participated in a February meeting of the Forum of International Respiratory Societies (FIRS) in Kyoto, Japan, along with representatives from Asociación Latinoamericana del Thorax (ALAT), the American Thoracic Society (ATS), the Asian Pacific Society of Respirology (APSR), the European Respiratory Society (ERS), the International Union Against Tuberculosis and Lung Disease (The Union), and the Pan African Thoracic Society (PATS). Established in 2001, the forum aims to promote advocacy in matters of global respiratory health and the identification of new areas for global initiatives. CHEST leaders attending included Dr. Darcy Marciniuk, FCCP; Dr. Barbara Phillips, FCCP; and Mr. Paul Markowski (3rd, 4th, and 5th from right, respectively).

national audiences to our programs, specifically to CHEST Annual Meeting and CHEST World Congress. Grant partnership opportunities are extended to sponsoring organizations that wish to cover registration, travel, housing, and per-diem living expenses for international fellows. As part of the program, we assign a CHEST liaison to each sponsored physician to further enhance his or her meeting experience. Again, this program makes CHEST-branded education more accessible throughout the world.

Knowing health-care professionals aren't always able to travel to our events, we capture education content to make it available on demand. We have hundreds of sessions from our CHEST Annual Meeting and CHEST Board Review available for purchase in the CHEST store at chestnet.org/store. Or, international partners can license this content, and provide it to health-care professionals in their areas. Both options extend the reach of our education programs to those who may not be able to participate in a live event.

On the leadership front, we continue to lead the promotion of lung health awareness around

the world. A founding member of the Forum of International Respiratory Societies (FIRS), we work with the world's leading respiratory societies to improve lung health globally. Our initiatives to date include declaring 2016 to 2025 as the Decade of the Lung and engaging organizations to improve lung health through prevention efforts. Under the Decade of the Lung umbrella, FIRS organizations brought awareness to the need for pneumonia prevention and stronger management strategies. More recently, CHEST participated with FIRS to raise global concerns of lung cancer on World Cancer Day, February 2.

As an established and recognized leader in chest medicine, CHEST is in an ideal position to advance lung health around the world. This is an opportunity we take seriously and will continue to focus on meeting our vision.

If you have thoughts or ideas about how we can enhance our work to be a global leader in chest medicine, feel free to connect with me. I invite you to follow me on Twitter (@PMarkowskiACCP), or look for me at upcoming CHEST events.

Continued from page 40

Call for case reports

Submission Deadline: April 1

Submit case reports for presentation during special sessions. Accepted case reports (excluding clinical case puzzlers) will be published in an online supplement to CHEST. Four types of case reports will be considered:

- Affiliate Case Reports
- Medical Student/Resident Case Reports
- Global Case Reports
- Clinical Case Puzzlers

Learn more and submit at chestmeeting.chestnet.org.

Call for moderators

Moderators are needed on-site during the meeting. Responsibilities include reviewing the abstracts and case reports prior to the meeting, then facilitating discussion, questions, and answers within your assigned session(s). All slide sessions and most poster sessions will have two moderators. Moderators will be recognized in the CHEST 2016 program and will receive a reduced registration rate to the meeting. Travel reimbursement will not be offered. Learn more at chestmeeting.chestnet.org.

The CHEST Foundation 2016 Grants Program

Application Deadline: April 30
The CHEST Foundation tradition of

recognizing and rewarding health-care professionals for scholarly projects and research continues. This year, a total of \$500,000 is available, including:

- The CHEST Foundation Research Grant in Lung Cancer - \$90,000 2-year grant
- CHEST Foundation Research Grant in Pulmonary Arterial Hypertension - \$50,000 1-year grant
- CHEST Foundation and the Alpha-1 Foundation Research Grant in Alpha-1 Antitrypsin Deficiency - \$25,000 1-year grant
- CHEST Foundation Research Grant in Pulmonary Fibrosis - \$30,000 1-year grant
- CHEST Foundation Research Grant in Chronic Obstructive Pulmonary Disease - \$50,000 1-year grant

- CHEST Foundation Research Grant in Venous Thromboembolism - \$30,000 1-year grant
 - CHEST Foundation Research Grant in Nontuberculous Mycobacteria - \$25,000 1-year grant
 - CHEST Foundation Research Grant in Women's Lung Health - \$10,000 1-year grant
 - CHEST Foundation Community Service Grant Honoring D. Robert McCaffree, MD, Master FCCP - up to \$15,000 1-year grant (multiple awards available!)
 - GlaxoSmithKline Distinguished Scholar in Respiratory Health - \$150,000 3-year grant
- See which grants you are eligible for, and apply today at chestnet.org/grants.

ABIM continues to expand options to earn MOC, extends practice assessment decision through 2018

BY DR. SERPIL C. ERZURUM, FCCP, AND DR. MICHAEL E. NELSON, FCCP, FOR THE ABIM PULMONARY DISEASE BOARD

On behalf of the American Board of Internal Medicine's (ABIM) Pulmonary Disease Board, we are excited to share the following updates to the Maintenance of Certification (MOC) program that was developed based on feedback from the internal medicine community and illustrates ABIM's commitment to ensuring that MOC recognizes the activities physicians are already doing in practice.

The first is an update on the partnership between ABIM and the Accreditation Council for Continuing Medical Education (ACCME) to make more CME activities available for MOC credit. The second is a recent announcement on ABIM's decision to not require practice assessment through 2018.

In fall 2015, responding to a call from physicians and medical societies to create a more flexible, streamlined process to combine continuing medical education (CME) activities with MOC requirements, ABIM and ACCME announced a partnership focused on providing ABIM board-certified physicians with access to more accredited CME activities that meet ABIM's MOC requirements. As this new partnership with ACCME expands, the number of options will continue to grow. ABIM currently accepts more than 600 CME activities for MOC credit. This includes 121 options within pulmonary disease, as well as many other options in internal medicine, critical care, and sleep medicine, among others. It is important to note that if you choose to maintain multiple certifications, the points you earn will apply to all certificates.

The other recent announcement is that ABIM **will not require** Practice Assessment, Patient Voice, and Patient Safety in its MOC program through December 31, 2018. This means that no physician will have their certification status changed for not having completed Practice Assessment, Patient Voice, and Patient Safety activities through December 31, 2018. Instead, ABIM will focus on efforts to improve these aspects of the MOC pro-

gram with input from practicing physicians. ABIM will continue to provide MOC credit for quality

improvement activities physicians choose to do that meet standards for MOC credit and will expand the

list of these activities recognized for MOC credit.

Continued on following page

Orenitram is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise capacity

FOR PULMONARY ARTERIAL HYPERTENSION

ORENITRAM DOSING ADAPTS



Introduce prostacyclin treatment early with Orenitram, which enables you to adjust dose based on tolerability and clinical response.

The only prostacyclin analogue in a tablet:

For PAH, a **progressive disease**¹⁻³ • **Early use in** **FC II and III**¹ • **Ability to transition from** **treprostinil** parenteral therapy^{1*}

Orenitram allows you to initiate treatment with 0.125 mg TID (~8 hrs apart) or 0.25 mg BID (~12 hrs apart), then titrate up or down every 3 to 4 days as needed. In the pivotal trial, dose was titrated based on clinical response and tolerability. If not tolerated, titrate slower or decrease dose by 0.25 mg. Avoid abrupt discontinuation. Orenitram tablets should be taken whole and with food. If a dose is missed, please refer to the Full Prescribing Information. Orenitram should not be used in patients with moderate hepatic impairment. Dose adjustments required for mild hepatic impairment.

*In a 24-week, multicenter, open-label study to establish safety and tolerability of transition, WHO Group 1 patients (FC I or II) on stable doses of IV/SC treprostinil as well as a PDE-5i and/or ERA were evaluated.

INDICATION

Orenitram is a prostacyclin vasodilator indicated for treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise capacity. The study that established effectiveness included predominately patients with WHO functional class II-III symptoms and etiologies of idiopathic or heritable PAH (75%) or PAH associated with connective tissue disease (19%).

When used as the sole vasodilator, the effect of Orenitram on exercise is about 10% of the deficit, and the effect, if any, on a background of another vasodilator is probably less than this.

IMPORTANT SAFETY INFORMATION FOR ORENITRAM

CONTRAINDICATIONS

- Orenitram is contraindicated in patients with severe hepatic impairment (Child Pugh Class C)

WARNINGS AND PRECAUTIONS

- Abrupt discontinuation or sudden large reductions in dosage of Orenitram may result in worsening of PAH symptoms
- Orenitram inhibits platelet aggregation and increases the risk of bleeding
- The Orenitram tablet shell does not dissolve. In patients with diverticulosis, Orenitram tablets can lodge in a diverticulum
- DRUG INTERACTIONS/SPECIFIC POPULATIONS**
- Concomitant administration of Orenitram with diuretics, antihypertensive agents, or other vasodilators increases the risk of symptomatic hypotension
- Orenitram inhibits platelet aggregation; there is an increased risk of bleeding, particularly among patients receiving anticoagulants
- Co-administration of Orenitram and the CYP2C8 enzyme inhibitor gemfibrozil increases exposure to treprostinil; therefore, Orenitram dosage reduction may be necessary in these patients
- Pregnancy Category C. Animal reproductive studies with Orenitram have shown an adverse effect on the fetus. There are no adequate and well-controlled studies in humans
- It is not known whether treprostinil is excreted in human milk or absorbed systemically after ingestion. Because many drugs are excreted in human milk, choose Orenitram or breastfeeding
- Safety and effectiveness in patients under 18 years of age have not been established
- There is a marked increase in the systemic exposure to treprostinil in hepatically impaired patients

ADVERSE REACTIONS

- In the 12-week placebo-controlled monotherapy study, adverse reactions that occurred at rates at least 5% higher on Orenitram than on placebo included headache, diarrhea, nausea, flushing, pain in jaw, pain in extremity, hypokalemia, and abdominal discomfort

OREIS1hcp.JAN16

Please see the Brief Summary of the Full Prescribing Information for Orenitram on the following page.

For additional information about Orenitram, visit www.orenitram.com or call 1-877-UNITHER (1-877-864-8437).

References

- Orenitram [package insert]. Research Triangle Park, NC: United Therapeutics Corporation; 2015.
- Clapp LH, Guring R. The mechanistic basis of prostacyclin and its stable analogues in pulmonary arterial hypertension: role of membrane versus nuclear receptors. *Prostaglandins Other Lipid Mediat*. 2011;120:56-71.
- McLaughlin VW et al. ACCF/AHA 2009 expert consensus on pulmonary hypertension: developed in collaboration with the ACCP, ATS, and the PHA. *Circulation*. 2009;119(16):2250-2290.

REQUEST AN
ORENITRAM
REPRESENTATIVE
OR VISIT
ORENITRAM.COM

**United
Therapeutics**
CORPORATION

© 2016 United Therapeutics Corporation.
All rights reserved. US/ORE/DEC15/146 Printed in USA.

orenitram[®]
treprostinil

EXTENDED-RELEASE TABLETS

dosing that adapts.

Continued from previous page

Even with these changes, it is important to remember that the MOC program still remains in place. ABIM board-certified physicians still need to take and pass an exam every 10 years and earn 100 MOC points every 5 years as well as complete some MOC activity every 2 years to participate in the program.

These changes, along with several other significant programmatic changes over the last 2 years, were based on input we have heard from you and your medical societies.

We encourage you to visit the Transforming ABIM blog to learn more about all of the changes. Subscribe to the blog to receive updates about ABIM's ongoing discussions with the internal medicine and subspecialty community

and upcoming opportunities to provide input.

To learn more about your specific requirements and deadlines or to check your certification status, sign in to ABIM's website to view your MOC status report.

We look forward to sharing more updates with you as we continue our work of ensuring the relevancy of MOC to pulmonary disease physicians across the country.


orenitram®
 treprostinil
 EXTENDED-RELEASE TABLETS

BRIEF SUMMARY

The following is a brief summary of the full prescribing information for Orenitram® (treprostinil) Extended-Release Tablets. Please review the full prescribing information before prescribing Orenitram.

INDICATIONS AND USAGE

Orenitram is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise capacity. The study that established effectiveness included predominately patients with WHO functional class II-III symptoms and etiologies of idiopathic or heritable PAH (75%) or PAH associated with connective tissue disease (19%). When used as the sole vasodilator, the effect of Orenitram on exercise is about 10% of the deficit, and the effect, if any, on a background of another vasodilator is probably less than this.

CONTRAINDICATIONS

Severe hepatic impairment (Child Pugh Class C).

WARNINGS AND PRECAUTIONS

Worsening PAH Symptoms upon Abrupt Withdrawal—Abrupt discontinuation or sudden large reductions in dosage of Orenitram may result in worsening of PAH symptoms.

Risk of Bleeding—Orenitram inhibits platelet aggregation and increases the risk of bleeding.

Use in Patients with Blind-end Pouches—The tablet shell does not dissolve. In patients with diverticulosis, Orenitram tablets can lodge in a diverticulum.

ADVERSE REACTIONS

Clinical Trials Experience—Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. In a 12-week placebo-controlled monotherapy study (Study 1; WHO Group 1; functional class II-III), the most commonly reported adverse reactions that occurred in patients receiving Orenitram included: headache, diarrhea, nausea and flushing. Table 1 lists the adverse reactions that occurred at a rate on Orenitram at least 5% higher than on placebo. Orenitram patients in Table 1 for Study 1 (N = 151) had access to 0.25 mg tablets at randomization. Approximately 91% of such patients experienced an adverse reaction, but only 4% discontinued therapy for an adverse reaction (compared to 3% receiving placebo). The overall discontinuation rate for any reason was 17% for active and 14% for placebo.

Orenitram was studied in a long-term, open-label extension study in which 824 patients were dosed for a mean duration of approximately 2 years. About 70% of patients continued treatment with Orenitram for at least a year. The mean dose was 4.2 mg BID at one year. The adverse reactions were similar to those observed in the placebo-controlled trials.

Table 1. Adverse Reactions with Rates at Least 5% Higher on Orenitram Monotherapy than on Placebo

Reaction	Treatment (%)	
	Orenitram (N=151)	Placebo (N=77)
Headache	63%	19%
Diarrhea	30%	16%
Nausea	30%	18%
Flushing	15%	6%
Pain in jaw	11%	4%
Pain in extremity	14%	8%
Hypokalemia	9%	3%
Abdominal discomfort	6%	0%

The safety of Orenitram was also evaluated in an open-label study transitioning patients from Remodulin. The safety profile during this study was similar to that observed in the three pivotal studies.

DRUG INTERACTIONS

Antihypertensive Agents or Other Vasodilator—Concomitant administration of Orenitram with diuretics, antihypertensive agents or other vasodilators increases the risk of symptomatic hypotension.

Anticoagulants—Treprostinil inhibits platelet aggregation; there is increased risk of bleeding, particularly among patients receiving anticoagulants.

Effect of CYP2C8 Inhibitors—Co-administration of Orenitram and the CYP2C8 enzyme inhibitor gemfibrozil in healthy adult volunteers increases exposure to treprostinil. Reduce the starting dose of Orenitram to 0.125 mg BID and use 0.125 mg BID increments every 3 to 4 days.

Effect of Other Drugs on Orenitram—Based on human pharmacokinetic studies, no dose adjustment of Orenitram is recommended when coadministered with either fluconazole, rifampin, sildenafil, bosentan, or esomeprazole.

Warfarin—A drug interaction study was carried out with Remodulin co-administered with warfarin (25 mg/day) in healthy volunteers. There was no clinically significant effect of either medication on the pharmacokinetics of treprostinil. Additionally, treprostinil did not affect the pharmacokinetics or pharmacodynamics of warfarin. The pharmacokinetics of R- and S- warfarin and the international normalized ratio (INR) in healthy subjects given a single 25 mg dose of warfarin were unaffected by continuous subcutaneous infusion of treprostinil at an infusion rate of 10 ng/kg/min.

USE IN SPECIFIC POPULATIONS

Pregnancy—Pregnancy Category C. Animal reproductive studies with treprostinil diolamine have shown an adverse effect on the fetus. There are no adequate and well-controlled studies in humans.

Labor and Delivery—The effect of Orenitram on labor and delivery in humans is unknown.

No treprostinil treatment related effects on labor and delivery were seen in animal studies.

Nursing Mothers—It is not known whether treprostinil is excreted in human milk or absorbed systemically after ingestion. Because many drugs are excreted in human milk, choose Orenitram or breastfeeding.

Pediatric Use—Safety and effectiveness in pediatric patients have not been established.

Geriatric Use—Clinical studies of Orenitram did not include sufficient numbers of patients aged 65 years and over to determine whether they respond differently from younger patients. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic or cardiac function, and of concomitant disease or other drug therapy.

Patients with Hepatic Impairment—Plasma clearance of treprostinil is reduced in patients with hepatic insufficiency. Patients with hepatic insufficiency may therefore be at increased risk of dose-dependent adverse reactions because of an increase in systemic exposure. Titrate slowly in patients with hepatic insufficiency, because such patients will likely be exposed to greater systemic concentrations relative to patients with normal hepatic function. In patients with mild hepatic impairment (Child Pugh Class A) start at 0.125 mg BID with 0.125 mg BID dose increments every 3 to 4 days. Avoid use of Orenitram in patients with moderate hepatic impairment (Child Pugh Class B). Orenitram is contraindicated in patients with severe hepatic impairment (Child Pugh Class C).

Patients with Renal Impairment—No dose adjustments are required in patients with renal impairment. Orenitram is not removed by dialysis.

OVERDOSAGE

Signs and symptoms of overdose with Orenitram during clinical trials reflect its dose-limiting pharmacologic effects and include severe headache, nausea, vomiting, diarrhea, and hypotension. Treat supportively.

IN MEMORIAM

Dr. Arthur Kotch



Dr. Arthur Kotch, FCCP, passed away on December 6, 2015. He started his career as junior faculty in the Pulmonary Division at the University of Pennsylvania. He was then recruited to Danbury Hospital, in Danbury, Connecticut, where over the years, he built the Division of Pulmonary Medicine, the Department of Respiratory Care, a Pulmonary Rehabilitation Unit, and the first Sleep Center in the state of Connecticut. He was a pulmonary, critical care, and sleep medicine physician who combined an encyclopedic knowledge with a very humanistic approach to life, displaying the ultimate dedication to trainees and his patients, and amazing service to his hospital and the community. The American College of Chest Physicians extends its condolences to the Kotch family.

This information was kindly provided to CHEST by Dr. Octavian C. Ioachimescu, FCCP, who was a dear friend of Dr. Kotch.

This month in *CHEST*: Editor's picks


BY DR. RICHARD S. IRWIN,
MASTER FCCP
EDITOR IN CHIEF, *CHEST*

Pregabalin and Speech Pathology Combination Therapy for Refractory Chronic Cough: A Randomized Controlled Trial. *By Dr. A. E. Vertigan et al.*

Parenteral Prostanoid Use at a Tertiary Referral Center: A Retrospective Cohort Study. *By Dr. B. R. Hay et al.*

Health-care Provider Screening and Advice for Smoking Cessation Among Smokers With and Without COPD: 2009-2010 National Adult Tobacco Survey. *By Dr. G. L. Schauer et al.*

Is There Any Reliable Clinical Evidence to Suggest That Acthar Is More Effective Than Other Forms of Corticosteroids in Treating Sarcoidosis and Other Diseases It Is Being Marketed to Treat? *By Dr. M. Metersky (Correspondence)*




Finding Common Ground: Professionalism and Acthar Prescribing Practices (Editorial, G/W Metersky Correspondence at left). *By Dr. Don Liss et al.*

Giants in Chest Medicine – Dr. Leonardo M. Fabbri. *By Dr. P. J. Barnes*

Technical Aspects of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration: CHEST Guideline and Expert Panel Report. *By Dr. M. M. Wahidi et al.*

Catching up with our Past Presidents

Where are they now? What have they been up to? CHEST's Past Presidents each forged the way for the many successes of the American College of Chest Physicians (CHEST), leading to enhanced patient care around the globe. Their outstanding leadership and vision are evidenced today in many of CHEST's current initiatives, and now it is time to check in with these past leaders to give us a look at what's new in their lives.



DR. KVALE

Dr. Paul Kvale, Master FCCP President, 2004-2005

Since my term as President of the American College of Chest Physicians, I have remained active with CHEST in several capacities, including serving as a reviewer for the McCaffree Community Service Awards and, currently, as Chair of the Compensation Committee.


I continued with research activities until the primary papers were published for the National Lung Screening Trial (NSLT) and the Prostate, Lung, Colon, and Ovarian (PLCO) Cancer Screening Trials were complete. I retired from active practice at Henry Ford Hospital at the end of June 2015. That was the 50th

Continued on page 54

Advanced Clinical Training in Pulmonary Function Testing

April 9-10

Innovation, Simulation,
and Training Center
Glenview, Illinois



CHEST
AMERICAN COLLEGE
OF CHEST PHYSICIANS

Gain practical experience with the necessary technical aspects for performing PFT calibration, maneuvers, and testing.

- Perform various tests on-site, including spirometry, flow-volume loops, lung volume measurement, and more, in accordance with accepted standards.
- Learn high-level interpretive strategies through case-based clinical examples.
- Participate in hands-on demonstrations and lectures addressing appropriate reference values, quality control processes, laboratory standards, and more.

> Register Now chestnet.org/live-learning

Who Should Attend?

Pulmonary physicians, new pulmonary function laboratory directors, midlevel pulmonary providers, nurse practitioners, physician assistants, family medicine providers, pulmonary rehabilitation providers, pulmonary fellows, and hospitalists are encouraged to attend.

CHEST
Annual Meeting
2016

LOS ANGELES
OCTOBER 22 - 26

Call for Abstracts and Case Reports

Connecting a Global Community in Clinical Chest Medicine



Call for Abstracts

Submit an abstract of your original investigative work for presentation at the meeting. Accepted abstracts will be published in an online supplement to CHEST and will be eligible for investigative awards from the CHEST Foundation. Two types of abstracts will be considered:

- Slide Presentations
- Poster Presentations

Call for Case Reports

Submit case reports for presentation during special sessions. Accepted case reports (excluding clinical case puzzlers) will be published in an online supplement to CHEST. Four types of case reports will be considered:

- Affiliate Case Reports
- Medical Student/Resident Case Reports
- Global Case Reports
- Clinical Case Puzzlers

> Submit Now chest2016.abstractcentral.com
Submission deadline: April 1

NAMDRC crystallizes its legislative and regulatory agendas for pulmonary medicine in 2016

BY PHIL PORTE
NAMDRC Executive Director

It is a presidential election year, and that usually signals a dearth of activity in Washington and on Capitol Hill. Recognizing that Congress hasn't been doing much at all for the past few years as acrimony reaches new heights, NAMDRC (the National Association for Medical Direction of Respiratory Care) is focusing on a limited number of issues that impact pulmonary medicine.

First, a recent study (A-02-1401013) by the HHS Office of the Inspector General (OIG) focused on one hospital in New Jersey, citing significant billing problems with its pulmonary (and cardiac) rehabilitation programs. The hospital was eventually required to repay the

NAMDRC continues to work with its sister societies to refine submissions to the CMS Coverage and Analysis Group to address issues related to home mechanical ventilation.

Centers for Medicare and Medicaid Services (CMS) over \$115,000 for errant billing, most of which was traced back to flaws in the Individual Treatment Plan (ITP) and undocumented medical need.

After a direct conversation on this

topic, CMS acknowledged that it was not aware of any broad focus on pulmonary rehabilitation programs and, indeed, the agency had no immediate plans to change its existing policies to provide more clarification for pulmonary rehabilitation programs. In fact, CMS encouraged NAMDRC to work with Medicare Administrative Contractors (MACs) in the event that we believed additional clarifications might be necessary/helpful. To that end, NAMDRC is encouraging the American Association of Cardiovascular & Pulmonary Rehabilitation (AACVPR) to take the lead, providing guidance to its members to ensure compliance with current CMS and MAC requirements.

Secondly, also related to pulmonary rehabilitation, NAMDRC and AACVPR may approach CMS for clarification regarding billing for G0424, the HCPCS (Healthcare Common Procedure Coding System) code for billing for pulmonary rehabilitation services provided in the hospital outpatient setting. Current regulations clearly permit billing of G0424 up to two times per day, but in a nuance in the hospital

outpatient rate setting announcement, it appears that G0424 is considered a bundled service, with a cap of one billable unit per day. We are also working with the American Association for Respiratory Care (AARC) to determine the frequency of multiple uses of G0424 compared with single use and may approach CMS for clarification if broad inconsistencies are uncovered.

As an update, NAMDRC continues to work with its sister societies to refine submissions to the CMS Coverage and Analysis Group to address issues related to home mechanical ventilation and bilevel/RADs (respiratory assist devices). Home mechanical ventilation policies are outdated as Medicare contractors rely on a 2001 decision memo that, needless to say, does not reflect the state-of-the-art standard of care in 2016. According to CMS regulations, the primary pathway for such change is a reconsideration of the current National Coverage Determination (NCD) for home mechanical ventilation and a request for a new NCD to address bilevel/RADs.

The largest challenge facing the

team working on these issues is the CMS expectation that in order to change current policy there must be well-documented, peer-reviewed support for change. And herein lies a notable problem—trying to prove negatives. On the home mechanical ventilation issue, there are obviously no randomized clinical trials that compare continued mechanical ventilation with frequency of death upon removal of mechanical

NAMDRC is encouraging the AACVPR to take the lead in providing guidance to its members to ensure compliance with current CMS and MAC requirements.

ventilation. On the bilevel issue, for example, current CMS policy focuses, in part, on the need for a trial without a back-up rate, despite the absence of any research that focused on that specific issue. Again, trying to prove negatives, or at least the best way around it, is continuing to be the greatest challenge on this effort.

If one thinks about this issue in a genuine macro perspective, one has to look at the original authorizing legislation that permits coverage in these two related areas. While home mechanical ventilation is not referenced in the statute, iron lungs are,

Continued on page 52



MR. PORTE

CHEST Foundation introduces 2016 NetWorks challenge

The CHEST Foundation launched its 2016 NetWorks Challenge on March 1, adding creative and meaningful prizes for NetWorks and members of various levels of participation. The criteria for assigning winners and awards are members' contributions in three categories (there will be two winners for each category):

- First half winners (announced July 1):
 - o Total amount contributed by a NetWorks Steering Committee
- Second half winners (announced at the Monday morning opening session at the 2016 CHEST Annual Meeting):
 - o Highest percentage of participation by NetWorks Steering Committee
- Annual meeting challenge (announced after the annual meeting):
 - o Highest percentage of participation by NetWorks membership



With the creation of six travel awards and a clinical research grant related to the winning NetWorks' subspecialty, we've created a vehicle for all members to embrace the foundation's mission – to champion lung health and to help fellow colleagues support each other's personal and professional growth.

"Many people think of the CHEST Foundation as the philanthropic arm of the College, but it really serves a much greater role as a champion of pulmonary health. No matter which aspect of lung health is most important to you, the

foundation is making an impact there. Giving to the foundation fosters the development of novel research, allows the provision of care to patients who might not otherwise receive it, and funds the creation of educational materials for both patients and their providers to improve the overall care of people with lung disease around the globe. And besides, it is a great way for me to thank CHEST for everything they have done for my own personal and professional growth over the last decade.

Even as a junior clinician, I made a point to give to the CHEST Foundation on an annual basis. Every gift, regardless of the amount, goes a long way to helping the foundation's mission."

– Dr. David A. Schulman, FCCP, Chair, Council of NetWorks

Visit chestnet.org/networkschallenge to learn more!



A NEW TREATMENT OPTION FOR PATIENTS WITH METASTATIC EGFR T790M MUTATION-POSITIVE NSCLC, AS DETECTED BY AN FDA-APPROVED TEST, WHO HAVE PROGRESSED ON OR AFTER EGFR TKI THERAPY

INDICATION

TAGRISSO is indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR tyrosine kinase inhibitor therapy.

This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

IMPORTANT SAFETY INFORMATION

- There are no contraindications for TAGRISSO
- Interstitial Lung Disease (ILD)/Pneumonitis occurred in 3.3% and was fatal in 0.5% of 813 TAGRISSO patients. Withhold TAGRISSO and promptly investigate for ILD in any patient presenting with worsening of respiratory symptoms indicative of ILD (e.g., dyspnea, cough and fever). Permanently discontinue TAGRISSO if ILD is confirmed
- QTc interval prolongation occurred in TAGRISSO patients. Of the 411 patients in two Phase II studies, 0.2% were found to have a QTc greater than 500 msec, and 2.7% had an increase from baseline QTc greater than 60 msec. Conduct periodic monitoring with ECGs and electrolytes in patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those who are taking medications known to prolong the QTc interval. Permanently discontinue TAGRISSO in patients who develop QTc interval prolongation with signs/symptoms of life threatening arrhythmia
- Cardiomyopathy occurred in 1.4% and was fatal in 0.2% of 813 TAGRISSO patients. Left Ventricular Ejection Fraction (LVEF) decline >10% and a drop to <50% occurred in 2.4% of (9/375) TAGRISSO patients. Assess LVEF before initiation and then at 3 month intervals of TAGRISSO treatment. Withhold TAGRISSO if ejection fraction decreases by 10% from pretreatment values and is less than 50%. For symptomatic congestive heart failure or persistent asymptomatic LV dysfunction that does not resolve within 4 weeks, permanently discontinue TAGRISSO
- Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during TAGRISSO treatment and for 6 weeks after the final dose. Advise males with female partners of reproductive potential to use effective contraception for 4 months after the final dose
- The most common adverse reactions (>20%) observed in TAGRISSO patients were diarrhea (42%), rash (41%), dry skin (31%) and nail toxicity (25%)

Please see Brief Summary of complete Prescribing Information.

Visit TAGRISSOhcp.com for more information



Continued from page 50

and the inference is somewhat obvious. In the event that CMS might agree with our recommendations but argues that it does not have the legislative authority to implement those changes because of current limitations within the law, we might

consider a legislative initiative to address that matter.

Of course, undertaking a legislative strategy to address coverage issues within Medicare is no small challenge. For example, in 1981 the then Health Care Financing Administration (HCFA) clearly stated, in writing, to NAMDRRC that pul-

monary rehabilitation was indeed a covered service. Some 20 years later, CMS declared that position no longer applicable, and it took several years of effort on Capitol Hill to create a specific benefit category for pulmonary rehab within the statute.

While no one is eager to take on

such a large undertaking, NAMDRRC has begun engaging some of the interested parties in preliminary discussions along the lines of “what if...” in the event that CMS conceptually agrees with our eventual recommendations, but claims there is no legislative authority to implement those recommendations.

TAGRISSO™ (osimertinib) tablet, for oral use

Brief Summary of Prescribing Information.
For complete prescribing information consult official package insert

INDICATIONS AND USAGE

TAGRISSO is indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy.

This indication is approved under accelerated approval based on tumor response rate and duration of response [see *Clinical Studies (14) in the full Prescribing Information*]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

DOSE AND ADMINISTRATION

Patient Selection

Confirm the presence of a T790M EGFR mutation in tumor specimens prior to initiation of treatment with TAGRISSO [see *Indications and Usage (1) and Clinical Studies (14) in the full Prescribing Information*]. Information on FDA-approved tests for the detection of T790M mutations is available at <http://www.fda.gov/companiondiagnostics>.

Recommended Dosage Regimen

The recommended dose of TAGRISSO is 80 mg tablet once a day until disease progression or unacceptable toxicity. TAGRISSO can be taken with or without food.

If a dose of TAGRISSO is missed, do not make up the missed dose and take the next dose as scheduled.

Administration to Patients Who Have Difficulty Swallowing Solids

Disperse tablet in 4 tablespoons (approximately 50 mL) of non-carbonated water only. Stir until tablet is completely dispersed and swallow or administer through naso-gastric tube immediately. Do not crush, heat, or ultrasonicate during preparation. Rinse the container with 4 to 8 ounces of water and immediately drink or administer through the naso-gastric tube [see *Clinical Pharmacology (12.3) in the full Prescribing Information*].

Dose Modification for Adverse Reactions

Table 1 Recommended Dose Modifications for TAGRISSO

Target Organ	Adverse Reaction ^a	Dose Modification
Pulmonary	Interstitial lung disease (ILD)/Pneumonitis	Permanently discontinue TAGRISSO.
Cardiac	QTc [†] interval greater than 500 msec on at least 2 separate ECGs ^b	Withhold TAGRISSO until QTc interval is less than 481 msec or recovery to baseline if baseline QTc is greater than or equal to 481 msec, then resume at 40 mg dose.
	QTc interval prolongation with signs/symptoms of life threatening arrhythmia	Permanently discontinue TAGRISSO.
	Asymptomatic, absolute decrease in LVEF ^c of 10% from baseline and below 50%	Withhold TAGRISSO for up to 4 weeks. • If improved to baseline LVEF, resume. • If not improved to baseline, permanently discontinue.
Other	Symptomatic congestive heart failure	Permanently discontinue TAGRISSO.
	Grade 3 or higher adverse reaction	Withhold TAGRISSO for up to 3 weeks.
	If improvement to Grade 0-2 within 3 weeks	Resume at 80 mg or 40 mg daily.
	If no improvement within 3 weeks	Permanently discontinue TAGRISSO.

^a Adverse reactions graded by the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (NCI CTCAE v4.0).

^b ECGs = Electrocardiograms

^c LVEF = Left Ventricular Ejection Fraction

[†] QTc = QT interval corrected for heart rate

CONTRAINDICATIONS

None.

WARNINGS AND PRECAUTIONS

Interstitial Lung Disease/Pneumonitis

Across clinical trials, interstitial lung disease (ILD)/pneumonitis occurred in 3.3% (n=27) of TAGRISSO treated patients (n=813); 0.5% (n=4) were fatal.

Withhold TAGRISSO and promptly investigate for ILD in any patient who presents with worsening of respiratory symptoms which may be indicative of ILD (e.g., dyspnea, cough and fever). Permanently discontinue TAGRISSO if ILD is confirmed [see *Dosage and Administration (2.4) and Adverse Reactions (6) in the full Prescribing Information*].

QTc Interval Prolongation

The heart rate-corrected QT (QTc) interval prolongation occurs in patients treated with TAGRISSO. Of the 411 patients in Study 1 and Study 2, one patient (0.2%) was found to have a QTc greater than 500 msec, and 11 patients (2.7%) had an increase from baseline QTc greater than 60 msec [see *Clinical Pharmacology (12.2) in the full Prescribing Information*].

In Study 1 and 2, patients with baseline QTc of 470 msec or greater were excluded. Conduct periodic monitoring with ECGs and electrolytes in patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those who are taking medications known to prolong the QTc interval. Permanently discontinue TAGRISSO in patients who develop QTc interval prolongation with signs/symptoms of life threatening arrhythmia [see *Dosage and Administration (2.4) in the full Prescribing Information*].

Cardiomyopathy

Across clinical trials, cardiomyopathy (defined as cardiac failure, pulmonary edema, ejection fraction decreased or stress cardiomyopathy) occurred in 1.4% (n=11) of TAGRISSO treated patients (n=813); 0.2% (n=2) were fatal.

In Study 1 and Study 2, Left Ventricular Ejection Fraction (LVEF) decline >10% and a drop to <50% occurred in 2.4% (9/375) of patients who had baseline and at least one follow up LVEF assessment.

Assess LVEF by echocardiogram or multigated acquisition (MUGA) scan before initiation of TAGRISSO and then at 3 month intervals while on treatment. Withhold treatment with TAGRISSO if ejection fraction decreases by 10% from pretreatment values and is less than 50%. For symptomatic congestive heart failure or persistent, asymptomatic LV dysfunction that does not resolve within 4 weeks, permanently discontinue TAGRISSO [see *Dosage and Administration (2.4) in the full Prescribing Information*].

Embryo-Fetal Toxicity

Based on data from animal studies and its mechanism of action, TAGRISSO can cause fetal harm when administered to a pregnant woman. In animal reproduction studies, osimertinib caused post-implantation fetal loss when administered during early development at a dose exposure 1.5 times the exposure at the recommended human dose. When males were treated prior to mating with untreated females, there was an increase in preimplantation embryonic loss at plasma exposures of approximately 0.5-times those observed in patients at the 80 mg dose level.

Advise pregnant women of the potential risk to a fetus.

Advise females of reproductive potential to use effective contraception during treatment with TAGRISSO and for 6 weeks after the final dose. Advise males with female partners of reproductive potential to use effective contraception for 4 months after the final dose [see *Use in Specific Populations (8.1), (8.3) and Clinical Pharmacology (12.3) in the full Prescribing Information*].

ADVERSE REACTIONS

The following adverse reactions are discussed in greater detail in other sections of the labeling: Interstitial Lung Disease/Pneumonitis [see *Warnings and Precautions (5.1) in the full Prescribing Information*]

QTc Interval Prolongation [see *Warnings and Precautions (5.2) in the full Prescribing Information*]

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The data described below reflect exposure to TAGRISSO (80 mg daily) in 411 patients with EGFR T790M mutation-positive non-small cell lung cancer who received prior EGFR TKI therapy, in two single arm studies, Study 1 and Study 2. Patients with a past medical history of ILD or radiation pneumonitis that required steroid treatment, serious arrhythmia or baseline QTc interval greater than 470 ms were excluded from Study 1 and Study 2. Baseline patient and disease characteristics were: median age 63 years, 13% of patients were ≥75 years old, female (68%), White (36%), Asian (60%), metastatic (96%), sites of brain metastases (39%), World Health Organization (WHO) performance status of 0 (37%) or 1 (63%), 1 prior line of therapy [EGFR-TKI treatment only, second line, chemotherapy-naïve (31%)], 2 or more prior lines of therapy (69%). Of the 411 patients, 333 patients were exposed to TAGRISSO for at least 6 months; 97 patients were exposed for at least 9 months; however no patient was exposed to TAGRISSO for 12 months.

In Studies 1 and 2, the most common (>20%) adverse reactions (all grades) observed in TAGRISSO-treated patients were diarrhea (42%), rash (41%), dry skin (31%), and nail toxicity (25%). Dose reductions occurred in 4.4% of patients treated with TAGRISSO. The most frequent adverse reactions that led to dose reductions or interruptions were: electrocardiogram QTc prolonged (2.2%) and neutropenia (1.9%). Serious adverse reactions reported in 2% or more patients were pneumonia and pulmonary embolus. There were 4 patients (1%) treated with TAGRISSO who developed fatal adverse reactions of ILD/pneumonitis. Other fatal adverse reactions occurring in more than 1 patient included pneumonia (4 patients) and CVA/cerebral hemorrhage (2 patients). Discontinuation of therapy due to adverse reactions occurred in 5.6% of patients treated with TAGRISSO. The most frequent adverse reactions that led to discontinuation were ILD/pneumonitis and cerebrovascular accidents/infarctions.

Tables 2 and 3 summarize the common adverse reactions and laboratory abnormalities observed in TAGRISSO-treated patients.

Table 2 Adverse Reactions (>10% for all NCI CTCAE* Grades or >2% for Grades 3-4) in Study 1 and Study 2

Adverse Reaction	TAGRISSO N=411	
	All Grades %	Grade 3-4 [†] %
Gastrointestinal disorders		
Diarrhea	42	1.0
Nausea	17	0.5
Decreased appetite	16	0.7
Constipation	15	0.2
Stomatitis	12	0
Skin disorders		
Rash ^a	41	0.5
Dry skin ^b	31	0
Nail toxicity ^c	25	0
Pruritus	14	0
Eye Disorders^d	18	0.2
Respiratory		
Cough	14	0.2
General		
Fatigue	14	0.5
Musculoskeletal		
Back pain	13	0.7
Central Nervous System		
Headache	10	0.2
Infections		
Pneumonia	4	2.2
Vascular events		
Venous thromboembolism ^e	7	2.4

* NCI CTCAE v4.0.

CHEST World Congress 2016: Don't miss cutting-edge education or Shanghai's attractions

When you travel to Shanghai to attend CHEST World Congress 2016, April 15 - 17, don't miss a minute of the cut-

ting-edge education sessions and simulation training. And, make some time to explore the great city of Shanghai. Knowing that your time

may be limited, we came up with a list of some of the best restaurants and local activities in Pudong, the popular Shanghai district where the

Shanghai International Convention Center is located.

Enjoy a walk or grab a cab to enjoy these nearby eats:

TAGRISSO™ (osimertinib) tablet, for oral use

2

- ^a Includes cases reported within the clustered terms for rash adverse events: Rash, rash generalized, rash erythematous, rash macular, rash maculo-papular, rash papular, rash pustular, erythema, folliculitis, acne, dermatitis and acneform dermatitis.
- ^b Includes dry skin, eczema, skin fissures, xerosis.
- ^c Includes nail disorders, nail bed disorders, nail bed inflammation, nail bed tenderness, nail discoloration, nail disorder, nail dystrophy, nail infection, nail ridging, onychoclasia, onycholysis, onychomadesis, paronychia.
- ^d Includes dry eye, vision blurred, keratitis, cataract, eye irritation, blepharitis, eye pain, lacrimation increased, vitreous floaters. Other ocular toxicities occurred in <1% of patients.
- ^e Includes deep vein thrombosis, jugular venous thrombosis, and pulmonary embolism.
- ^f No grade 4 events have been reported.

Additional clinically significant adverse reactions occurring in 2% or more of patients treated with TAGRISSO included cerebrovascular accident (2.7%).

Table 3 Common Laboratory Abnormalities (≥20% for all NCI CTCAE Grades) in Study 1 and Study 2

Laboratory Abnormality	TAGRISSO N=411	
	Change from Baseline All Grades (%)	Change from Baseline to Grade 3 or Grade 4 (%) ^a
Clinical Chemistry		
Hyponatremia	26	3.4
Hypermagnesemia	20	0.7
Hematologic		
Lymphopenia	63	3.3
Thrombocytopenia	54	1.2 ^b
Anemia	44	0.2
Neutropenia	33	3.4

^a The only grade 4 laboratory abnormality was 1 patient with grade 4 thrombocytopenia.

DRUG INTERACTIONS

Drug interaction studies with inhibitors, inducers or substrates of CYP enzymes and transporters have not been conducted with TAGRISSO.

Effect of Other Drugs on Osimertinib

Strong CYP3A Inhibitors

Avoid concomitant administration of TAGRISSO with strong CYP3A inhibitors, including macrolide antibiotics (e.g., telithromycin), antifungals (e.g., itraconazole), antivirals (e.g., ritonavir), nefazodone, as concomitant use of strong CYP3A inhibitors may increase osimertinib plasma concentrations. If no other alternative exists, monitor patients more closely for adverse reactions of TAGRISSO [see *Dosage and Administrations (2.4) and Clinical Pharmacology (12.3) in the full Prescribing Information*].

Strong CYP3A Inducers

Avoid concomitant administration of TAGRISSO with strong CYP3A inducers (e.g., phenytoin, rifampicin, carbamazepine, St. John's Wort) as strong CYP3A inducers may decrease osimertinib plasma concentrations [see *Clinical Pharmacology (12.3) in the full Prescribing Information*].

Effect of Osimertinib on Other Drugs

Avoid concomitant administration of TAGRISSO with drugs that are sensitive substrates of CYP3A, breast cancer resistance protein (BCRP), or CYP1A2 with narrow therapeutic indices, including but not limited to fentanyl, cyclosporine, quinidine, ergot alkaloids, phenytoin, carbamazepine, as osimertinib may increase or decrease plasma concentrations of these drugs [see *Clinical Pharmacology (12.3) in the full Prescribing Information*].

USE IN SPECIFIC POPULATIONS

Pregnancy

Risk Summary

Based on data from animal studies and its mechanism of action, TAGRISSO can cause fetal harm when administered to a pregnant woman. There are no available data on TAGRISSO use in pregnant women. Administration of osimertinib to pregnant rats was associated with embryolethality and reduced fetal growth at plasma exposures 1.5 times the exposure at the recommended human dose [see *Data*]. Advise pregnant women of the potential risk to a fetus.

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically-recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Data

Animal Data

When administered to pregnant rats prior to embryonic implantation through the end of organogenesis (gestation days 2-20) at a dose of 20 mg/kg/day, which produced plasma exposures of approximately 1.5 times the clinical exposure, osimertinib caused post-implantation loss and early embryonic death. When administered to pregnant rats from implantation through the closure of the hard palate (gestation days 6 to 16) at doses of 1 mg/kg/day and above (0.1-times the AUC observed in patients at the recommended dose of 80 mg), an equivocal increase in the rate of fetal malformations and variations was observed in treated litters relative to those of concurrent controls. When administered to pregnant dams at doses of 30 mg/kg/day during organogenesis through lactation Day 6, osimertinib caused an increase in total litter loss and postnatal death. At a dose of 20 mg/kg/day, osimertinib administration during the same period resulted in increased postnatal death as well as a slight reduction in mean pup weight at birth that increased in magnitude between lactation days 4 and 6.

Lactation

Risk Summary

There are no data on the presence of osimertinib in human milk, the effects of osimertinib on the breastfed infant or on milk production. Administration to rats during gestation and early lactation was associated with adverse effects, including reduced growth rates and neonatal death [see *Use in*

Specific Populations (8.1) in the full Prescribing Information]. Because of the potential for serious adverse reactions in breastfed infants from osimertinib, advise a lactating woman not to breastfeed during treatment with TAGRISSO and for 2 weeks after the final dose.

Females and Males of Reproductive Potential

Contraception

Females

Advise females of reproductive potential to use effective contraception during treatment with TAGRISSO and for 6 weeks after the final dose [see *Use in Specific Populations (8.1) in the full Prescribing Information*].

Males

Advise male patients with female partners of reproductive potential to use effective contraception during and for 4 months following the final dose of TAGRISSO [see *Nonclinical Toxicology (13.1) in the full Prescribing Information*].

Infertility

Based on animal studies, TAGRISSO may impair fertility in females and males of reproductive potential. It is not known if the effects on fertility are reversible [see *Nonclinical Toxicology (13.1) in the full Prescribing Information*].

Pediatric Use

The safety and effectiveness of TAGRISSO in pediatric patients have not been established.

Geriatric Use

One hundred eighty-seven (45%) of the 411 patients in clinical trials of TAGRISSO were 65 years of age and older, and 54 patients (13%) were 75 years of age and older. No overall differences in effectiveness were observed based on age. Exploratory analysis suggest a higher incidence of Grade 3 and 4 adverse reactions (32% versus 25%) and more frequent dose modifications for adverse reactions (23% versus 17%) in patients 65 years or older as compared to those younger than 65 years.

Renal Impairment

No dedicated clinical studies have been conducted to evaluate the effect of renal impairment on the pharmacokinetics of osimertinib. Based on population pharmacokinetic analysis, no dose adjustment is recommended in patients with mild [creatinine clearance (CL_{cr}) 60-89 mL/min] or moderate (CL_{cr} 30-59 mL/min) renal impairment. There is no recommended dose of TAGRISSO for patients with severe renal impairment (CL_{cr} <30 mL/min) or end-stage-renal disease [see *Clinical Pharmacology (12.3) in the full Prescribing Information*].

Hepatic Impairment

No dedicated clinical studies have been conducted to evaluate the effect of hepatic impairment on the pharmacokinetics of osimertinib. Based on population pharmacokinetic (PK) analysis, no dose adjustment is recommended in patients with mild hepatic impairment [total bilirubin <upper limit of normal (ULN) and AST between 1 to 1.5 times ULN or total bilirubin between 1.0 to 1.5 times ULN and any AST]. There is no recommended dose for TAGRISSO for patients with moderate or severe hepatic impairment [see *Clinical Pharmacology (12.3) in the full Prescribing Information*].

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Interstitial Lung Disease/Pneumonitis

Inform patients of the risks of severe or fatal ILD, including pneumonitis. Advise patients to contact their healthcare provider immediately to report new or worsening respiratory symptoms [see *Warnings and Precautions (5.1) in the full Prescribing Information*].

QTc Interval Prolongation

Inform patients of symptoms that may be indicative of significant QTc prolongation including dizziness, lightheadedness, and syncope. Advise patients to report these symptoms and to inform their physician about the use of any heart or blood pressure medications [see *Warnings and Precautions (5.2) in the full Prescribing Information*].

Cardiomyopathy

- TAGRISSO can cause cardiomyopathy. Advise patients to immediately report any signs or symptoms of heart failure to their healthcare provider [see *Warnings and Precautions (5.3) in the full Prescribing Information*].

Embryo-Fetal Toxicity

- TAGRISSO can cause fetal harm if taken during pregnancy. Advise pregnant women of the potential risk to a fetus.
- Advise females to inform their healthcare provider if they become pregnant or if pregnancy is suspected, while taking TAGRISSO [see *Warnings and Precautions (5.3) and Use in Specific Populations (8.1) in the full Prescribing Information*].

Females and Males of Reproductive Potential

- Advise females of reproductive potential to use effective contraception during treatment with TAGRISSO and for 6 weeks after the final dose [see *Use in Specific Populations (8.3) in the full Prescribing Information*].
- Advise males to use effective contraception during treatment and for 4 months after the final dose of TAGRISSO [see *Use in Specific Populations (8.3) in the full Prescribing Information*].

Lactation

Advise women not to breastfeed during treatment with TAGRISSO and for 2 weeks after the final dose [see *Use in Specific Populations (8.2) in the full Prescribing Information*].

Distributed by:

AstraZeneca Pharmaceuticals LP
Wilmington, DE 19850

TAGRISSO is a trademark of the AstraZeneca group of companies

©AstraZeneca 2015

3182206 11/15 Issued 11/15

Upscale restaurants

Club Jinmao

86F, Grand Hyatt Hotel, No.88, Century Avenue, Pudong New Area

This is the highest local authentic Shanghai restaurant, located on the 86th floor. Diners will enjoy the seafood soup and other delicious dishes while appreciating the charming scenery of Pudong.

The House of Roosevelt / Bund 27

No.27 Zhongshan Dong Yi Lu. Vicinity: The Bund

This is one of the largest wine emporiums in Shanghai. With the largest wine list in Asia (3,800 labels), the nine-floor venue has a brasserie, wine cellar, rooftop terrace, and private members' club.

Whampoa Club

5F, No. 3, the Bund, No.3 Zhongshan Dong Yi Lu., Huangpu District (near Guangdong Road)

Check out this famous luxury restaurant on the Bund. The chef is known for adding many novel ingredients to traditional cuisine, and you won't want to miss the smoked fish and the fried shrimp balls.

Moderately priced restaurants

Lang Yi Fang

5F, Super Brand Mall, No. 168, West Lujiazui Road, Pudong District (near West Yincheng Road)

The restaurant serves authentic Shanghai Benbang dishes at reasonable prices. The crab bean curd, smoked fish, and Babao Duck are its signature dishes.

Yang's Fry Dumpling

54-60 Wujiang Lu (near Nanjing Xi Lu)

The Yang's Fry chain is, if not the originator, then clearly the benchmark for Shanghai's home-grown pan-fried pork dumpling, the shengjian bao. They're a stone-cold Shanghainese street food classic and a cousin to Shanghai's more famous soup dumpling, the xiaolongbao.

Takumi

IFC Pudong, 4/F, 8 Shiji Da Dao

This Japanese robata and sake bar in the IFC Mall specializes in grilled meats and vegetables.

Looking for a quick excursion during a break in your education schedule? These nearby activities will

Continued on following page

CHEST World Congress 2016



Continued from previous page

offer you a glimpse into Shanghai's charm and history:

The Bund - a famous waterfront and regarded as the symbol of Shanghai for hundreds of years. It has been called a museum of international architecture. You can also find ritzy shopping and high-end restaurants and bars at this swanky attraction.

Huangpu River - Take in the bustling city and the local architecture from this enjoyable vantage point. There are boat tours available ranging from a quick ferry ride to 3-hour cruises.

The Oriental Pearl TV Tower - This high tower, at 1,536 feet, is the world's sixth and China's second tallest TV and radio tower. However, even more alluring than its height is its unique, attractive architectural design. Visitors travel up and down the tower in double-decker elevators and receive an

introduction to the tower in English and Chinese.

Shanghai World Financial Center (SWFC) - The second tallest skyscraper in mainland China, this building aims to be a symbol of the world's finance. Visitors can enjoy sights of the city from the observatory or the Park Hyatt Hotel.

We know you'll enjoy Shanghai and CHEST World Congress 2016's extensive educational offerings. You'll receive relevant updates on patient care, and practice management strategies will offer insight, perspective, and inspiration you can seamlessly incorporate into your practice to stay at the forefront of clinical chest medicine.

Begin planning your trip to Shanghai now with help from Shanghai's tourism website, meet-in-shanghai.net. Learn more about CHEST World Congress 2016, and register today at chestworldcongress2016.org.

Continued from page 49

anniversary of employment at HFH, coincident with HFH celebrating its 100th founding anniversary. I continue to serve every couple of weeks with teaching sessions with the pulmonary fellows on a voluntary basis. This pro bono work is consistent with the objectives that I stated when I became President of CHEST.

My wife Susan and I have continued to travel internationally, now about one to two such trips each year. A river cruise in Portugal was the highlight in late 2014 and another on the Danube River from Budapest to Nuremberg was our itinerary in late 2015. We also spend about 6

weeks each year at our home on Hilton Head Island, South Carolina, and our intentions are to enjoy even more time there going forward.

Since I retired, I have enrolled as an undergraduate student at Wayne State University, taking a course in geology just "for fun." Geology is a field of science that I could not work into my schedule as a pre-med student, so now I have the time and opportunity. One of my grandsons has joined me as I returned to a childhood hobby of building flyable model airplanes. I golf with several friends twice a week, and I wish I still had the game that I had at age 25!! Susan and I will continue to travel and see things that we enjoy together.

Enhance your reading experience.

FREE APP DOWNLOAD
Optimized for mobile and tablets

chestphysician.org
iOS, Android and Amazon Kindle



CHEST[®] Physician
THE NEWSPAPER OF THE AMERICAN COLLEGE OF CHEST PHYSICIANS

chestphysician.org




Live Learning Courses

Advanced Clinical Training in Pulmonary Function Testing
April 9-10

Critical Care Ultrasonography: Integration Into Clinical Practice
May 5-7

Advanced Critical Care Echocardiography
June 2-4

Transesophageal Echocardiography (TEE)
June 5

Comprehensive Pleural Procedures
June 17-18

Difficult Airway Management
July 15-17

Mechanical Ventilation: Advanced Critical Care Management
July 29-31

Bronchoscopy Procedures for the Intensivist
August 6-7

Ultrasonography: Essentials in Critical Care
September 9-11

Cardiopulmonary Exercise Testing (CPET)
September 16-18

Comprehensive Bronchoscopy With Endobronchial Ultrasound
September 23-25

Critical Care Ultrasonography: Integration Into Clinical Practice
November 11-13

Ultrasonography: Essentials in Critical Care
December 2-4

> Learn More chestnet.org/live-learning

CHEST Board Review
Phoenix, Arizona
August 19-28

CHEST Annual Meeting
CHEST 2016
October 22-26
Los Angeles, California



Calendar subject to change.
For most current course list and more information, visit chestnet.org/live-learning.

CHEST[®]
World Congress
2016

世界胸科大会
CHINA
Shanghai • April 15-17



SHANGHAI, CHINA • APRIL 15-17

CHEST Membership Offer

Not a member? Register for CHEST World Congress 2016 to receive a free 6-month Basic membership trial, beginning May 2016.

Don't miss CHEST World Congress 2016, organized with support of the Chinese Thoracic Society. CHEST World Congress connects clinicians from around the world specializing in pulmonary, critical care, and sleep medicine to offer:

- Relevant, innovative, and diverse education opportunities similar to the CHEST Annual Meeting in North America
- Original research and guideline recommendations from the journal *CHEST*
- Networking and social opportunities to connect you with influential international professionals from your field

> Register Now chestworldcongress2016.org

Offered with the support of:



'Cautious optimism' about MACRA implementation

BY GREGORY TWACHTMAN
Frontline Medical News

WASHINGTON – Coming regulations to implement the MACRA legislation also could include sweeping reforms to meaningful use and quality reporting programs, said Dr. Steven J. Stack, president of the American Medical Association.

Dr. Stack expressed “cautious optimism” that the regulations would help doctors to return to focusing on treating patients and away from meeting the myriad of regulatory requirements that have piled up in recent years.

The AMA has been working closely with the Centers for Medicare & Medicaid Services and “very candidly and very constructively.” The agency has “demonstrated a willingness to reconsider things,” Dr. Stack said at the AMA National Advocacy Conference.

The regulations to implement MACRA (the Medicare Access and CHIP Reauthorization Act of 2015) “offers CMS an uncommonly robust opportunity to take things like [the Physician Quality Reporting System], meaningful use, value-based purchasing and reconceptualize, now that we have the opportunity under one rulemaking, to say how should all of these really work together,” Dr. Stack said.

Indeed, during a keynote address at the AMA conference, CMS Administrator Andy Slavitt said one of the goals for the agency this year was to simplify things for doctors.

“We must reduce burden and give physicians back more time to spend with patients,” Mr. Slavitt said. “Several years ago, we launched an initiative that is reducing regulatory burden and saving hospitals \$3.2 billion over 5 years. But we are barely scratching the surface.

“We have a strategic effort this year designed to reduce burden and create efficiencies in the physician’s office,” Mr. Slavitt said.

He hinted that the MACRA regulations would be used to redefine how health IT is utilized, noting the emphasis will be on rewarding outcomes that technology helps achieve, rather than simply incentivizing the use of it; providing more flexibility to meet physician needs; leveling the playing field to allow more competition from vendors; and to address ongoing interoperability issues.

The concern Dr. Stack addressed during the press meeting was the ongoing opioid epidemic, one of the few things he expects to see legislative action on during this presidential election year.

He called for thoughtful, comprehensive solutions to addressing the problem so that it allows patients with a true medical need for chronic pain management to be able to continue to have access to needed prescription pain medications.

Arbitrary prescribing caps and other fixes that, on the surface, are simple and easy to implement, should be avoided, he said.

“Those kinds of approaches for this problem

could have the really undesired consequences of rather than solving the problem,” Dr. Stack said, adding that they could drive even more people from prescription pills to heroin.

That “causes deaths far more rapidly than the other stuff, which takes tens of millions of Americans with legitimate chronic pain who are legitimately suffering and throwing them into horrific life problems without access to care they need.”

As an adjunct, Dr. Stack also addressed drug pricing, using naloxone, which is used to help patients experiencing and opioid overdose, as an example of a drug that has skyrocketed in price.

In looking at 5 years of drug prices in his state of Kentucky, naloxone has gone up from just over \$4.50 a pill in 2010 to \$38 a pill in 2015.

“If there is one thing that I will be absolutely clear on as a physician in the United States, this is not the time for the pharmaceutical industry to play games in the midst of an epidemic that taking over a quarter-million people’s lives over the documented course of this problem,” Dr. Stack said.

“This is the time for the pharmaceutical industry to do its part and make sure that naloxone is as cheap as water from a tap so that patients in need can get the care they need and have this life-saving drug. This is not a profiteering opportunity for anyone,” he added.

gtwachtman@frontlinemedcom.com

What will you do to help champion lung health?



Apply for a grant today.
Submission Deadline: April 30

CHEST
FOUNDATION

Our grant winners have:

- Created asthma boot camps across the largest school district in San Antonio, reaching hundreds of students and their families in five elementary schools in the district.
- Trained underserved communities in sub-Saharan Africa by providing critical care training to future doctors in Tanzania.
- Implemented randomized clinical trials for patients with unexplained exacerbations of COPD in Spain.

CHEST Foundation grant winners are doing innovative and impactful work all over the globe. Your team could be next. Learn more about how you can be one of the next CHEST Foundation grant recipients.

> Submit Today chestnet.org/grants

CHEST® Board Review
2016

Exam-Focused Board Review

Our premier board review courses review the information you should know for board certification exams. Whether you need to certify, recertify, or simply review, our courses offer a thorough review you can put to the test with confidence.

Make plans to attend these board review courses at the Arizona Biltmore Hotel in Phoenix. Discounted room rates available.

	Critical Care Medicine Board Review August 19-22
	Pediatric Pulmonary Medicine Board Review August 19-22
	Sleep Medicine Board Review August 24-26
	Pulmonary Medicine Board Review August 24-28

Attend optional sessions August 23:

- ABIM SEP Modules
- Mechanical Ventilation

Special Offers to Enhance Your Study

- Register for a board review course and receive the audio files (mp3) from the corresponding board review on demand product for free—up to a \$1,495 value! (Offer excludes pediatric pulmonary medicine.)
- Register for a board review course and receive a 30% discount off the video files (mp4) from the corresponding board review on demand product.

Details available at boardreview.chestnet.org.

> Register Now boardreview.chestnet.org

Supreme Court: Fate of health care cases uncertain

BY ALICIA GALLEGOS
Frontline Medical News

The fate of several high-profile health care cases remains uncertain after the death of U.S. Supreme Court Justice Antonin Scalia.

The eight remaining justices will hear oral arguments on and weigh in on a range of cases this term. Justice Scalia's death however, means the possibility of a tie vote in some cases, which could lead to conflicting case law across states.

"Most Supreme Court decisions are not decided on a 5-to-4 split, so presumably regular business will continue as to most of the cases they are deciding," said Timothy S. Jost, health law professor at Washington and Lee University in Lexington, Va. "However, for some of the most important cases in health care – like the abortion decision or the contraceptive decision – it was likely there was going to be a 5-to-4 split. Of those cases, the justices can either hold them over or vote, in which case there [could] be a 4-to-4 split."

If the court divides equally on a case, the lower court's decision is affirmed. But the case would not have a Supreme Court precedent, meaning the lower ruling would apply only in the circuit court's jurisdiction, said Eric J. Segall, a professor of law at Georgia State University, Atlanta.


In *Whole Woman's Health v. Cole*, also known as *Whole Woman's Health v. Hellerstedt*, for instance, a split would uphold an appellate decision that allowed abortion restrictions in Texas to go forward. In that case, the state is battling health providers over a mandate that abortion providers must have admitting privileges at a hospital within 30 miles and that abortion clinics must meet the same requirements as those of ambulatory surgical centers (ASCs). The 5th U.S. Circuit Court of Appeals ruled that the regulations do not impose an undue burden on a patient's right to get an abortion.

"If a 5-4 [Supreme Court decision] upheld those restrictions, that would be national law for the whole country, and it would be a huge deal," Mr. Segall said in an interview. "If it's a 4-4 tie, than in Texas and two other states, the Texas decision would still be good law, but it would have no effect outside that circuit."

In the case of *Zubik v. Burwell* however, a split vote would mean nationwide differences in how the Affordable Care Act's contraceptive mandate is applied, said Ilya Shapiro,

a senior fellow in constitutional studies at the Cato Institute. The *Zubik* case centers on whether the ACA contraceptive-coverage mandate and its "accommodation" violates the Religious Freedom Restoration Act by forcing religious nonprofits to act in violation of their beliefs. The 8th U.S. Circuit Court of Appeals struck down the exception twice, ruling that forcing organizations to offer contraceptive coverage – even indirectly – violates their religious rights. The 8th Circuit's decisions are at odds with rulings by the 2nd and 5th Circuits.

Because of the conflicting lower court opinions, if the *Zubik* case



JUSTICE ANTONIN SCALIA

were decided 4-4, "the regulation [would be] in place in parts of the country and not in others," Mr. Shapiro said in an interview. "That seems untenable. Cases like that especially, the court would likely delay the arguments that are currently scheduled until the next term."

Justices can decide whether to vote or rehear cases that were already heard with Justice Scalia in attendance, but are not yet decided. They can also dismiss or wait to address cases next term. Decisions that were made with Justice Scalia's vote, but were not yet published, will be void, Mr. Shapiro said. As for Justice Scalia's replacement, Mr. Shapiro noted that even if President Obama makes a nomination and it is confirmed by the Senate, it would be too late to consider cases this term.

Mr. Segall stressed that it's too early to tell how Justice Scalia's death will impact ongoing and future cases and the court as a whole.

"We don't really have a precedent for this," he said. "We've had vacancies before, but we've never had a vacancy in an election year where [the Court comprised] four conservative Republicans and four liberal Democrats. I think we should all step back. There are so many imponderables."

What's on the docket?

The Supreme Court is set to decide a number of significant health law cases this term. Here are some of the most pressing ones and the issues at stake.

Zubik v. Burwell

Argument date: March 23, 2016
The court will decide whether an accommodation under the ACA contraceptive mandate violates the Religious Freedom Restoration Act by forcing religious nonprofits to act in violation of their beliefs, when the government has not proved that this compulsion is the least restrictive means of advancing a compelling interest. The accommodation clause refers to an exception for organizations that oppose coverage for contraceptives but are not exempted entities such as churches. The plaintiffs argue the process serves as a trigger that enables contraceptive use and makes the groups complicit. The government argues the exception does not impose a burden on the groups and that courts should not disregard the interest of employees who may not share employers' religious beliefs.

Whole Woman's Health v. Cole

Argument date: March 2, 2016
Justices will weigh whether two Texas regulations place an undue burden on a woman's right to access an abortion. The regulations mandate that abortion providers have admitting privileges at a hospital within 30 miles of an abortion clinic in order to provide the service, and that all abortion clinics meet the same requirements as those of ambulatory surgical centers (ASCs). The plaintiffs, who are clinics and doctors, argue that both restrictions are unnecessary and limit access to abortion services. The Texas Department of State Health Services states the restrictions are reasonable and effective measures that raise the standard of care for abortion patients and ensure health and safety. The case is sometimes cited as *Whole Woman's Health v. Hellerstedt*.

Universal Health Services v. United States ex rel. Escobar

Argument date: To be determined
In question is whether the legal theory used by the federal government to bring False Claims Act (FCA) lawsuits is valid. The case centers on a patient who died after receiving care by Universal Health Services Inc. (UHS) in Lawrence, Mass. The patient's parents sued UHS under both the federal and state False Claims Act laws alleging that UHS providers were improperly licensed and made fraudulent government claims. The Supreme Court will answer whether the implied certification test for determining when claims "sufficiently plead falsity" under the FCA is constitutional and if so, if the relevant statute needs to explicitly state the conditions of payment with which the defendant allegedly failed to comply. Physician associations are concerned that a ruling for the plaintiff will expand the FCA's reach and increase false claim lawsuits against health providers.

Gobeille v. Liberty Mutual Insurance Company

Argument date: Dec. 2, 2015
The Supreme Court will decide whether a self-funded insurer must share certain information, such as claims and member data, with Vermont's all-payer database. The state argues the information is needed to improve the cost and effectiveness of health care and that an adverse ruling would chill reform efforts in other states with similar databases. Liberty Mutual, which maintains a self-insured health plan for its employees, argues that the Employee Retirement Income Security Act of 1973 (ERISA) preempts state statutes that provide for "all payer" health care databases, and that it does not have to supply the information. Analysts say the case will ultimately decide to what extent federal law can facilitate the centralized management of health care.

Supreme Court analysts predict the eight justices will announce their decisions – or lack thereof – during the last week of June.

Justice Scalia was known as the high court's most vocal conservative

and was the longest-serving current justice on the court, hearing cases for 29 years.

agallegos@frontlinemedcom.com
On Twitter @legal_med

CLASSIFIEDS

Also available at MedJobNetwork.com

PROFESSIONAL OPPORTUNITIES



Critical Care Intensivist Employment Opportunity

Join a Leading Healthcare System in South Florida

Memorial Healthcare System is seeking a critical care physician to join its intensivist group. Successful candidates will demonstrate excellent clinical skills, a broad knowledge base and dedication to providing high quality, evidence-based patient care. Applicants must be BE/BC in critical care medicine. Currently, the critical care program comprises 28 full-time intensivists and six critical care ARNPs.

- 12-hour in-house shifts (7 am–7 pm or 7 pm–7 am); no responsibilities outside of in-house shifts
- Approximately 14 shifts per month
- Highly competitive salary differential available if full time nocturnist position desired

This is a full-time employed position within the multispecialty Memorial Physician Group. The position offers competitive benefits and a compensation package that is commensurate with training and experience. Professional malpractice and medical liability are covered under sovereign immunity.

About Memorial Healthcare System

Memorial Healthcare System is one of the largest public healthcare systems in the United States. A national leader in quality care and patient satisfaction, Memorial has ranked 11 times since 2008 on nationally recognized lists of great places to work – in Modern Healthcare magazine, Florida Trend magazine and Becker's Hospital Review, just to name a few.

Memorial's facilities include its flagship, Memorial Regional Hospital, one of the largest in Florida; Memorial Regional Hospital South; Joe DiMaggio Children's Hospital, the only freestanding children's hospital in Broward and Palm Beach counties; Memorial Hospital West; Memorial Hospital Miramar; Memorial Hospital Pembroke; and Memorial Manor, a US News five-star-rated nursing home.

Memorial's work environment has been rated by employees and physicians alike as an open-door, inclusive culture that is committed to safety, transparency and, above all, outstanding service to patients and families.



mhsemp072

For more information on this opportunity, please visit memorialphysician.com

Moving? Look to Classified Notices for practices available in your area.

SOUTHEASTERN OHIO

Holzer Health System is seeking a BE/BC Pulmonologist for an Office-Based practice at our main campus in Southeastern Ohio with a minimum of 10 days a month call, including one weekend.

Single hospital coverage, 266-bed regional referral hospital offering 24/7 hospitalist coverage and physically attached to the clinical practice in Gallipolis.

The salary is competitive and benefits are excellent!

- Guaranteed 2 year salary floor with immediate production incentive
- Signing bonus
- Educational loan repayment
- Relocation expense reimbursement
- Malpractice insurance provider by Holzer
- Life and Long Term Disability insurance provided by Holzer
- Attractive retirement options
- Starting at 5 weeks' vacation; increases with tenure
- Up to 5 days off for Category 1 tested CME
- Health, dental and vision insurance available for provider and family

Contact *Kenny Coughenour*
Physician Recruiter at 740-446-5205 or
kcoughen@holzer.org
to find out more about this position!

Pulmonology/ Intensivist

Join eight university trained, Board Certified Pulmonary, Critical Care and Sleep Medicine physicians. Our integrated multi-specialty physician clinic and hospital includes a Level II Trauma Center and an accredited sleep center. Practice with strong colleagues in the region's tertiary referral center.



Contact: **Rochelle Woods**
1-888-554-5922
physicianrecruiter@billingsclinic.org
billingsclinic.org

billingsclinic.com



Physician-Led Medicine in Montana

Billings Clinic is nationally recognized for clinical excellence and is a proud member of the **Mayo Clinic Care Network**. Located in the magnificent Rocky Mountains in Billings, Montana, this friendly college community has great schools, safe neighborhoods and family activities. Exciting outdoor recreation minutes from home. 300 days of sunshine!



Inpatient Pulmonary/Critical Care Position in Maine:

Join a vibrant Inpatient Pulmonary and Critical Care group of five in beautiful Maine! Central Maine Medical Center (CMMC) is seeking a BC/BE Pulmonary/Critical Care Physician to help provide pulmonary and critical care services to medical, surgical, trauma, and cardiac patients.

CMMC is a 250 bed, full service regional referral center with busy trauma, cardiothoracic, interventional radiology, vascular, and neurosurgical programs. We have a state-of-the-art 19 bed ICU and a separate 16 bed cardiothoracic unit.

Competitive salary and benefits including CME, paid vacation, student loan repayment, 403b match, and relocation fees. Work schedule revolves around a 6 day on and 6 day off philosophy, with no longer than 12 hour shifts per day. There is no outpatient clinic work.

Residents and visitors enjoy an extraordinary lifestyle that revolves around top school systems, ski resorts, lake and ocean water sports, theatre, and world-class dining.

Interested applicants may submit CV to Julia Lauver, Medical Staff Recruiter, Central Maine Medical Center, 300 Main Street, Lewiston, ME 04240. Email: JLauver@cmhc.org. Fax: 207/795-5696. Call: 800/445-7431. Visit our website, www.cmmc.org.

CMS clarifies how to report overpayments

BY ALICIA GALLEGOS
Frontline Medical News

There is finally some clarity about how to report and return Medicare overpayments, under a final rule released by the Centers for Medicare & Medicaid Services Feb. 11.

The final regulation clarifies that health providers have identified an overpayment when they “have or should have, through the exercise of reasonable diligence, determined [they have] received an overpayment and quantified the amount of the overpayment.”

CMS holds that large and small providers have a duty to ensure claims are accurate and appropriate and to report and return overpayments they have received.

Overpayments must be reported and returned only if identified within 6 years of the date the payment was received – down from the 10 years included in the proposed rule released in 2012. Physician organizations and

other health care stakeholders had criticized the proposal, calling the 10-year time frame unreasonable and burdensome.

The revised definition of identification makes more sense for physicians, particularly that identification exists when providers have quantified the amount of the overpayment, said Scot T. Hasselman, a Washington health law attorney. In many cases, it takes time to decipher how much money is owed after discovering a potential overpayment, he said in an interview.

“This all goes to: When does the clock begin ticking for the 60 days?” he said. “The language in the final rule provides for a standard that is easier to apply.

The 6-year time frame is also more reasonable and will save practices money by limiting their audit obligations, Mr. Hasselman noted.

The final rule also allows the 60-day deadline for returning overpayments to be suspended if a provider requests an extended repayment schedule. In the past, “people could be in a real pickle if they didn’t have the money to return,” Mr. Hasselman said. “This [provision] is important, especially for smaller [practices] and physicians who may not have big credit lines or the cash

flow of an institutional provider.”

The final rule also clarifies how to report overpayments. Providers and suppliers must use an applicable claims adjustment, credit balance, self-reported refund, or another appropriate process to satisfy the obligation to report and return overpayments, the rule states. If a provider



Refusing to allow scalable responses is unfortunate for practices unable to react robustly to overpayments.

MR. CLARK

has reported a self-identified overpayment using the self-referral disclosure protocol managed by CMS or the self-disclosure protocol managed by the HHS Office of Inspector General (OIG), the provider is considered to be in compliance with the rule.

But the final rule is not entirely positive, according to Houston-based health law attorney Michael E. Clark. Many health providers had requested clarification about the level of resources small providers are expected to devote to investigating potential overpayments. Commenters sug-

gested CMS allow for more defined overpayment responses based on provider size and resources. The agency did not do so, saying that providers “large and small have a duty to ensure claims are accurate and appropriate and to report and return overpayments they have received.”

Refusing to allow scalable responses



It takes time to decipher how much money is owed after discovering a potential overpayment.

MR. HASSELMAN

es is unfortunate for practices that do not have the ability to react to overpayments as robustly as larger chains, Mr. Clark said.

“The agency was unwilling to go that far,” Mr. Clark said. “They’re not going to give a lesser standard for smaller providers. They’re going to look at the facts and circumstances. It gives [CMS] subjectivity, whereas doctors would rather have more clarification and objectivity.”

agallegos@frontlinemedcom.com
On Twitter @legal_med

CLASSIFIEDS

Also available at MedJobNetwork.com

PROFESSIONAL OPPORTUNITIES

PRESBYTERIAN

PULMONARY / CRITICAL CARE PHYSICIAN

Presbyterian Healthcare Services (PHS) is seeking a Pulmonary/Critical Care trained physician to join our established group.

The physician will consist of 75% Critical Care and 25% Pulmonary.

PHS is a non-profit integrated health-care system that employs over 600 providers and includes a healthplan.

Benefits include medical, dental, vision, 403(b) plus match, CME, malpractice coverage (tail insurance included), competitive salary, sign on bonus and relocation assistance.

For more information, please contact:

Kelly Herrera
505-923-5662
kherrera@phs.org

CHARLOTTE, NC

*Immediate Physician Opportunities –
Charlotte, NC area!*

Carolinas HealthCare System (CHS) is currently recruiting Pulmonary/Critical Care physicians for the Charlotte Metro region. CHS uses an integrated System approach to Pulmonary/Critical Care, combining established clinical practices with the innovative technology of a tele-ICU program. This is an opportunity to work for a progressive healthcare system and practice in a high-acuity environment with a large group of Pulmonary/Critical Care colleagues. Available positions offer a variety of opportunities in subspecialty disease specific care, interventional procedures, teaching and research. All candidates must be board certified/eligible in Pulmonary and/or Critical Care Medicine. Please send your CV to Elaine Haskell at elaine.haskell@carolinashealthcare.org or call 704-631-1127.

OHIO CRITICAL CARE MEDICINE – DAYTON, OH

Excellent opportunity for BC/BE CCM physician to join growing 36+ physicians' private practice CCM/ID/Hospitalist/Endocrine group. Dayton is located in southern-western, OH. The metropolitan area of 800,000 offers many cultural, sports and recreational activities, excellent public and private school systems and affordable housing. Competitive salary and outstanding benefit package. Not a J-1 Visa opportunity.

Send CV or call:

Becky Kronauge
Practice Administrator
33 West Rahn Road
Dayton, OH 45429
PH: (937) 433-8990 ext. 124
FAX: (937) 433-8681
Email: rkronauge@sdacc.com
Web: www.sdacc.com

Hendersonville - Western North Carolina

BC/BE Pulmonary/Critical Care Medicine Physician inpatient/outpatient hospital-employed practice opportunity (Sleep Medicine optional) 1:3 call. Practice adjacent to 222-bed UNC Health Care-affiliated Pardee Hospital. Beautiful Hendersonville, WNC (near Asheville). No Visa Sponsorship. No Placement Firm Inquiries. **CV to:** Lilly Bonetti (828) 694-7687 lilly.bonetti@pardeehospital.org www.pardeehospital.org

 CHEST™ Physician

— CLASSIFIEDS —

For Deadlines and
More Information, Contact:

Lauren Morgan
Tel: (267) 980-6087
lmorgan@americanmedicalcomm.com

 FRONTLINE
MEDICAL COMMUNICATIONS

Disclaimer CHEST PHYSICIAN assumes the statements made in classified advertisements are accurate, but cannot investigate the statements and assumes no responsibility or liability concerning their content. The Publisher reserves the right to decline, withdraw, or edit advertisements. Every effort will be made to avoid mistakes, but responsibility cannot be accepted for clerical or printer errors.

NETWORKS: Informatics, transplant, VTE in transgender women

Clinical Research NetWork

Utility of clinical informatics in current practice

With the increasing use of digital medical information and the resultant voluminous health-care data, there has been an increased demand for translating these data into meaningful knowledge that enhances population health outcomes. That is the role of clinical informatics, which is a discipline that resides at the intersection of three major domains: the health system, clinical care, and information technology.

Clinical documentations, computerized physician orders entry, clinical decision support, data display, device integration, and e-prescription are common examples of the use of informatics in our daily practices. A document can be designed with pertinent links that are relevant to the clinician with built-in smart-data elements capturing data for future use. Order-sets can be utilized as part of care pathways to standardize the health-care delivery and to ensure compliance with quality metrics and regulatory requirements. Clinical decision support aims to improve safety. The visual display of specific data elements represents the basis for clinical dashboards and score cards for use in individual patient care. These clinical datasets can be used in disease management of populations, utilizing analytic tools that are necessary for population management. Automating scoring systems that facilitate identification of populations at risk is another example of informatics tools. The use of telemedicine, with its expanded categories, including tele-monitoring (e-ICU, tele-rounding, tele-homecare), tele-consultation, tele-visits, and tele-pharmacy, represents another growing application of informatics.

While the use of informatics has great opportunity toward optimization of health-care delivery, it comes with many challenges. These include cost (of designing, testing, analyzing, implementing), workflow changes, decreased bedside presence, alarm fatigue, data validation, data security, limited prognostication, difficulty in capturing unstructured data, challenging interoperability, and relatively slower technologic development compared with the rapidly increasing clinical demand. Clinical informatics is crucial and provides opportunities to enhance health-care delivery, yet its success is dependent on thoughtful analysis, design, and implementation.

Dr. Adel Bassily-Marcus, FCCP
Steering Committee Member

Transplant NetWork

Update: Referring and selecting candidates for lung transplantation

While there have been several recent therapeutic discoveries for patients with advanced heart and lung disease, transplantation remains

an important treatment consideration. As the clinical course of most cardiopulmonary diseases may be highly variable and sometimes marked by acute and rapid deterioration, early referral for transplantation should be remembered. Early referral does not necessarily mean that a patient will immediately be placed on a transplant waiting list; rather, it allows time for transplant providers to evaluate a patient's candidacy and work with referring providers to optimize any comorbidities or other factors that may increase a candidate's mortality. Early referral allows more time for educating patients about transplant; monitoring disease status; determining the appropriate time for wait-listing; and fostering trust among patients, their caretakers, and the transplant team.

Recognizing the emergence of new data regarding the appropriate selection of patients for lung transplantation, the International Society of Heart and Lung Transplantation (ISHLT) recently updated their Consensus Report for the Selection of Lung Transplant Candidates (*J Heart Lung Transplant*. 2015;34:1-15). Unlike previous editions from 1998 and 2006, the current report highlights several novel issues affecting contemporary candidate selection, such as changes to lung allocation, use of mechanical ventilation and extracorporeal technology for bridging patients to transplant, pediatric and multiorgan transplantation, and the expansion of candidate selection criteria, including new limits of age, comorbidities, and underlying recipient infections. Also addressed is the selection of candidates for re-transplantation, a procedure more commonly considered now for some recipients with graft dysfunction. Using this updated report, providers can more capably identify and refer patients who are most likely to benefit from transplantation.

Dr. Keith M. Wille, FCCP
Steering Committee Member

Women's Health NetWork

Thromboembolic risk in transgender women

Recently, the binary concept of gender has been challenged and definitions have undergone evolution. The estimated 700,000 people in the United States who are transgender do not have adequate access to well-informed health care (Rubin. *The Lancet*. 2015;386[9995]:727).

Gender identity disorder is often treated with hormonal therapy in order to suppress endogenous hormonal phenotype and amplify desired traits (Hembree et al. *J Clin Endocrinol Metab*. 2009;94:3132). The endocrine guidelines recommend targeting a physiologic range for hormone therapy so as to minimize risk of thrombotic events.

Venous thromboembolism (VTE) is the major complication of male to female transsexuals (van Kesteren et al. *Clin Endocrinol*.

1997;47[3]:337). Earlier observational studies found a 6% to 8% or up to a 20-fold increased risk of VTE in transwomen treated with oral ethinyl estradiol. This product is associated with increased coagulation (Toorians et al. *J Clin Endocrinol Metab*. 2003;88[12]:5723), and the risk has decreased since implementation of newer formulations and transdermal routes of estrogen (van Kesteren et al) (Gooren et al. *J Clin Endocrinol Metab*. 2008;93[1]:19). In the largest and most recent cohort studied, transwomen taking various preparations of hormonal therapy had increased incidence of VTE (5.1%) (Wierckx et al. 2013. doi: 10.1530/EJE-13-0493). Of those who suffered VTE, approximately half were within the first year of treatment and most were smokers.

Limited available research into VTE risk during hormone therapy in the transgender patient requires thoughtful consideration of risks and benefits, paying attention to the important role hormones play in the identity of these women. There is an increased need for education for health-care providers to better understand specific challenges faced by populations not falling within the traditional cultural paradigm.

Dr. Debasree Banerjee,
Dr. Stephen E. Lapinsky
Steering Committee Members

Additional Reading

2011 Williams Institute report. <http://williamsinstitute.law.ucla.edu/wp-content/uploads/Gates-How-Many-People-LGBT-Apr-2011.pdf>
Injustice at Every Turn report. www.thetaskforce.org/static_html/downloads/reports/reports/ntds_full.pdf
World Professional Association for Transgender Health



DR. BASSILY-MARCUS



DR. LAPINSKY



DR. BANERJEE

INDEX OF ADVERTISERS

Allergan	
Avycaz	27
AstraZeneca	
Symbicort	9-14
DALIRESP	24-26
Corporate	36-37
TAGRISO	51-53
Bayer Healthcare Inc.	
Adempas	16-19
Boehringer Ingelheim Pharmaceuticals, Inc.	
OFEV	29-34
EKOS Corporation	
Corporate	60
Genentech USA, Inc.	
Esbriet	2-5
GSK group of companies	
Nucala	21
ANORO	41-45
Mount Sinai - National Jewish Health Respiratory Institute	
Corporate	39
United Therapeutics Corporation	
Orenitram	47-48



History's greatest instruments really get the blood moving.



EKOS CORPORATION | 888.400.3567 | EKOSCORP.COM



FDA CLEARED INDICATIONS: The EkoSonic® Endovascular System is indicated for the ultrasound-facilitated, controlled, and selective infusion of physician-specified fluids, including thrombolytics, into the vasculature for the treatment of pulmonary embolism; the controlled and selective infusion of physician-specified fluids, including thrombolytics, into the peripheral vasculature; and the infusion of solutions into the pulmonary arteries. Instructions for use, including warnings, precautions, potential complications, and contraindications can be found at www.ekoscorp.com. Caution: Federal (USA) law restricts these devices to sale by or on the order of a physician. **THE CE MARK (CE0086) HAS BEEN AFFIXED TO THE EKOSONIC® PRODUCT WITH THE FOLLOWING INDICATIONS:** **Peripheral Vasculature:** The EkoSonic® Endovascular Device, consisting of the Intelligent Drug Delivery Catheter (IDDC) and the MicroSonic™ Device (MSD), is intended for controlled and selective infusion of physician-specified fluids, including thrombolytics, into the peripheral vasculature. All therapeutic agents utilized with the EkoSonic® Endovascular System should be fully prepared and used according to the instruction for use of the specific therapeutic agent. **Pulmonary Embolism:** The EKOS EkoSonic® Endovascular System is intended for the treatment of pulmonary embolism patients with ≥ 50% clot burden in one or both main pulmonary arteries or lobar pulmonary arteries, and evidence of right heart dysfunction based on right heart pressures (mean pulmonary artery pressure ≥ 25mmHg) or echocardiographic evaluation.

EKOS and EkoSonic are registered trademarks of EKOS Corporation, a BTG International group company. BTG and the BTG roundel logo are registered trademarks of BTG International Ltd.